KPBMA Directory 2018

2018 DIRECTORY OF KOREAN
PHARMACEUTICAL INDUSTRY
2018
Table of Contents
Greetings ..................................................................................................................................................................... 004

Overview of the Korean Pharmaceutical Industry ............................................................................................ 005
Information of Pharmaceutical Companies ........................................................................................................ 009
- Regular Members
- Associated Members
KPBMA Member Company List ............................................................................................................................. 233
No Company Page No Company Page No Company Page No Company Page
28 Elyson Pharmaceutical Co. Ltd. 068 56 Korea Otsuka Pharmaceutical Co.,Ltd. 131 84 Seoul Pharma Co.,Ltd. 188
Regular Members
29 GC Pharma 070 57 KOREA PHARMA CO., LTD. 133 85 SHIN POONG PHARM. CO., LTD. 190
A~G 30 Green Cross Cell Corporation 074 58 Korea Prime Pharm. Co., Ltd. 135 86 SINSIN Pharmaceutical Cp., Ltd. 192
1 Ahngook Pharmaceuticals Co., Ltd. 010 31 GUJU PHARM. CO. LTD. 077 59 KOREA UNITED PHARM.INC. 137 87 SK Chemicals Co., Ltd. 194
2 AJU PHARM CO., LTD. 012 60 Korea Vaccine 139 88 SS Pharm.Co.,Ltd. 196
3 Astellas Pharma Korea 014 H~K 61 KOREAN DRUG CO., LTD. 141 89 Suheung Capsule. Co., Ltd. 198
4 BC World Pharm. Co., LTD. 016 32 Hana Pharm Co., Ltd 079 62 KUKBO SCIENCE 143 90 Taejoon Pharmaceutical 200
5 Binex Co., Ltd. 018 33 HanAll Bio Pharma 081 63 Kukje Pharma Co., Ltd. 145 91 Taiguk Pharm. co., Ltd. 203
6 Boryung Pharmaceutical Co., Ltd. 020 34 HANDOK Inc. 083 64 Kwang Dong Pharmaceutical Co.,Ltd. 147 92 THERAGEN ETEX CO., LTD. 205
7 CHO-A PHARM.CO.,LTD. 022 35 Hankooksinyak Pharm. Co., Ltd. 086 65 Kyongbo Pharmaceutical Co., Ltd. 149 93 Union Korea Pharma Co., Ltd. 207
8 Chong Kun Dang Pharmaceutical Co. 024 36 HANLIM PHARM. CO., LTD. 088 66 Kyowa Hakko Kirin Korea Co., Ltd. 151 94 WHITE LIFE SCIENCE 209
9 CJHealthCare Corp. 027 37 Hanmi Pharm. Co., Ltd 090 67 Kyung Dong Pharm. Co., Ltd. 154 95 WhanIn Pharm Co., Ltd. 211
10 CMG Pharmaceutical Co., Ltd. 030 38 Han Wha Pharma Co., Ltd. 092 68 Kyung Nam Pharm. Co, Ltd 156 96 Won Kwang Pharm. Co., Ltd 213
11 CORESTEM Inc. 032 39 Hawon Pharmaceutical Corporation 094 97 WOORIDUL PHARMACEUTICAL LTD. 215
12 CTCBIO, Inc 034 40 Humedix Co., Ltd 096 M~Y 98 YOOYOUNG PHARMACEUTICAL 217
13 Daewoo Pharmaceutical Co., LTD 036 41 HUONS CO., LTD. 098 69 Medica Korea Co., Ltd. 158 99 Yuhan Corporation 219
14 Daebong LS Co., Ltd 038 42 Hyundai Pharm 100 70 MG Co., Ltd. 160 100 Yuyu Pharma., Inc. 221
15 DAE HWA PHARMACEUTICAL CO., LTD. 040 43 ICURE Pharmaceutical Inc 102 71 MOTHER'S PHARMACEUTICAL CO., LTD. 162
16 DAEWON Pharm. Co., Ltd 042 44 IKSU PHARMACEUTICAL CO., LTD. 104 72 Myung In Pharm. Co., Ltd. 164
Associated Members
17 Daewoong Pharmaceutical Co., Ltd. 044 45 ILDONG Pharmaceutical 107 73 Myung Moon Pharm. Co., Ltd. 166
18 DAI HAN PHARM. CO., LTD. 046 46 Ilsung Pharmaceuticals 109 74 Pharmbio Korea Co., Ltd 168 101 C&R Research Inc. 223
19 Daiichi Sankyo Korea 048 47 IL-YANG PHARM. CO., LTD. 111 75 PMG Pharm 170 102 CrystalGenomics, Inc. 225
20 Dalim BioTech Co., Ltd. 050 48 ISU Abxis Co., Ltd. 115 76 Richwood Pharmaceutical Co., Ltd. 172 103 GL PharmTech 227
21 DHP KOREA CO.,LTD. 052 49 JEIL Pharmaceutical Co., Ltd. 117 77 RP Bio 174 104 Medi Help line 230
22 DongKoo Bio&Pharma Co., Ltd. 055 50 JINYANG PHARM. Co., Ltd. 119 78 SamChunDang Pharm. Co., Ltd. 176 105 Pharmicell Co., Ltd. 231
23 Dongkook Pharmaceutical Co., Ltd. 057 51 JW Pharmaceutical Corporation 121 79 SAMA PHARM CO.,LTD. 178
24 Dongkwang Pharm. Co., Ltd. 059 52 KMS Pharm Co., Ltd. 123 80 Samik Pharm. Co., Ltd. 180
25 DONGWHA PHARM 061 53 Kolmar Korea Co.,Ltd. 125 81 Samil Pharm. Co., Ltd. 182
26 Dong-A ST(Science & Technology) 063 54 Kolon Pharma 127 82 Samjin Pharmaceutical Co., Ltd. 184
27 Dongsung Bio Pharm 066 55 Korea Arlico Pharm Co.,Ltd. 129 83 Samyang Biopharmaceuticals Corporation 186
2 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 3

Greetings Overview of Korea’s Pharmaceutical Industry
The market size of Korea’s pharmaceutical industry was USD 18.7 billion (as of 2016), making up 1.8% of
approximately USD 1.1 trillion of the global pharmaceutical market, 1.2% of domestic GDP, and 4.3% of domestic
manufacturing GDP. During the same period, domestic pharmaceutical production was USD 16.2 billion with
export and import volumes accounting for USD 3.1 billion and USD 5.6 billion respectively, while domestic
biopharmaceutical production was USD 1.73 billion, composing 9.2% of the domestic pharmaceutical market. As
of 2016, there were 737 pharmaceutical companies who manufactured drug products. Of these, 367 manufactured
Greetings from Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA). This is Jung-Hee finished drug products, 204 manufactured drug substance, and 379 manufactured quasi drugs. Average revenue
Lee, Chairman of the Directors Board. for publicly-traded pharmaceutical companies was USD 143 million, while 45 drug manufacturers generated
USD 100 million or more in revenue and two manufacturers (Yuhan Corporation and Green Cross) recorded USD 1
Representing about 200 KPBMA member companies, I would like to express my sincere gratitude to all the
billion or more (as of 2016).
relevant readers who have interest in Korean pharmaceutical industry.
Korean pharmaceutical companies are manufacturing quality medicines in compliance with ICH guidelines as Market Size (Unit: USD million, %)
well as Pharmaceutical Affairs Act in Korea, in order to provide consumers with safe medicines. 2012 2013 2014 2015 2016
Market size (yearly growth rate) 17,060 (0.32) 17,648 (0.51) 18,395 (0.24) 16,992 (-0.69) 18,729 (12.94)
As a result, the Ministry of Food and Drug Safety in Korea was able to join PIC/S in 2014, and became the
Production 13,943 14,955 15,593 15,004 16,212
regular member of ICH in 2016.
Export 2,077 2,128 2,416 2,946 3,121
Even with short history of 120 years, the Korean pharma industry was able to develop 29 new drugs(NCEs) Import 5,194 4,821 5,219 4,948 5,638
and as of the end of 2016, 82 incrementally modified drugs was developed by Korean pharma companies. As for Trade balance -3,117 -2,693 -2,803 -2,002 -2,517
clinical trials, Seoul is the best city of all city level in terms of the number of clinical trials. Biopharmaceuticals
are other area that Korea is making real result. Following the recent trend, efforts to combine the advanced IT
technology with new drug development is being made to usher in the 4th industrial revolution.
Pharmaceutical Production and Quality
The purpose of KPBMA Directory is to provide all related people from government, international organization
and companies oversea with precise information regarding Korean pharma companies, thus to facilitate co-
Management Capacities
operation. Following the 2016 version, the KPBMA spared no efforts to list precise and recent information of each Equipped with advanced production and quality management capacities, Korean pharmaceutical manufacturers
Korean company to highlight the strength of KPBMA member companies. are producing high quality pharmaceutical products. Additionally, efforts by domestic drug manufacturers to
I hope that this directory can be helpful to promote the cooperation between Korean companies and readers. As improve Good Manufacturing Practice since the mid-2000’s, have allowed them to build cGMP facilities compliant
for the KPBMA, we will make a promise to continue to update the information of the directory. with what are required by major countries such as the U.S.
Thank you. As regulatory and quality management systems for drugs have improved with the sincere efforts of regulatory
and private agencies, Korean drugs are now receiving great confidence as quality drugs not only from countries
in Southeast Asia, Central and South America, but also from those in Europe and the U.S.. Furthermore, recent
Jung-Hee Lee, Chairman of the Directors Board, KPBMA efforts by the Ministry of Food and Drug Safety (MFDS) to introduce Quality by Design (QbD) are leading Korea’s
pharmaceutical industry to establish a production infrastructure that will meet the requirements that are expected
of advanced countries.
Korea also boasts world-class drug regulatory systems. The MFDS having joined the Pharmaceutical Inspection
Cooperation Scheme (PIC/s) in May, 2014, is an international testament to the quality and management

capabilities of Korean drug manufacturers, and has improved export conditions, including inspection exemptions product that obtained a marketing authorization from the US FDA in 2016. And it only took the world’s first
of local drug manufacturing plants located in the PIC/s member nations. In addition, gaining Membership to the antibody biosimilar Remsima by Celltrion four years to exceed the USD 1 billion mark in aggregate export
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for revenues since its launch in 2013.
Human Use (ICH) in November, 2016, has proved that the level of drug regulatory systems in Korea is on par with
that of advanced countries, including the U.S., Japan and the EU, and has earned Korea elevated standing as one
of the countries that is leading drug regulatory policies. This is expected to be a great stepping stone for Korea to Vigorous Global Market Entry
advance in the global market as it will create favorable circumstances conducive to signing mutual agreements
Korean drug manufacturers equipped with a global competitive edge in new drug development and drug
with other national regulatory authorities and discussing exemptions required for gaining marketing approvals.
formulation technologies, production management facilities and quality control practices are successfully entering
markets around the world.
Investments in R&D In 2016, Korean-manufactured drug products reached markets in 188 countries, and total export volume was
USD 3.121 billion which was an 8.6% increase from the year before. Thus, the Korean pharmaceutical industry
Domestic drug manufactures are well aware that the pharmaceutical industry is technology-intense, thus they
had embarked on a high growth trajectory with an annual average growth rate of 13.6% between 2011 and 2016.
have been making greater investments to develop new drugs.
Furthermore, 27 drug manufacturers opened 69 local offices, and 18 pharmaceutical companies conducted 64
The average spending on R&D in 2016 by drug manufacturers was 6.0% of sales revenues, and that figure
clinical trials overseas (as of 2014).
reached 8.9% in publicly-traded drug manufacturers. In particular, Innovative Pharmaceutical Companies (selected
by the Ministry of Health and Welfare) spent 11.7% of revenue, far exceeding the 3.7%-mark recorded in the In 2015 and 2016, when technology exports occurred in earnest, Korean drug manufacturers signed 25
manufacturing sector. The R&D budget of drug manufacturers in 2016 hit USD 1.156 billion with an annual technology export contracts with multinational pharmaceutical companies, and in 2017 alone, eight technology
average increase of 6.7% over the previous five years. export contracts were concluded with their total volume reaching close to USD 1.23 billion.
Drug Export Volume by Export Destination (Unit: USD 1,000, %)
Development of New Drugs

2016
Ranking Export destination Change
Finished drug product Source material Sum
1 Japan 158,180 304,626 462,806 -6.6
Since the development of Korea’s first drug product “Sunpla Injection (cancer treatment)” in 1999, 29 new drugs
2 Croatia 397,830 28 397,858 356.1
have been developed in Korea as of March, 2018. With an average annual roll-out of 1.7 new drugs from 1999 to
3 Ireland 2,771 228,835 231,606 75.1
2017, Korea is gradually becoming a global pharmaceutical powerhouse. Furthermore, there are close to 20 drug 4 China 112,084 95,938 208,022 23.8
products that have established a foothold in major global pharmaceutical markets including the U.S. and Europe. 5 Vietnam 158,980 23,472 182,452 31.6
And starting with Amosartan (hypertension treatment) in 2009, 83 Incrementally Modified Drugs (IMD) had been Total 1,711,325 1,409,072 3,120,397 5.9
developed as of the end of 2016.
Government’s Policies to Promote and Support

Biopharmaceuticals the Pharmaceutical Industry
Four out of the seven globally commercialized stem cell therapy products were developed in Korea and they
In December 2017, the government announced the Second Comprehensive Plans to Promote and Support the
include the world’s first stem cell therapy, Hearticellgram-AMI (Pharmicell). Additionally, a hemophilia treatment
Pharmaceutical Industry (Second Comprehensive Plans) to help make the pharmaceutical and healthcare sectors
NBP601 (AFSTYLA) developed by SK Chemical, became the first new domestically-developed biopharmaceutical
as a whole, leading industries that will drive innovative growth.

When the new administration took office in May 2017, it identified pharmaceuticals as a future-oriented new
industry in its National Initiatives that can create high added value, and presented the Second Comprehensive
Plans in which a blue print detailed how to further grow the pharmaceutical industry in the future.
The Second Comprehensive Plans, with their vision of “Catapulting into a Pharmaceutical Powerhouse
Information of
that Offers Health and Jobs to the Public,” are composed of four specific areas, namely, R&D, employment
opportunities, export support measures and streamlining of rules and regulations.
1. Ways to strengthen R&D efforts to improve new drug development capacities
Pharmaceutical
- Foster promising areas for the next generation that will lead the Fourth Industrial Revolution, and
sophisticate support mechanisms that will improve new drug development success rates while increasing
pharmaceutical R&D investments that are designed to benefit the public
Companies
2. Ways to foster professional talent and help start businesses aimed at securing future growth
engines in the pharmaceutical industry
- Build a pool of pharmaceutical talent in different disciplines, create quality jobs, and lay the foundation for
new businesses that will help increase the number of pharmaceutical and biopharmaceutical growth drivers.
3. Seek ways to reinforce export support systems based on field demands 2018 DIRECTORY OF KOREAN PHARMACEUTICAL INDUSTRY
- Lay the foundation to help domestically-manufactured drug products enter global markets, help domestic
pharmaceutical companies strengthen export capacities, and support domestic drug manufacturers in order
to overcome entry barriers to respective markets.
4. Find ways to lay the foundation for the domestic pharmaceutical industry to help Korea become a
leading pharmaceutical country.
- Help boost private investments by offering policy loans, tax cuts, and strengthening institutional foundations
to help develop more new drugs, while simultaneously implementing rules and regulations that can improve
the pharmaceutical ecosystem.
8 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY

Main Products
Ahngook Pharmaceuticals Co., Ltd. Product (Ingredient)

1. Synatura Syrup (Ivy leaf 30% Ethanol Ext. 2.625mg/
Use
Antitussive and
Exporting Countries
Iran, South Africa, Mexico,
Remarks
New herbal medicine
mL + Coptis Rhizoma Butanol Ext. 0.875mg/mL) Expectorant Colombia, Vietnam, Kuwait with new composition
10mg&20mg: Treatment of New formulation
2. Valkyrie OD!FS (Tadalafil 5mg, 10mg, 20mg) erectile dysfunction - Orally Dissolving in a
5mg: Treatment of ED, BHP Few Seconds
1st chirally pure
3. Letopra Tab.(S-Pantoprazole 10/20mg) Treatment of GERD, PPI Kuwait, Vietnam
S-pantoprazole
Company Profile New and non-opioid
4. Anycough Cap.(Theobromine 300mg) Relief of cough symptom Kuwait
antitussive
Ahngook is a fully integrated pharmaceutical company dedicating to
1st chirally pure
development, manufacture, marketing, and sales of good medicines 5. Levotension Tab.(S-amlodipine 2.5/5mg) Hypertension Philippines, Vietnam
S-amlodipine
in Korea since 1959. And currently Ahngook has a strong presence
Functional dyspepsia.
in Respiratory, Gastroenterology, and Cardiovascular. For the future 6. Anytin SR tab. (Trimebutine maleate 300mg) - -
Irritable Bowel Syndrome
growth Ahngook is concentrating its R&D efforts on Bio products as
Primary Hyperlipidemia
well as various chemical products. 7. Sustar Tab.(Rosuvastatin 5/10/20mg) Guatemala -
and mixed dyslipidemia
Ahngook is dreaming to be a global company. It has its own entity in Benign Prostatic Philippines, Vietnam,
8. Xaltrin XL Tab.(Alfuzosine HCL 10mg) -
Representative China and is trying to expand its presence outside Korea. Ahngook Hyperplasia Guatemala, Peru
JIN AUH(President & CEO) has entered several out-license agreements and a number of 9. C urost Granules Prevention and continuos
Philippines, Vietnam -
export agreements with many overseas partners. Ahngook has (Montelukast Sodium 4.16mg) therapy of asthma
Headquarter Address many differentiated products and it is flexible for collaboration and
613 Siheung-daero, Yeongdeungpo-gu, business models to ensure for mutual benefits with its partners. R&D Pipeline
Seoul 07445, Korea
Ingredient Code Use Stage of Development
Foundation Date
Sep. 03. 1959 AG-1301 Naturalsubstance new drug Respiratory Therapeutics Non-clinical
Research Focus AK903 Natural substance new drug Periodontal disease treatment Phase 2 Clinical Study
IMDs, NCEs and Bio drugs AG-1502 IMD Circulatory system treatment Research
Total Staff AGB-P1 IMD Musculoskeletal Therapeutics Research
510 persons
UAI-101 Compound drug Metabolic disease treatment Non-clinical
Representative Phone
AG-B1511 Bio better (long acting) Neutropenia Non-clinical
82-2-3289-4200
AG-B1512 Bio better (long acting) Human Growth Hormone Deficiency Non-clinical completed
Web
www.ahn-gook.com AG-B1622 Bio Drug Immune anticancer agent Research
Contact Person
Jay Kim New Active Substances
Contact Phone Product (Ingredient) Use Approval Date/Country
82-2-3289-4359 Anycough cap. (Theobromine 300mg) Antitussive Jun. 2008, Korea
Contact E-mail Synatura Syrup (Ivy leaf 30% Ethanol Ext. 2.625mg/mL+ Mar. 2011, Korea, Iran,
Antitussive & Expectorant
kguy0821@ahn-gook.com Coptis Rhizoma Butanol Ext. 0.875mg/mL) Kuwait, South Africa
Financial Figures
Apr. 2017, Korea
Rupafin Tab. (Rupatadine 10mg) Antihistamine
Summary (1 Million Won) (In-licensed product)
Fiscal Year 2015 2016 2017
Sales 180,435 100,529 175,000 Others
R&D Expenditure 15,875 15,467 13,282
We welcome inquiries about our products export or R&D collaboration. Also we are specialized in the development of NCE and
Capital 175,667 144,554 176,178 IMD drugs for domestic development. If you are interested in Korean market, please feel free to contact us.

Main Products
AJU PHARM CO., LTD. Product (Ingredient)

1. Ceftriaxone Sod 0.25, 0.5, 1.0g Injection
Use
Antibiotics
Exporting Countries
Georgia etc.
Remarks
-
2. Cefotaxime Sod 0.25, 0.5, 1.0g Injection Antibiotics Mongolia etc. -
3. Ezetimibe+Rosuvastatin
Cardiovascular Peru etc. -
10/5, 10/10, 10/20mg Tablet
4. Eperison HCl 75mg SR Tablet Neuro-Muscular Azerbaijan etc. -
Company Profile 5. Omeperazole+NaHCO3

Gastro-Intestinal - -
20/1100, 40/1100mg Tablet
Founded in 1953, Aju Pharm has been well know as a quality-oriented
6. Candesartan 8, 16mg Tablet Circulatory Philippines etc. -
pharmaceutical company. 120+ pharmaceutical products comprised
of in-licensed products, our own value-added products, generics. 7. Pregabalin 75mg, 150mg Capsule CNS Peru etc. -
medical devices, and consumer health products. 8. Bisoprolol fumarate+Hydrochlorothiazide
Circulatory Philippines etc. -
Exporting products to more than 15 countries, always developing new 10/6,25, 5/6.25, 2.5/6.25mg Tablet
opportunities around the world. 9. Thiotic acid 25mg Injection Antioxidant Vietnam etc. -
10. Olive leaf extract Spray Daily throat care Saudi Arabia etc. Food Item
Representative
Joong-Kil KIM
Headquarter Address
#600 Gyeongin ro, Guro-gu, Seoul, Korea
R&D Pipeline
Foundation Date
1953. Ingredient Use Stage of Development
Research Focus Esomeprazole+ NaHCO3 Tablet Gastro-Intestinal Under clinical trial

Antibiotics, Cardiovascular
Total Staff
About 400
82-2-2630-0700 Others
Representative Fax Olea, our consumer health brand, aspires to help people live healthier lives by offering dietary supplements and other consumer
82-2-849-4123 health products made with the highest quality olive leaf extract.
Web Medical device(Soft tissue repairs and reconstruction).
www.ajupharm.co.kr Biocomposite and bioabsorbable suture anchors for rotator cuff repair(First biocomposite suture anchor developed in Korea) and
Disposable cannula with dual silicone seal system
Contact Person
Jeeyoun Sung
Contact Phone
82-2-2630-0729
Contact E-mail Financial Figures
export@ajupharm.co.kr Summary (1 Million Won)
Fiscal Year 2015 2016 2017
Sales 85,504 104,029 118,700
R&D Expenditure 2,401 2,226 -
Capital 4,200 4,200 4,200

Main Products
Astellas Pharma Korea Product (Ingredient)

1. Harnal D(Tamsulosin HCI)
Use
benign prostatic hyperplasia
Exporting Countries
Japan
2. Vesicare(Solifenacin Succinate) Overactive Bladder Netherland
3. Oldeca(Barnidipine HCl) Hypertension Japan
4. Berasil(Beraprost sodium) Peripheral Arterial Disease Japan
5. Protopic(Tacrolimus) Atopic Dermatitis Japan
Company Profile
6. Nasea(Ramosetron HCI) Nausea and Vomiting Japan
Astellas Pharma Korea., Inc. is alocal subsidiary of Japanese
7. Prograf(Tacrolimus) Post-transplant rejection Ireland
pharmaceutical corporate with superior R&D and worldwide sales
network. It was founded in April 1st 2005 by merging of Fujisawa 8. Irribow(Ramosetron HCI) Irritable Bowel Syndrome Japan
pharma Korea.,Co.and Yamanouchi pharma Korea.,Co,with 100% 9. Rapamune(Sirolimus) Post-transplant rejection -
Japanese ownership.
10. Perdipine(Nicardipine HCI) Hypertension -
Representative
Jeong Hai Do
Headquarter Address
6F, Kumha Bldg.41-2, Chungdam-Dong,
Kangnam-Ku, Seoul, Korea
Foundation Date
2005.04.01.
Total Staff
246 persons
82-2-3448-0504
Representative Fax
82-2-3448-0510
Web
www.astellas.com/kr
Financial Figures
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 105,800 132,300 150,400
R&D Expenditure - - -
Capital 11,500 11,500 11,500

Main Products
BC World Pharm. Co., LTD. Product (Ingredient) Use Exporting Countries

Vietnam,
1.Meropenem 500mg, 1g, 2g / Injection Antibiotics
Philippines and etc.
Vietnam, Philippines,
2. Imipenem 500mg+Cilastatin Sodium
Antibiotics Nigeria,
500mg / Injection
Mongolia and etc.
Azerbaijan,
3.Citicoline sodium 500mg/2ml / Injection Central nervous system
Dominica and etc.
Company Profile 4. Nicardipine HCl
Circulatory system Taiwan and etc.
We are a pharmaceutical company that discovers, develops, produces 10mg/10ml, 2mg/2ml / Injection
and markets formulations. We are actively engaged in R&D, including 5. Vancomycin HCl 1g / Injection Antibiotics Yemen and etc.
depot injectables, liposomes, and fast dissolving tablets. 6. Methylprednisolon Sodium Succinate
Adrenal gland hormone Vietnam and etc.
40mg/ Injection
We are certified as Korea Innovative Pharmacetical Company (KIPC)
by Korea Ministiry of Health & welfare and designated as Advanced 7. Piroxicam 20mg/1ml / Injection Anti-inflammatory Vietnam and etc.
Technology Center (ATC) by Korea Ministry of Knowledge Economy. 8. Acetaminophen 325mg+Tramadol HCl
Anti-inflammatory Myanmar and etc.
37.5mg / Tablet
Our newly facility constructed will be approved according to EU GMP
Headquarter Address 9. Glibenclamide 5mg+Metformin HCl 500mg,
standards by 2018. The manufacturing site construction dedicated for
Gyung Building, 78, Gaepo-ro, 22-gil, Glibenclamide 2.5mg +Metformin HCl 500mg/ Anti-Diabetes Bolivia and etc.
Carbapenem injection started in this year.
Tablet
Gangnam-gu, Seoul, 139-961, Korea
Foundation Date 10. Acetazolamide 500mg/ Injection Circulatory system Iran and etc.
1980.03.19.
Research Focus
DDS (Drug delivery system) R&D Pipeline
Total Staff Classification Code Use Stage of Development
272 persons BCWP-D001 Anti-cancer Formulation
Representative Phone BCWP-D004 Anti-cancer Formulation
82-2-2182-0400
BCWP-D006 Anti-cancer Non-Clinical
Web
Long-acting Microsphere Injection BCWP-D007 Parkinson's disease Formulation
www.bcwp.co.kr
BCWP-D008 Alzheimer's disease Formulation
Contact Person
David Kim BCWP-D009 Anti-schizophrenia IND
Contact Phone BCWP-D010 Anti-schizophrenia Formulation
82-2-2182-0452
BCWP-Y001 Anti-cancer Tech transfer
Contact E-mail
Liposomal Injection BCWP-Y002 Anti-fungal Pre-Clinical
tree365@bcwp.co.kr
BCWP-Y004 Analgesia Formulation
Financial Figures BCWP-A001 Antibiotics Pre-Clinical

Gastroretentive
BCWP-C003 Hyperlipidemia/DM Clinical
Fiscal Year 2015 2016 2017 BCWP-E001 Anti-emetic Launching
Sales 41,414 45,657 50,207 Fast-dissolving Tab. BCWP-E003 ADHD Formulation
R&D Expenditure 5,794 6,556 6,649 BCWP-E004 Antiulcerant PIII
Capital 1,335 1,335 1,461

Main Products
Binex Co., Ltd. Product (Ingredient)
1. C ontract Development and Manufacturing

Use Exporting Countries
Service - Binex manufactures client's

products both in API and finished form based
- -
on clients' need. Products are manufactured
at GMP quality with proficiency at reduced
time and cost.
Company Profile 2. Human Growth Hormone Growth Hormone Deficiency -
Binex is currently comprised of three main business sectors: biologics, 3. Small molecule products digestion, ophthalmic solution, etc. -
chemicals, and cell therapy. As the only biologics CDMO in Korea,
Binex plays the key role in solving the manufacturing bottleneck of
biopharmaceutical industry with accumulated experience and US and
EU-GMP facility.
R&D Pipeline
Ingredient Use Stage of Development
Representative Infliximab Rheumatoid Arthritis and other Phase 1 in Korea and Japan for
Myoung-Ho Jeong (Remicade biosimilar) inflammatory conditions Rheumatoid Arthritis
Headquarter Address
#368-3 Dadae-ro, Saha-gu, Busan, 604-
846, Republic of Korea
Foundation Date
1985.03.21.
Research Focus
biosimilar
Total Staff
300 persons
82-32-850-3235
Representative Fax
82-32-850-3299
Web
http://www.bi-nex.com
Financial Figures
Fiscal Year 2009 2010 2011
Sales 32,252 47,243 53,458
R&D Expenditure 4,349 706 4,663
Capital 7,800 8,357 9,379

Main Products
Boryung Pharmaceutical Co., Ltd. Product (Ingredient) Use Exporting Countries

Mexico, Brazil,
Remarks
1. Kanarb Tab. (Fimasartan) Anti hypertension NCE(New chemical entity)

Russia, China,
2. Cilnidipine Tab. Anti hypertension - 4th generation CCB
3. Lafutidine Tab. Gastric Ulcer, Gastritis - new generation H2RA
4. Gelfos Susp. (ALPO4) Antacid China, Taiwan Top Antacid in East Asaia.
Company Profile 5. Pitavastatin Hyperlipimedia Japan API
Boryung Pharmaceutical Co., Ltd has put a strong presence as 6. Oncology Injectable Anticancer Chemotherapy ASEAN, MENA -
TOP leading company in Korean pharmaceutical market since its 7. Cephalosporin Injectable Antibiotics Japan PMDA approved
foundation in 1963. Boryung has made its continuous efforts and
investment on R&D to produce high-quality products in its specialty
areas such as cardiovascular, gastrointestinal, antineoplastic,
antibiotics drugs and API. Boryung has devoted itself to achieve the
aspiration of company, “Dedicating to the health of mankind.”
In particular, Kanarb (Fimasartan, 8th ARB NCE for anti- hypertension) R&D Pipeline
Representative
Tae-Hong, Choi has been already licensed out to 14 Latin countries including Mexico Compound Name Code Use Stage of Development
& Brazil, Russia and China (16 countries in total). Following the launch
Headquarter Address of Kanarb in Mexico in Sept. 2014, further global market development Kanarb + CCB combo BKC002 Hypertension P3
#136, Changgyeonggung-ro, Jongno-gu, has been accelerated. In 2015, Kanarb is going to be licensed to Hypertension
Seoul, Korea APAC & MENA regions and be launched in Russia, Brazil, and China Kanarb + Statin combo BKC003 P3
Hyperlipimedia
Foundation Date in a few years. Also, the projects heading to the reference countries
Hypertension
1963.10.01. such as EU & Japan have been carried out. Kanarb + CCB + Statin combo BKC004 P1
Hyperlipimedia
Research Focus Following the remarkable success in Kanarb, Boryung is confident to
Incrementally modified drugs BNT002 Dementia P1
Cardiovascular, Oncology make another success story with its next key pipeline, Lafutidine(new
generation H2RA), Cilnidipine (4th generation CCB), and Gelfos (Top New Chemical Entity BNT001
Hypertension
Discovery
Total Staff antacid in East Asia), with its best clinical values in class. Diabetes mellitus
1,100 persons
Focus Area : Cardiovascular, Gastro-ntestinal, Antibiotics, Oncology, Gene therapy BCB002 Liver cancer P1
API synthesis Vaccine BVN002 Vaccine P3
82-2-708-8000
Vaccine BVN003 Vaccine PC
Representative Fax
82-2-744-0682
Web
www.boryung.co.kr
Contact Person
Micheal park
Jay Kim
Contact Phone Financial Figures New Active Substances
82-2-708-8032 Product (Ingredient) Use Approval Date/Country
82-2-708-8051 Summary (1 Million Won)
Fiscal Year 2012 2013 2014 Fimasartan Anti-hypertension Korea / 2011
Contact E-mail
jrpark@boryung.co.kr Sales 312,075 327,279 359,491 - - Mexico / 2014
jaykim@boryung.co.kr R&D Expenditure 9% 7.4% 7.2%
- - Ecuador / 2014
Capital 17,440 18,283 19.170

Main Products
CHO-A PHARM.CO.,LTD. Product (Ingredient)

1. Uratonyl (L-Ornithine-L-Aspartate)
Use
Acute,Chronic
Exporting Countries
Vietnam
2. Hemopoly
Iron deficiencya anemia Vietnam
(Ferric hydroxide polymaltose complex)
3. Calcitonic (Calcium Lactate) Calcium deficiency Vietnam
4. Elemmen (Adenosine, Thymidine) Acute, chronic, hepatitis anemia Vietnam
Company Profile 5. N
ew Hem (Ferrous gluconate hydrate,
Iron deficiencya anemia Yemen
Manganese gluconate, Copper gluconate)
CHO-A PHARM.CO.,LTD. has put all efforts to develop and supply 6. Lyvitol (L-Lysine HCl, Inositol,
excellent medicine under a corporate slogan, "Keep People Healthy Nutrition disorder Vietnam
Cyanocobalamin)
and Happy Away from Diseases" since establishment in 1988. With
7. Ronalamin (Calcium Lactate) Calcium deficiency Vietnam
fast growth over the last 20 years, CHO-A PHARM, is one of the
leading pharmaceutical company in Korea producing about 300kinds 8. Manpos (L-Arginine-L-Aspartate) Physical mental asthemia Guatemala
of drugs especially OTC products and health foods. CHO-A PHARM. 9. Babycolcol Reduction of symptoms resulting from the cold Mongolia
began producing drinkable double-neck ampoule under technical
cooperation with Laphal of France in 1994 and currently has 30kinds 10. Ginseng Korea (Korean Ginseng Ex.) Reduces fatigue, improve mental conditions. Vietnam
Representative of proudcts and exports them to Vietnam, Yemen and Guatemala.
Mr. Sung-Hwan Cho(CEO)
After establishing a manufacturing factory in 1994, CHO-A has
Headquarter Address invested to improve quantity and maximize production capacity by
1F Ace-Techno Tower, 55-7 obtaining an approval of KGMP in 1995 as well as ISO 9001 for the
Mullea-dong 3ga, Youngduengpo-gu, first time in the pharmaceutical industry in 1996. Through the CHO-A
Seoul, Korea Bio technical R&D center, CHO-A succeeded producing a somatic-
Foundation Date cell cloned pig for the first time in Korea and cloned a pig with EPO
1988. gene character coverted in 2005. Thereby CHO-A is expected to be a
prominent biotech company of the next generation.
Total Staff
270 persons
82-2-2166-4000
Representative Fax
82-2-2166-4111
Web
www.choa.co.kr
Financial Figures
Fiscal Year 2008 2009 2010
Sales 24,709 29,567 34,943
R&D Expenditure 1,623 1,502 1,296
Capital 39,514 39,875 42,237

Main Products
Chong Kun Dang Pharmaceutical Co. Product (Ingredient)

1. Lipilou (atorvastatin calcium anhydrous)
Use
Hyperlipidemia
Exporting Countries
Asia
2. Dilatrend (carvedilol) Hypertension -
3. Cipol-N (cyclosporine) Immunosuppressant Asia, S. America
4. Tacrobell (tacrolimus) Immunosuppressant Japan, Asia
5. Candemore plus (candesartan + HCTZ) Hypertension Asia
Company Profile
6. Sarlotan (losartan potassium) Hypertension -
Chong Kun Dang Pharmaceutical Corporaiton (CKD) was spin-off from
7. Imotun (avocado-soya) Arthritis -
CKD Holdings on November 2, 2013. CKD is a new organization to
manufacture, sales and market the pharmaceutical products, and has 8. Pregrel (clopidogrel resinate) Myocardial infarction -
the excellent capabilities to develop new chemical entities (NCEs), 9. Avelox (moxifloxacin hydrochloride) Antibiotics -
incrementally modified drugs and generics. CKD has invested over
12.3% of annual revenues for R&D (2016), and succeded to develop 10. Telminuvo (telmisartan, S-amlodipine) Hypertension -
NCEs such as CAMTOBELL®, anti-cancer drug and DUVIE®, anti-
diabetic drug.
Representative
Young-Joo Kim Camtobell® was launched in 2004, as the first CKD new drug
developed by its own technology. Based upon this successful
Headquarter Address experience, Duvie® (Lobeglitazone) which is a thiazolidinedione (TZD) R&D Pipeline
#8, Chungjeong-ro, Seodaemun-gu Seoul derivative for type 2 diabetes has been launched on February 2014.
120-756, Korea Ingredient Use Stage of Development
CKD has the capacity to research and develop drugs in broad areas:
Foundation Date CKD-351 Glaucoma Phase II
New Chemical Entity (NCE), Incrementally Modified Drug (IMD), and
1941. Biologics with a focus on antineoplastic, metabolic, immune and CKD-337 Dyslipidemia Phase I/III
Research Focus cardiovascular diseases.
CKD-333 Hypertension & Hyperlipidemia Pre-Clinical
Oncology, Immunology, Metabolism,
Cardiovascular CKD-391 Dyslipidemia Phase III
Total Staff CKD-11101 Anemia Phase III

1,864 persons CKD-396 Type 2 Diabetes Phase I
Representative Phone CKD-393 Type 2 Diabetes Pre-Clinical
82-2-2194-0300
CKD-516 Colorectal cancer Phase I/II
Web
CKD-381 Peptic ulcer Phase I
http://www.ckdpharm.com
CKD-394 Anti-coagulant Phase I
Contact Person
Ki-Su Lee CKD-519 Dyslipidemia Phase II
(Head of Global Business Division)
CKD-581 Multiple myeloma Phase I/II
Contact Phone
CKD-841 Cancer Phase I
82-2-3149-7849
Financial Figures CKD-495 Gastritis Phase II
Contact E-mail
global@ckdpharm.com Summary (1 Million Won) CKD-506 Autoimmune disease Phase I
Fiscal Year 2014 2015 2016 CKD-504 Huntington’s disease Phase I
Sales 544,130 544,130 831,986
CKD-12101 Neutropenia Pre-Clinical
R&D Expenditure 74,727 91,359 102,178
Capital 23,523 23,523 23,523 CKD-508 Dyslipidemia Pre-Clinical

R&D Pipeline
Ingredient
CKD-509
Use
Oncology
Stage of Development
Pre-Clinical
CJHealthCare Corp.
CKD-701 AMD Pre-Clinical
CKD-702 NSCLC Pre-Clinical
Company Profile
CJ HealthCare, which launched as a professional pharmaceutical
subsidiary of CJ Group on April 1, 2014, is preparing for the future
through its active investment in R&D and Open Innovation.
New Active Substances CJ Healthcare has concentrated on developing innovative new drugs,
Product (Ingredient) Use Approval Date biopharmaceuticals, and Incrementally Modified Drug in a variety of
therapeutic groups.
Camtobell (belotecan) Ovarian cancer, SCLC October 22, 2003 / South Korea
The new drug for gastroesophageal reflux disease (CJ-12420/
Duvie(lobeglitazone sulfate) Type II diabetes July 4, 2013 / South Korea Representative ingredient name: Tegoprazan), which is currently being developed,
Seok Hee KANG is now attracting attention as a drug that can shake the market for
Headquarter Address digestive system drugs in the near future.
CJ CheilJedang Center, 330, Dongho-ro, Tegoprazan has been recognized for its competitiveness both
Jung-gu, Seoul 04560, Republic of Korea domestically and internationally, and has achieved technology export
Foundation Date of 100 billion won to China < Shandong Luoxin Pharmaceutical Group
1.April 2014. Stock Co., Ltd.> in 2015.
Research Focus
digestive disorders, anti-cancer,
and immune diseases
Total Staff
1,200 persons
82-2-6740-2119
Web
www.cjp.co.kr
Contact Person
Headquaters
Contact Phone
82-2-6740-2169
CJHC_business@cj.net
(Global Business) Summary (1 Million Won)
cjhealthcare.open@cj.net Fiscal Year 2015 2016 2017
(R&D Business Development) Sales 463,100 520,800 -
Capital - - -

Main Products R&D Pipeline
Product (Ingredient) Use Exporting Countries Compound Name Code Use Stage of Development
Southeast Asia, Africa, Tegoprazan CJ-12420 Gastric Acid-Related Disorders NDA
Treatment of anemia of hemodialysis The Middle East, North
1. Epokine Inj. (rh-EPO) UNDISCLOSED CJ-14199 NASH PC
patients with end-stage renal disease Africa and CIS, Latin
America
JAK-1 inhibitor CJ-15314 Rheumatoid Arthritis PC
Southeast Asia, Africa,
Chemotherapy in advanced cancer patients The Middle East, North Atorvastatin, Metformin CJ-30056 Type 2 Diabetes / Hyperlipidemia NDA
2. Leukokine Inj. (rh- G-CSF)
and Neutropenia caused by acute Leukemia Africa and CIS, Latin Valsartan, Amlodipine, Rosuvastatin CJ-30060 Hypertension / Hyperlipidemia P3
America
Valsartan, Amlodipine, Atorvastatin CJ-30061 Hypertension / Hyperlipidemia P3
Treatment of serious, life-threatening
3. Vancorin Inj.(Vancomycin) China
infections by gram-positive bacteria Gastric Acid-Related Disorders /
Tegoprazan, Clopidogrel CJ-30064 DC
Antithrombotics
Treatment of serious infections Southeast Asia,
4. Tapocin Inj.(Teicoplanin)
by gram-positive bacteria Latin America Tegoprazan CJ-30065 Gastric Acid-Related Disorders DC
Treatment of acute bacterial sinusitis, acute - CJ-30066 Type 2 diabetes DC
5. Moveloxin I.V. solution bag (Moxifloxacin) bacterial exacerbation of chronic bronchitis, Southeast Asia
community acquired pneumonia and so on - CJ-30067 Type 2 diabetes DC
Treatment of Vancomycin-resistant Darbepoetin alfa biosimilar CJ-40001 Renal Anemia P3
6. Cinezolid I.V. solution bag (Linezolid) Southeast Asia
Enterococcus faecium infections
- CJ-40010 Hand, Foot & Mouth Disease PC
7. Calmtop Inj.(Irinotecan) Treatment of colorectal cancer Southeast Asia
Ranibizumab biosimilar CJ-40012 Macular edema PC
Treatment of pleural mesothelioma
8. Pemta RTU Inj.(Pemetrexed) Southeast Asia
and non-small cell lung cancer
9. OmapOne Lipid Inj.
Lipid emulsion for intravenous nutrition Southeast Asia
(Soybean oil, MCT, olive oil and fish oil)
10. OmapOne Peripheral Inj.

Emulsion for infusion Southeast Asia
(Lipid, Amino acids and Glucose)
11. Machkhan Tab. (Candesartan, Amlodipine) Treatment of hypertension -
12. Vogmet (Voglibose, Metformin) Treatment of diabetes -
13. CONDITION CONDITION LADY

Anti-hangover drink China, Japan, Vietnam
(Hyaluronic acid)
14. HONGSAMJIN
(4 years old red ginseng extract)
Red Ginseng drink Vietnam
HONGSAMJIN GOLD
(6 years old red ginseng extract)
15. HUTGAESOO Natural oriental raisin tea with zero calories

-
(Oriental raisin tree fruit extract concentrate) and caffein

Main Products
CMG Pharmaceutical Co., Ltd. Product (Ingredient)

1. Kanarb Tab. (Fimasartan)
Use
Erectile dysfunction
Exporting Countries
Taiwan, Hongkong
Remarks
20, 10, 5mg
2. Amlodipine/Valsartan Tab. Hypertension - 5/80, 5/160, 10/160mg
3. Mosapride Tab. Acid reflux, IBS - 5mg
4. Rebamipide Tab. Gastric ulcer - 100mg
5. Loxoprofen Tab. Anti-inflammation - 60mg
Company Profile
6. Rosuvastatin Tab. Hyperlipidemia - 5, 10, 20mg
CMG Pharmaceutical is a fast growing mid-cap company listed Fatigue recovery,
in KOSDAQ stock market in Korea. R&D focus area includes 7. Multi-Vitamin Tab. - Vit B1, B2, B6, C, E
inflammation
development of targeted cancer therapeutics (NCE), IMDs including
Oral Soluble Film and fixed-dose combinations of established drugs 8. Hyaluronic acid micro needle Cosmetic Mexico, Ukraine -
with therapeutic areas in cancer, CNS and cardiovascular disease. 9. Hyaluronic acid injectable Skin filler - -
CMG is seeking Open Innovation partnership in various areas 10. Vitamin C solution Hair loss, scalp care - -
including licensing, marketing/sales, R&D collaboration and Joint
Representative Venture investment in healthcare industry.
Joohyung Lee
Headquarter Address
CHA Bio Complex, Pangyo-ro 335, R&D Pipeline
Bundang-gu, Seongnam, Gyeonggi-do
13488, Republic of Korea Compound Name Code Use Stage of Development
Foundation Date Aripiprazole ODF - Schizophrenia, Bipolar I disease US Pre-NDA, 505(b)(2)

August 1, 2001. NCE CHC-2014 Solid cancer Phase 1 Study Candidate
Research Focus NCE CCN-002 Lung/stomach cancer Pre-clinical
NCE, IMD, Oral Soluble Film
NCE CCN-006 Prostate/bladder cancer Pre-clinical
Total Staff
212 persons NCE CNN-006 Alzheimer's disease Pre-clinical
Representative Phone NCE CCN-007 Solid cancer Hit selection

82-31-881-7600 Orlistat - Obesity Reformulation
Web
http://cmgpharma.com/
Contact Person
Haekwan Eo
Contact Phone Others
82-31-881-7679
CMG, part of CHA Hospital Group, is open to discuss business collaborations including open innovation, M&A, JV, R&D, and
Contact E-mail Financial Figures investment with foreign companies and investors.
hkeo@chamc.co.kr
Fiscal Year 2015 2016 2017(E)
Sales 27,042 32,970 41,535
R&D Expenditure 6,009 2,404 2,799
Capital 44,149 54,354 54,431

Main Products
CORESTEM Inc. Product (Ingredient)

1. NEURONATA-R
Use
Amyotrophic Lateral Sclerosis (ALS)
Exporting Countries
All
Remark
MFDA approval in 2015
Company Profile R&D Pipeline

CORESTEM is a bio-pharmaceutical company specializing in research Compound Name Code Use Stage of Development
and development of personalized stem cell therapies for incurable
Allogenic Stem Cell CS20AT04 Systemic Lupus Erythematosus Phase I
disease.
Autologous Stem Cell CS10BR05 Multiple System Atrophy Phase I
We developed the world’s first stem cell therapeutic product for ALS
(Amyotrophic Lateral Sclerosis) name of NEURONATA-R, received the Allogenic Stem Cell HYNR-CS-Allo Amyotrophic Lateral Sclerosis IIT
permission of medicines by Korea’s Ministry of Food and Drug Safety
Autologous Stem Cell NEURONATA-R Anoxic Brain Injury IIT
in July 2014 and began commercialized medication to patients in
Representative February 2015. Cartilage-derived Precursors CS30MS02 Osteoarthritis Preclinical
Kyung Suk Kim CORESTEM, a global stem cell biotechnology company, leads the
Headquarter Address market in meeting patient expectations beyond national, ethical
24, Pangyo-ro 255beon-gil, Bundang-gu, and economic limitations through ongoing research into incurable
Seongnam-si, Gyeonggi-do, Korea diseases.
Foundation Date
2003.
Research Focus
Personalized stem cell therapy for
incurable diseases
Total Staff
52 persons
82-2-497-3711
Web
http://corestem.com/en/
Contact Person
Yon Hui Sarah Kim
Contact Phone
82-70-4707-3544
yhkim@corestem.com
Fiscal Year 2015 2016 2017 (~Sep.)
Sales 18,571 17,953 50,037
R&D Expenditure 740 2,003 1,530
Capital 67,092 77,761 83,096

Main Products
CTCBIO, Inc Product (Ingredient) Use Exporting Countries
Lebanon, Iraque,
1. Sildenafil treatment of erectile dysfunction
Taiwan, Japan etc.
Company Profile R&D Pipeline

CTCBIO is a Korean pharmaceutical company which holds top 50 Compound Name Code Use Stage of Development
domestic pharmaceutical companies as solid clients and is involved
Donepezil free base CDFF0212 Treatment of Alzheimer's disease NDA applied
in co-operative partnership with international pharmaceutical
companies. Its pharmaceutical business covers development and bioequivalence test /
Treatment of primary enuresis, nocturnal
production of super-generics with drug formulation and delivery Desmopressin CDFF0612 review of specification and
enuresis
technology. We are specialized in micro-encapsulation using fluid bed test method completed
and OSF formulation. CTCBIO is capable of manufacturing various Entecavir CDFF0511 Treatment of chronic hepatitis B virus NDA applied
types of oral dosage forms and has business capabilities starting from
Representative formulation development and all the way to commercial production. 20mg: approved
Tadalafil CDFF0213 Treatment of erectile dysfunction
Ho Yeon Cho 5mg, 10mg : NDA applied
Headquarter Address Clomipramine/sildenafil CDFR0812 Treatment of premature ejaculation IND (phase II) applied
13, 40-gil, Jungdae-ro, Songpa-gu, Seoul, Treatment of duodenal and gastric ulcer,
Rep. of Korea omeprazole/sodium hydrogen caronate CDFR0209 GERD and symptoms of gastroesophageal NDA applied
Foundation Date reflux disease
June. 1993. eathartic for colonology and preoperatic
sodium picosulfate etc. CDFR0613 Phase I
Research Focus treatment
Finished Formulations
Total Staff
258 persons
82-1661-8800
Representative Fax
82-2-449-3886
Web
www.ctcbio.com
Contact Person
Chae Young Ban
Contact Phone
82-70-4033-0233 Financial Figures
Contact E-mail
ban@ctcbio.com
Fiscal Year 2012 2013 2014
Sales 129,800 123,400 -
Capital 125,400 150,500 -

Main Products
Daewoo Pharmaceutical Co., LTD 1. O

Product (Ingredient)
riginal Relief Eye Drops
Use Exporting Countries Remarks
OTC
Relieves red, Irritated eyes USA
(Tetrahydrozoline HCl 0.5mg/Ophthalmic Eye Drops) (USA OEM)
2. Advanced Relief Eye Drops
Relieves red, Irritated eyes, OTC
(Tetrahydrozoline HCl 0.5mg + Dextran 70 1mg + Polyethylene USA
Hydrating moisturizer (USA OEM)
glycol 400 10mg + Povidone 10 mg/Ophthalmic Eye Drops)
3. Hyalsan Eye Drops
1) Single-use disposable type 0.8 mL
Keratoconjunctival epithelial
Company Profile (Sodium hyaluronate 0.8mg/Ophthalmic Eye Drops)
disorder
Vietnam -
2) Multi-use type
Since its founding in 1976, Daewoo Pharmaceutical has endeavored (Sodium hyaluronate 1mg/Ophthalmic Eye Drops)
to promote the public health with 3 business principles-sincerity, 4. T obeson Eye Drops
correctness, research. Eye steroids, Antiallergics Vietnam -
(Tobramycin 3mg, Dexamethason 1mg/Ophthalmic Eye Drops)
We have focused on the business of ethical drugs in the past 30 5. Taspen-ER Tablet Other Analgesics,
- -
years in Korea. With the business experience, Daewoo has effort on (Acetaminophen 650mg/Tablet, Extended Release) Antipyretics
continuous research, development and investment about facilities 6. Eperisone Tablet (Eperisone HCl 50mg/Tablet) Skeletal muscle relaxants Vietnam, Thailand -
and human resources. 7. Simvasterol Tablet (Simvastatin 20mg/Tablet) Antilipidemic agents - -
Representative Now, Deawoo is preparing to become a global pharmaceutical 8. P antezol Tablet
Dr. Yong-Hoon Ji MD company with new-drugs pipline, particularly anti-angiogenesis and (Pantoprazole sodium sesquihydrate 45.1mg, as Pantoprazole H+ Pump inhibitors - -
Headquarter Address anticancer drug for the next 10 years. We are investing for world 40mg/Tablet)
153 Dadae-ro, Saha-gu class product facilities to increase oversea business and accomplish 9. Pseudoephedrine Tablet
Decongestants, Nasal prep - -
R&D projects in Daewoo R&D institute. Daewoo has committed (Pseudoephedrine HCl 30mg/Tablet)
Busan, Republic of Korea
Contract Manufacturing Organization(CMO) business with sufficient 10. Romicin Tablet (Roxithromycin 150mg/Tablet) Macrolide antibiotics Vietnam -
Foundation Date technical and marketing resources.
April. 1976.
Even in challenging internal and external enviroment, Daewoo will be
Research Focus a competent global pharmaceutical company with recognized ability.
Ophthalmic product formula modification
R&D Pipeline
& customization, Development of Focus Area : Opthalmic Products / Cancer Drugs / Generic Drugs
Compound Name Code Use Stage of Development
targeted cancer drugs with inhibition of
Int. CL.
angiogenesis : A61K 31/335 :A61K 35/74
Total Staff Rivaroxaban : C12P 7/62 :A61P 29/00 Anti-inflammatory Non-clinical
280 persons Application number
: 10-2010-0029016
Int. CL.
82-51-204-3831 : A61K 31/335 :A61K 31/335
Macrolactin A and its
Representative Fax : A61P 19/02 :A61P 19/00 Anti-angiogenesis Non-clinical
derivatives
82-51-202-3397 Application number
: 10-2011-0012707
Web
Int. CL.
http://www.daewoopharm.co.kr The prevention
: A61K 31/335 :A61K 31/365
or treatment of
Contact Person Macrolactin Compounds : A61P 1/00 :A61P 29/00 Non-clinical
Financial Figures inflammatory
Ji-Hoon Suh Application number
bowel disease
: 10-2012-0011924
Contact Phone Summary (1 Million Won)
Int. CL.
82-2-3477-1731 Fiscal Year 2012 2013 2014
: A61K 31/335 :A61K 31/365
Contact E-mail Sales 36,025 41,479 46,448 Macrolactin Compounds : A61P 35/00 Anticancer Drug Non-clinical
shortyj8@daewoopharm.com R&D Expenditure 1,414 1,547 1,180 Application number
Capital 24,141 27,205 24,246 : 10-2013-0089955

Main Products
Daebong LS Co., Ltd Product (Ingredient)

1. Erdosteine
Use
Expoctorant
Exporting Countries
-
Remarks
API
2. Olmesatan medoxomil Hypotensive Agent - API
3. Valsatan Hypotensive Agent - API
Mexico,Latin America
4. Amlodipine besylate Hypotensive Agent API
and the Caribbean
Company Profile
Daebong LS specializes in pharmaceutical raw materials and
cosmetics and is committed to our mission to be “a company that
providesthe best solutions to enable people to live healthier and R&D Pipeline
more beautiful lives” Through our “Total Solutions for Human Better-
Compound Name CAS No Use Stage of Development
Being”, we work to improve the Quality of Life (QoL) for all human
beings. Rivaroxaban 366789-02-8 Pilot scale process development
Anticoglurant
We develop the API of major anti-aging, respiratory, hypertension and Apixaban 503612-47-3 Lab scale process development
Representative digestive-system treatments and medicines and supply excipients Sitagliptin phosphate · H2O 654771-77-9 Pilot scale process development
Jin Oh Park to domestic companies as an agent for global companies. We are
Vildagliptin 274901-16-5 Antidiabetics Pilot scale process development
also able to meet the demands of our customers as we provide a
Headquarter Address Total Service by supplying the pharmaceutical technologies we have Linagliptin 668270-12-0 Lab scale process development
123, Neungheodae-ro 649 beon-gil developed through our collaboration with top Formulation ventures to Sarpogrelate HCl 135159-51-2 Antithrombotic Lab scale process development
Namdong-gu, Incheon, Korea our client companies.
Cilostazol 73963-72-1 antiplatelet Lab scale process development
Foundation Date Focus Area : Erdosteine, Olmesatan medoxomil, Valsatan, Amlodipine
1986. besylate Acetyl L-carnitine HCl 5080-50-2 Amino Lab scale process development
Research Focus L-carnitine 541-15-1 Acids Derivatives Lab scale process development
API Rosuvastatine Ca 147098-20-2 Antiarteriosclerotic Lab scale process development
Total Staff Etoricoxib 202409-33-4 NSAIDs Lab scale process development
120 persons
Tobramycin sulfate 49842-07-1 Antibiotics Lab scale process development
Choline fenofibrate 856676-23-8 Dyslipidemia Plant scale process development
82-32-712-8800
Linoleamide Seriol - Pseudo Ceramide Lab scale process development
Representative Fax
82-32-817-8808 Linoleneamide Serinol - Pseudo Ceramide Lab scale process development
Web Cetyl ethylhexanoate 59130-69-7 Emollient Lab scale process development
www.daebongls.co.kr Pentaerythritol
7299-99-2 Emollient Lab scale process development
Contact Person tetra(2-ethylhexanoate)
Hyun Cheol Kim Hydrogenated Natural Oil - Skin Conditioning Lab scale process development
Contact Phone
Contact E-mail
nano75@daebongls.co.kr New Active Substances
Fiscal Year 2014 2015 2016
Sales 47,696 53,414 63,362 Product (Ingredient) Use Approval Date
R&D Expenditure 1,524 1,856 2,422 Launched in 4Q

Pro Multi White Cysteine Whitening/Antiinflammatory Agents
Capital 5,543 5,543 5,543 2015(Korea)

Main Products
DAE HWA PHARMACEUTICAL CO., LTD. Product (Ingredient) Use Exporting Countries Remarks
New
1. Liporaxel solution (paclitaxel 10mg/mL) Gastric cancer - formulation as
oral solution
Relieve of
2. PROTASE Tab. Myanmar, Vietnam,
inflammatory -
(Bromelain 40mg, Crystallized Trypsin 1mg) Cambodia
symptoms
3. Top-Roll Soft capsules Tonic, nutritive Myanmar, Cambodia,
Company Profile -
(Korea Ginseng 100mg with multivitamins) supplement Bolivia, Ghana and others
DAEHWA Pharmaceutical Co., Ltd., was established in the spirit of “contribute 4. ALMETAMIN Tab. Acute rash, allergic
Ethiopia, Cambodia -
to society by providing a more human-centered pharmaceutical business.” Its
(Betamethasone 0.25mg, Dexchlorpheniramine maleate 2mg) rhinitis
main goal is to improve National health and people’s life. Vietnam, Bolivia,
5. D
EMACOT Cream (Batamethasone dipropionate 0.64mg,
Allergic dermatitis Cambodia, Ghana, -
Since its foundation in 1984, DAEHWA continuously seeks new paths for its Clotrimazole 10mg, Gentamicin sulfate 1.0mg)
Mongolia
business development with a consistent progress-oriented core-target.
Relief of symptoms of Bolivia, Cambodia,
6. KEBANON Plaster (Ketoprofen 30mg) -
With its own platform technologies, DAEHWA produces APIs and finished muscular pain Hongkong, Vietnam
products. Some of them are: Cephametyl, which is ranked third in the oral Relief of symptoms of
7. LOXONA Plaster (Loxoprofen 56.7mg) Cambodia, Hongkong -
Representative cephalosporin antibiotic market; Flospan, ranked first in the antispasmodic muscular pain
market; and Liporaxel Solution, which is the result of DAEHWA’s 17 year- Respiratory distress
Eun-Seok, Kim
study and which achieved astonishing results proving its efficacy, safety caused by airway
Headquarter Address 8. RESNALIN Patch (Tulobuterol 0.5/1/2mg) Myanmar, China -
and convenience. DAEHWA’s DH-LASED technology created this first oral obstruction of
495, Hanu-ro, Hoengseong-eup, Paclitaxel anticancer drug in the world. bronchial asthma
Hoengseong-gun, Gangwon-do, Republic DAEHWA also developed DH-HERBAL Technology specialized for elderly Treatment of chronic
of Korea people, and represents the biggest unique CMO Company for transdermal 9. BARATIS ODF (Entecavir 0.5/1mg) hepatitis B virus - -
infection
Foundation Date drug delivery system (TDDS) product in Korea.
Wrinkle Made in
1984.01.19 DAEHWA invests more than 10% of its sales into R&D and focuses most 10. Amalian Filler (Hyaluronic acid) Worldwide
improvement Germany
Research Focus of its company resources into the development of QoL products. DAEHWA
API, TDDS, Finished product, etc. currently exports more than 60 products to 20 countries in the world.
DAEHWA runs a representative office in Vietnam, and took over Redoxbio
Total Staff Inc. as well as a German cosmetics & medical device manufacturing and
350 persons R&D Pipeline
distribution company. Consequently, DAEHWA has grown from a middle-
Representative Phone sized Korean company into a global company specialized in pharmaceutical Compound Name Code Use Stage of Development
82-2-6716-1071 products. Breast cancer, Gastric cancer,
Paclitaxel DHP107 Non-small cell lung cancer, Clinical Study Phase II & III
Web
Ovarian cancer
www.dhpharm.co.kr
Jujube extract DHP1401 Dementia Clinical Study Phase II
Contact Person
Han-Woong, Seo Ramosetron DHP26002 Antiemetics New formulation
Contact Phone DHP23007 DHP23007 Antiviral agent New formulation

82-2-6716-1071 DHP32002 DHP32002 Rare disease Pre-Clinical Study
shw0817@dhpharm.co.kr
Fiscal Year 2015 2016 2017
Sales 72,191 81,960 86,204
R&D Expenditure 3,710 5,074 5,470
Capital 30,960 30,960 30,960

Main Products
DAEWON Pharm. Co., Ltd Product (Ingredient) Use

Anti-inflammatory,
Exporting Countries Remarks
*12th Korean
1. Pelubi/Pelubi CR Tab. (Pelubiprofen 30/45 mg) analgesic(RA, OA, BP, Mongolia, Georgia
New Drug
Fever)
Supplementation of Philippines, Nigeria, Export Over
2. Oramin Soft Capsule (Ginseng, Multi Vitamin)
vitamins and minerals Myanmar, Iran, etc 30 Countries
3. T rigel Susp. Vietnam, Cambodia, Export Over
High-potency antacid
(Aluminum hydroxide gel, Magnesium, Oxethazaine) Taiwan, Peru, etc 10 Countries
Company Profile Guatemala, Iran, Export Over
4. Megex-I Susp.(Megestrol acetate) Anorexia and cachexia
Since the establishment in 1958 with a founding idea of “Realization of Colombia, Taiwan 10 Countries
human health”, Daewon Pharm has produced reliable and safe medicines by 5. C odaewon Tab. /Syrup (Dihydrocodeine, Guaifenesin, Potent Antitussives, Hongkong,Mongolia
-
securing world-class manufacturing facilities and superior R&D capabilities. Methylephedrine, etc) Expectorants Cambodia
We, Daewon Pharm is a capable company that has developed new drugs 6. Renamezin Cap.(Oral adsorptive charcoal) Renal failure Taiwan -
using excellent technological basis and manufacturing facility. We are
7. Freefol MCT Inj. (Propofol Inj.) Anesthesia, sedation Ukraine, Syria, Georgia -
devoting ourselves to develop numerous new products to improve the quality
of life, and trying our best to become the representative pharmaceutical Taiwan, Guatemala,
8. Wontran ER Tab.(Acetaminophen, Tramadol) Pure analgesic *IND Drug
company of the Republic of Korea. Hongkong
Representative We, Daewon Pharm has developed Pelubi, Pelubi CR Tab. (pelubiprofen
Seung Ho Baek, Seung Ryel Baek 30mg, 45mg), the first NSID-class antiphlogistic/analgesic drug in Korea.
Hyangnam factory is a new GMP standard applied high-tech facility equipped
Headquarter Address
with excellent infrastructures, and manufactures internal solid dosage forms,
Cheonhodaero 386, Sungdong-gu, Seoul, injections, sex hormone drugs, and other various products.
Korea. R&D Pipeline
Starting from sales expansion to Vietnam in 1994, we are currently exporting
Foundation Date our products to China and 40 other countries in Asia, South America, Compound Name Code Use Stage of Development
January 7, 1958. Middle-East, Africa, and further. By licensing-out new drugs, incrementally
NCE DW-325 Hyperlipidemia -
modified drugs, and high-value original drugs such as Pelubi Tab, Megex-I
Research Focus Suspension(anti-cancer supplement), and Privituss Suspension(antitussive) to NCE BAL-110 Prostate, Cervical Cancer -
DDS Research, New Drug Chronic large pharmaceutical markets like China, Daewon Pharm is preparing another
diseases, Improving dosage forms rapid growth. We are also moving forward to export medical devices such as NCE DW-4301 Hyperlipidemia -
hearing aids. BIO (TERROSA™) Osteoporosis -
Total Staff
870 persons Delight, a subsidiary company specialized in hearing aid business, produces
IMD DW-1404 RHINITIS -
hearing aids using 3D scanner and patented technology called 'standarized
Representative Phone hearing aid.' We provide worldwide customers high performance hearing IMD DW-1501 Hypertension/Hyperlipidemia -
82-2-2204-7000 aids with reasonable price, delivering joy and happiness of hearing.
IMD DW-1502 Neuropathic Pain -
Representative Fax Focus Area : Ethical Drug, Over-the-Counter Drug, Contract Manufacturing,
Medical Instrument IMD DW-1601 Acute Bronchitis -
82-2-499-9110
IMD DW-1606 Osteoporosis -
Web
www.daewonpharm.com
Contact Person
Junggun Park
Contact Phone Financial Figures
82-2-2204-7086
Contact E-mail New Active Substances
Fiscal Year 2015 2016 2017(E)
jgpark45@daewonpharm.com
Sales 216,187 240,722 270,000 Product (Ingredient) Use Approval Date
R&D Expenditure 16,713 18,978 20,000 Anti-inflammatory, analgesic

Pelubi/Pelubi CR Tab. (Pelubiprofen 30/45 mg) -
Capital 194,749 214,682 230,426 (RA, OA, BP, Fever)

Main Products
Daewoong Pharmaceutical Co., Ltd. Product (Ingredient) Use Exporting Countries
Australia, Canada, CIS 12 countries,

EU 28 countries, Hong Kong, Macao,
Glabellar lines, Post stroke,
1. Nabota (Botulinum toxin type A / Injectable) LATAM 15countries, Macao, Middle East
Upper limb spasticity
10 countries, Philippines, South Africa,
Taiwan, Thailand, Turkey, USA, Vietnam
Chile, Columbia, Hong Kong,
Dental sinus lifting,
2. Novosis (rhBMP-2 / Lyophilized Powder) Indonesia, Malaysia, Peru,
Company Profile Spinal fusion
Philippines, Thailand, Vietnam
Daewoong Pharmaceutical was established in 1945 and has Diabetic foot ulcer, Algeria, Armenia, Azerbaijan, Egypt,
become one of the leading pharmaceutical companies in Korea with 3. Easyef (rhEGF / Topical Solution, Ointment) Oral mucositis, Georgia, Iraq, Jordan, Russia, Syria,
approximately 800 million USD in annual revenues. Acute wound healing Turkey, Uruguay
As it is our vision to become a global healthcare group, Daewoong Belarus, Ecuador, Georgia, Hong Kong,
4. Caretropin (Somatropin /Injectable) Growth hormone deficiency
Pharmaceutical has established 3 manufacturing sites in Indonesia Iran, Kazakhstan, Peru, Ukraine, Uruguay
and China and 8 branch offices in China, Japan, Indonesia, Thailand,
Algeria, Azerbaijan, Georgia, Indonesia,
Vietnam, Philippines, India and USA. Thus, we are actively striving to 5. Eposis (rhEPO / Injectable)
Anemia in end stage renal
Iraq, Kazakhstan, Mongolia, Sri Lanka,
export our high value added portfolio to the world. diseases
Representative Syria, Thailand, Turkey, Vietnam
Jongwook Lee As it is our mission to provide the most beneficial total solutions in Concomitant hypertension
pharmaceuticals and services that contribute to improving the quality 6. Olostar (Olmesartan, Rosuvastatin / Tablet) Australia, Canada, Japan, Taiwan, USA
Headquarter Address and dyslipidemia
12, Bongeunsa-ro 114-gil, Gangnam-gu, of life of valued consumers, we have been reinforcing R&D capacities
Azerbaijan, China, Georgia, Iraq, Jordan,
Seoul, Republic of Korea through the establishment of R&D centers globally in Korea, China, Liver & bile disease including
7. Ursa (Ursodeoxycholic acid / Tablet, Capsule) Kazakhstan, Malaysia, Mongolia,
India and Indonesia and focusing on developing new chemical cholestasis, Gallstone, etc.
Philippines, Ukraine, Uruguay, Vietnam
Foundation Date entities, biologics, incrementally modified drugs and high-value
1945. added APIs. Our most recent R&D achievements include the initiation 8. Albis (Ranitidine, Bismuth, Sucralfate / Tablet)
Gastric & duodenal ulcer,
Azerbaijan, Ecuador, Georgia, Vietnam
of Phase II trials for our reversible acid pump antagonist, DWP14012, Gastritis
Research Focus
GI, CV, Neuroscience & Pain, Fibrotic an NCE expected to become the best in its class based on its potent Prostate cancer,
9. L uphere depot
Disease, Immuno-Oncology, Autoimmune acid suppressive effect. Furthermore, we foresee great potential for Endometriosis, Japan, Malaysia, Myanmar, Russia
(Leuprorelin Acetate / Injectable)
DWP17011, a PRS inhibiting anti-fibrosis NCE that has demonstrated Precocious puberty
Disease
both anti-fibrotic and anti-inflammatory effects with a novel MOA, Complicated skin and skin
Total Staff which have been demonstrated in the pre-clinical studies that have structure infections,
1,600 persons been conducted. 10. Meropenem (Meropenem / Injectable) Complicated intra-abdominal USA
Representative Phone infections,
82-2-550-8800 Bacterial meningitis
Web
www.daewoong.com R&D Pipeline
Contact Person
Doyoung (Brian) Kim
APA (Reversible) DWP14012 Gastrointestinal Disease Phase II
Contact Phone
82-2-550-8112 SGLT-2 inhibitor DWP16001 Diabetes Phase I
Financial Figures
Contact E-mail PRS Inhibitor DWP17011 Fibrotic disease Pre-clinical
doyoung.kim@daewoong.co.kr Summary (1 Million Won)
Ion channel blocker DWJ208 Neuropathic pain, cancer pain Pre-clinical
Fiscal Year 2015 2016 2017
Dual Target Inhibitor DWJ212, 213 Autoimmune disease (RA) Research
Sales 800,517 797,010 861,500
R&D Expenditure 99,924 107,993 92,000 Long acting insulin DWP457 Diabetes Research
Capital 492,694 517,660 563,642 Undisclosed Protein DWJ815 Osteoarthritis Research

Main Products
DAI HAN PHARM. CO., LTD. Product (Ingredient) Use

Myelography, angiography, urography, Computerized-
Exporting Countries
Vietnam, Costa Rica,
1. Iohexol Inj. 300 (Iohexol 300mg/50mL)
tomography(CT)-contrast enhancement Philippines
Myelography, angiography, urography, Computerized-
2. Iohexol Inj. 350 (Iohexol 350mg/50mL) Vietnam
tomography(CT)-contrast enhancement
3. Luminal 10% Inj. Sedation (if urgently required), epilepsy and status
Vietnam
(Phenobarbital sodium 100mg/ml) epilepticus
pneumonia, acute pyelonephritis, multiple urinary tract
Company Profile 4. Lefquin Infusion (Levofloxacin 500mg) infection, acute sinusitis, infection of skin and tissue, Philippines, Vietnam
DAI HAN PHARM. Co., Ltd. makes Good Pharmaceutical Products in etc.
the GMP plant, We make Infusions (Bag, Glass bottles), Injections 1. Anesthesia: epidural anesthesia, nerve block, Hong Kong, Philippines,
(PE, PP Ampoules), Solutions for external use and Contrast Media 5. Lidocaine HCL 2% (Lidocaine HCL 2%) infiltration anesthesia and surface anesthesia. Myanmar, Mongolia,
2. Internal medical use: ventricular arrhythmia. Costa Rica
products. We have exported the product since 2005.
Supply of vitamins and prophylaxis of deficiency of Cambodia, Vietnam,
Focus Area : Infusion, Injection, Contrast Media, and Solutions for 6. Pan-B-Comp Inj. (Vitamin B complex)
vitamin B series Philippines
external uses. 1.Prophylaxia and treatment of hemorrhage disease for
Iran, Vietnam,
7. Vitamin K1 Inj. (Phytonadione 10mg/ml) a newborn
Philippines, Myanmar
Representative 2.Hypoprothrombinemia
Yoonwoo Lee 8. O
rni Inj. Vietnam, Azerbaijan,
Hepatic coma, Treatment of precoma
(L-Ornithin L-Aspartate 500mg/1ml) Uzbekistan, Mongolia
Headquarter Address 9. H
eparogen Inj. Detoxication of liver disease(hepatitis and sequela, Vietnam, Azerbaijan,
3 Seonyu-ro 45-Gil Yeongdeungpo-gu (L-Ornithin L-Aspartate 100mg/1ml) tissue damage, hepatic cirrhosis) Mongolia
Seoul Hemorrhage(by leukimia, aplastic anemia, purpura,
10. Tranexamin Inj. 500mg Vietnam, Philippines,
Foundation Date cancer, pulmonary hemorrhage, renal hemorrhage,
(Tranexamic acid 500mg/5ml) Myanmar
Oct. 14, 1945. genital bleeding, etc.)
Treatment and prophylaxis of vitamin B6 deficiency
Research Focus 11. Bidoxin inj. (Pyridoxine HCl 100mg/ml) Costa Rica, Mongolia
symptom
Injections and Infusions 12. Ketorolac Inj.
Severe pain Philippines, Panama
Total Staff (Ketorolac tromethamine 30mg/mL)
621 persons 13. Sod. Bicarbonate Inj. Iraq, Philippines,
Acidosis, Acute pruritus
(Sod. Bicarbonate 8.4%) Costa Rica
Representative Phone Rheumatic arthritis, osteoarthritis,
82-2-2678-8445 14. Piroxicam Inj. (Piroxicam 20mg/ml) Vietnam
ankylosing spondylitis etc.
Representative Fax Disturbance of consciousness by head trauma and
15. Statirin Inj. (Citicoline 500mg/2ml) Vietnam, Myanmar
82-2-2671-9636 surgery of brain etc.
Respiratory tract, ENT infections, renal or urinary tract
Web 16. Ciprofloxacin Inj.
infections, genital infection including gonorrhoea, GI Philippines
www.daihan.com (Ciprofloxacin 2mg/mL)
infections, bone or joint infections, etc.
Contact Person Supply of amino acids in following cases
George Kim 17. Aminohex Inj. (Aminoacid Infusion) (Hypoproteinemia, hypoalimentation, and before/after Vietnam, Mongolia
surgery)
Contact Phone Supply of amino acids in following cases
82-2-2620-8952 Financial Figures 18. Amicomplex Inj. (Aminoacid Infusion) (Hypoproteinemia, hypoalimentation, and before/after Mongolia
surgery)
Contact E-mail
Summary (1 Million Won) Improvement of encephalopathy due to acute/chronic
hskim@daihan.com
Fiscal Year 2015 2016 2017 19. Hepavia Inj. (Aminoacid Infusion) hepatic impairment, supply of amino acids to a patient Vietnam, Mongolia
Sales 124,276 139,437 150,000 with hepatic impairment
R&D Expenditure - - - Relief of bronchial asthmatic paroxysm, symptoms by Costa Rica, Philippines,
20. Epinephrine Inj. (Epinephrine 1mg/ml)
serum disease, hives and angioneurotic edema. Mongolia
Capital - - -

Main Products
Daiichi Sankyo Korea Product (Ingredient)
1. Olmetec (Olmesartan)
Use
Anti Hypertension
Exporting Countries
Imported
2. Olmetec plus (Omesartan + Hydrothiazide) Anti Hypertension Imported
3. Mevalotin (Pravastatin) Anti dislipidemia Imported
4. Sevikar (Olmesartan+amlodipine) Anti Hypertension Imported

Company Profile 5. Cravit (Levofloxacin) Antibiotics Imported
Daiichi Sankyo Korea.,Ltd. is the Korean subsidiary of Daiichi Sankyo 6. Sunrythm (Pilsicainide HCI) Antiarrhythmic agent Imported
Japan, a global Pharmaceutical enterprise. Consolidation of the
Daiichi Pharmaceuticals Co.,Ltd. and Sankyo Co. Ltd., gave birth to 7. Effient (Prasugrel) Antiplatelet agent Imported
Daiichi Sankyo Korea Co.,Ltd. in April 2007, which since its launch
has expanded its domain of expertise from anti-inflammatory area to
cardiovascular area. Daiichi Sankyo Korea offers a fluoroquinolone
antibacterial agent named Cravit, an anti-hypertension agent Olmetec
and sevikar as well as an anti-dyslipidemia agent Mevalotin. The
Representative company will continue to make strides forward to secure a leading
Mr. Dae Jung Kim / CEO status in the pharmaceutical industry by leveraging and further
Headquarter Address diversifying its product offerings.
Posco Center west wing 3rd floor, Daiichi Sankyo
Daechi4-dong 892, Kangnam gu. Seoul
The Daiichi Sankyo Group is dedicated to the creation and supply of
Foundation Date innovative pharmaceutical products to address the diversified, unmet
July 16, 1990. medical needs of patients in both mature and emerging market.
Total Staff While maintaining its portfolio of marketed pharmaceuticals for
122 persons hypertension, hyperlipidemia, and bacterial infections, the Group is
engaged in the development of treatments for thrombotic disorders
Representative Phone and focused on the discovery of novel oncology and cardiovascular-
82-2-3453-3300 metabloic therapies. Furthermore, the Daiichi Sankyo Group has
Representative Fax created a "Hybrid Business Model" which will respond to market and
82-2-3452-9756 customer diversity and growth opportunities across the value chain.
For more information, please www.daiichisankyo.com
Web
www.daiichisankyo.co.kr
Financial Figures
Fiscal Year 2008 2009 2010
Sales 36,300 50,200 56,700
Capital - - -

Main Products
Dalim BioTech Co., Ltd. 1. M

etformin hydrochloride 500mg

Azerbaijan,
Remark
World 1st combination of

Oral hypo-glycemics
+ Gliclazide 80mg Tab Uzbekistan Metformin HCl + Gliclazide
2. Repaglinide 0.5mg/1mg/2mg Tab Oral hypo-glycemics - World 1st generics
3. R epaglinide 1mg/2mg
Oral hypo-glycemics - World 1st generics
+ Metformin HCl 500mg Tab
Company Profile
Dalim Biotech is a family company of Dalim Corporation Co., Ltd, 4. Norepinephrine bitartrate 2mg/1ml Amp Acute hypotension,
Thailand -
started to produce the medicines at first hand that were released (Norepinephrine 4mg/10mg/20mg) Shock
by importation or production partnership after it was established in 5. C onjugated equine estrogens Postmenopausal
2001, and concentrated on the area of endocrinology led by diabetes - World 1st generics
0.3/0.625mg Tab syndrome
to affirm its position as the best company specializing in the area
of diabetes despite a short time. Moreover, it came to produce and 6. Tibolone 2.5mg Tab
Postmenopausal
-
apply hormone preparations at first hand which have depended syndrome
on importation only by completing the construction of building to Produced by Dalim BioTech’s
Representative 7. D
esogestrel 0.15mg
exclusively produce sex hormone site in 2006. Contraceptive - facility (Dedicated sex
Jong sup Chung + Ethinyl Estradiol 0.02mg Tab
hormonal premiss)
Headquarter Address Emergency
8. Levonorgestrel 1.5mg Tab -
107, Jeyakgongdan 3-gil, Hyangnam-eup, contraceptive
Hwasung-si, Gyeonggi-do, Korea,
Solely produced by Dalim
9.Carbimazole 5/10mg Tab Hyperthyroidism -
Foundation Date BioTech in Korea
2001.
10.Cholecalciferol concentrate powder 10mg
Research Focus Tab.(Cholecalciferol 1,000IU)
Highest strength of Vitamin D
Endocrinology(Diabetes, Thyroid, Sex Cholecalciferol concentrate powder 70mg
Vitamin D deficiency - (Cholecalciferol 30,000IU) in
hormone), Vitamin D Tab (Cholecalciferol 7,000IU)
Korea
(Finished Pharmaceutical Products) Cholecalciferol concentrate powder 300mg
Tab (Cholecalciferol 30,000IU)
Total Staff
200 persons Diabetic neuropathy,
11. Evening primrose oil 450mg Soft cap.
Atopic eczema, - Developed 1st in the world
Representative Phone ( -linolenic acid 40mg)
Breast pain
82-2-3140-3787
Web
www.dalimpharm.co.kr
Contact Person
Mr. Mark Choi
Contact Phone
82-2-3140-3787
Financial Figures
Contact E-mail
plan787@dalimpharm.co.kr Summary (1 Million Won)
Fiscal Year 2015 2016 2017
Sales 29,345,548 31,469,565 35,00,000
R&D Expenditure 1,746,84 1,416,375 2,000,000
Capital 500,000 500,000 500,000

Main Products
DHP KOREA CO.,LTD. Product (Ingredient) Use Remarks
· P reservative-free, 30 Single Dose

1. T earinfree EYE DROPS Keratoconjuntival epithelial disorder with Units per Box
(Sodium Hyaluronate 0.1%) symptoms following : · 6 mL Multi Dose Bottle
1. E ndogenous disease: Sjogren syndrome,
2. T earinS EYE DROPS Dry eye syndrome. · P reservative-free, 30 Single Dose
(Sodium Hyaluronate 0.18%) 2. E nthetic disease: Drug-induced trauma Units per Box
after operation, Enthetic disease due to
Company Profile 3. T earinF EYE DROPS wearing contact lenses. · P reservative-free, 30 Single Dose
(Sodium Hyaluronate 0.3%) Units per Box
DHP KOREA was created for the purpose of being an special
company in the field of ophthalmic drugs. As the leading ophthalmic · F or the temporary relief of burning,
drugs company in Korea, DHP KOREA seeks to be a world-class that irritation, and discomfort due to dryness of
4. D
r.Fresh EYE DROPS · P reservative-free, 30 Single Dose
continuously tries to meet customer’s need by offering safe and the eye or exposure to wind or sun.
(Sodium Carboxymethylcellulose 0.5%) Units per Box
stable drugs. Also, we make constantly effort to comfort demand ·M ay be used as a protectant against further
irritation.
of various customers, through ceaseless produce and offer more
developed products. · F or the increase tear production in patients
Focus Area : Ophthalmic Drugs whose tear production is presumed to be · P reservative-free, 30 Single Dose
Representative 5. DryFree EYE DROPS (Cyclosporine 200ug)
suppressed due to ocular inflammation Units per Box
Yoeu Daehoon associated with keratoconjunctivitis sicca.
Headquarter Address
· Open angle glaucoma
1106 starvalley, 99, Digital-ro 9-gil, . F or the reduction of elevated intraocular
Geumcheon-gu, Seoul, Korea 6. T earsopt Free EYE DROPS (Dorzolamide · P reservative-free, 10 Single Dose
pressure in patients with open-angle
HCl 22.26mg Timolol Maleate 6.83mg) Units per Box
Foundation Date glaucoma or ocular hypertension who are
insufficiently responsive to beta-blocker.
August. 30, 2005.
Research Focus · P reservative-free, 10 Single Dose
7. Floson EYE DROPS (Fluorometholone 1mg) . To treat eye inflammation
Ophthalmic Drugs (Dry eye, Anti- Units per Box
glaucoma, Anti-allergy/inflammatory/
. F or the allergic, noninfectious conjunctivitis
infective, etc) & keratitis, severe swelling & hyperaemia,
Total Staff noninfectious inflammation of the anterior
110 persons 8. F lotera EYE DROPS (Fluorometholone segment of the eye (including anterior · P reservative-free, 10 Single Dose
1mg, Tetrahydrozoline HCl 250ug) uveitis, episcleritis & scleritis) and post- Units per Box
Representative Phone operative conditions.
82-2-2027-0078 . Inflammation after operation (glaucoma,
cataract)
Representative Fax
82-2-2027-0079 . T o treat by helping to kill the bacteria which
9. LevoFresh EYE DROPS (Levofloxacin 0.5%) · 6 mL Multi Dose Bottle
are causing the infection.
Web
http://www.dhpkorea.co.kr · Tired Eyes
· P reservative-free, 30 Single Dose
Contact Person 10. SmileO2Tears EYE DROPS (Sodium Chloride · Dryness
Units per Box
Ko Jin-Sook 5.5mg, Potassium Chloride 1.5mg) · Contact Lens Discomfort
· 15 mL Multi Dose Bottle
Financial Figures · Dimed Eyes
Contact Phone
82-43-230-0304 Summary (1 Million Won) · P reservative-free, 10 Single Dose
11. Allervid EYE DROPS · T o treat itching associated with allergic
Fiscal Year 2012 2013 2014 Units per Box
Contact E-mail (Olopatadine HCl 1.11mg) conjunctivitis.
· 6 mL Multi Dose Bottle
jsko@dhpkorea.co.kr Sales 21,870 26,850 32,566
R&D Expenditure 181 245 342 12. KetofinFree EYE DROPS · T o treat itching associated with allergic · Preservative-free, 30 Single Dose
Capital 7,490 44,914 56,716 (Ketotifen Fumarate 552ug) conjunctivitis. Units per Box

Product (Ingredient) Use Remarks
13. FINECLE EYE DROPS (Chondroitin

Sodium Sulfate 2mg, Cyanocobalamin
· Dryness
· Redness DongKoo Bio&Pharma Co., Ltd.
· Gritty Feeling/Foreign Body Sensations
100ug , Dipotassium Glycyrrhizinate · Preservative-free, 30 Single Dose
· Photophobia (sensitivity to light)
1.5mg, Naphazoline HCl 20ug, Units per Box
· Itching
Panthenol(pantothenol) 500ug,
· Blear Eyes/Dimed Eye
Pyridoxine HCl 500ug)
· Hard Contact Lens Discomfort
14. one&day FRESH EYE DROPS

· Tired Eyes Company Profile
(Chondroitin Sodium Sulfate 5mg, Hydr
· Dryness · Preservative-free, 30 Single Dose
oxypropylmethylcellulose(hypromellose)
2910 3mg, Potassium Chloride 800ug,
· Hard Contact Lens Discomfort Units per Box Since 1970, DongKoo Bio&Pharma Co., Ltd. has been evolving into a
· Dimed Eyes global healthcare leader. DongKoo Bio&Pharma, consolidated with
Sodium Chloride 4.4mg)
world-class research centers and PIC/s fulfilled GMP facilities, is in
15. Eyemarine EYE DROPS vigor expanding its commercial territories to global markets in the
(Aminocaproic acid 10mg, · Epidemic[contagious] Conjunctivitis a stye
· Preservative-free, 10 Single Dose
field of generic drugs and contract manufacturing. The company is
Dipotassium Glycyrrhizinate 2mg, · Itching also growing its influence in stem cell technology, developing world
Units per Box
Sulfamethoxazole Sodium 40mg, · Blear Eyes/Dimed Eye 1st SVF extraction kit (SmartX) and stem cell conditioned media
Taurine(aminoethylsulfonic acid) 2mg) cosmeceutical (CELL BLOOM). With synergy between bio technology
Representative and pharmaceutical, DongKoo Bio&Pharma pursues a total healthcare
16. Predia EYE DROPS (Phenylephrine HCl · Mydriasis required treatment or · Preservative-free, 30 Single Dose
Yong Joon, CHO solution that contributes in improving people’s quality of life.
5mg, Tropicamide 5mg) Accommodative Units per Box
Headquarter Address
B-14F, Mstate, 114, Beobwon-ro, Songpa-
gu, Seoul, South Korea
Foundation Date
May 1st, 1970.
Total Staff
R&D Pipeline
217 persons
Code Use Stage of Development
DHPNP01 Dry Eye Plant scale process development 82-2-2684-5421
DHPNP02 Dry Eye Plant scale process development Web

www.dongkoo.co.kr
DHPNP03 Glaucoma Lab-scale process development
Contact Person
DHPNP04 Glaucoma Formulation development Ji-Yong, Park
Contact Phone
DHPNP05 Allergic conjunctivitis Formulation development
82-2-2684-5421 (Ext:387)
DHPNP06 Cataract Formulation development
Contact E-mail
jyp@dongkoo.co.kr
Financial Figures
Fiscal Year 2015 2016 2017
Sales 80,369 87,363 102,500
R&D Expenditure 3,929 4,116 6,125
Capital 2,409 3,414 3,811

Main Products
1. Dermotasone MLE Cream

Dongkook Pharmaceutical Co., Ltd.
Inflammation reacting to corticoide ASEAN
(Mometasone Furoate1mg/g)
2. Uropa SR Tablet 0.2 mg|
BPH ASEAN
(Tamsulosin HCl 0.2mg)
3. Heparos Soft Capsule
Hepatic function supplement ASEAN
(L-cystine 250mg, Choline Bitartrate 250mg)
Company Profile
4. Cernilton Tablet
BPH, CP/CPPS ASEAN
(Cernitin T60 60mg, Cernitin GBX 3mg) Dongkook Pharmaceutical was founded in 1968 and from the early
stage since its foundation, Dongkook has concentrated on R&D and
5. A-Clo Cream
Herpes Labialis ASEAN technology innovation.
(Acyclovir 50mg, Hydrocortisone 10mg)
We, Dongkook Pharmaceutical is well known for its OTC products
6. A.C. Cure MLE Gel
Acne ASEAN boasting of high brand values in Korea. Besides OTC products,
(Benzoyl Peroxide 33.3mg/g, Adapalene 1mg/g)
Dongkook has developed and produced outstanding therapeutic
7. Amepox Soft Capsule (L-Cystine 500mg) Acne ASEAN products through various clinical trials, e.g. Pofol Injection,
8. Betatriol Ointment Representative intravenous anesthetic agent, and Lorelin Depot, an anti-cancer
(Betamethasone Dipropionate 0.643mg/g, Psoriasis ASEAN Hung Joo, Oh agent, earning raves in both domestic and overseas markets.
Calcipotriol 50ug/g)
Headquarter Address Dongkook completed its registration in PMDA of Japan regarding
7, Teheran-ro 108-gil, Gangnam-gu, Seoul, GMP approval and product registration for the finished product such
9. Priga Capsule (Pregabalin) Central, peripheral neuropathic pain ASEAN
Korea as Antibiotic agent, and anesthetic agent. Teicoplanin acquired
COS(Certificate of Suitability) in 2009 from EDQM, and also
Lactation prevention and inhibition, Foundation Date completed the GMP approval in TGA of Australia in 2010.
10. Caverlactin Tablet (Cabergoline 0.5mg) ASEAN
hyperprolactinemia Oct, 1968.
Currently, Dongkook Pharmaceutical exports finished pharmaceutical
Research Focus products and API to over 50 countries around the world. It seeks to
Nano-emulsions, Long-acting release, grow into a global leading pharmaceutical company that is trusted
Liposomal drug, HA dermal filler, and loved by all domestic and overseas customers backed by the
Antibiotics, etc. greatest global competitiveness.
R&D Pipeline
Total Staff Focus Area : Nano-emulsions, Long-acting release, Liposomal drug,
Compound Name Code Use Stage of Development 718 persons HA dermal filler, Antibiotics, etc.
- DKB15001 BPH Completed non-clinical study Representative Phone
82-2-2191-9800
Omega3+ Atorvastatin DKB15003 Hyperlipidemia DDI
Representative Fax
82-2-2191-9869
Web
www.dkpharm.co.kr/english
Contact Person
Ms. Eugene Jang
Financial Figures
Contact Phone
Fiscal Year 2016 2017 2018
Contact E-mail
jeg@dkpharm.co.kr Sales 304,408 323,496 356,829
R&D Expenditure 10,414 12,271 17,049
Capital 22,230 22,230 22,230

Main Products
Product (Ingredient/Formulation)) Use Exporting Countries
Japan, Brazil, Uruguay, Russia,
Dongkwang Pharm. Co., Ltd.
1. Profofol Injection General Anaesthesia Georgia, Iran, UAE, Iraq,
Philippines, Thailand, etc.
Mexico, Peru, Uruguay, India,
2. Leuprolide Acetate Injection Prostatic Cancer Endometriosis
Iran, Pakistan, Kazakhstan, etc.
3. Octreotide LAR lnjection Acromegaly Carcinoid Tumors Chile, Peru, etc.
Injectable implant for filling wrinkles Peru, Mexico, Georgia, Company Profile
4. Cross-linked Hyaluronic Acid Injection
and folds in skin Indonesia, Philippines, Syria, etc.
Dongkwang has been contributing to advancement of pharmaceutical
5. Sodium Hyaluronate Injection Osteoarthiritis Under registration
industry by developing pharmaceutical products for over the past 60 years
Austrailia, Japan, Spain, France, since its establishment in 1952. We are always striving for 'Fulfillment of
6. Teicoplanin(API) Antibiotics UK, Begium, Brazil, Greece, Human Health and Human Happiness' with 3 ideas of its philosophy.
Turkey, Tunisia, Ukraine, etc.
One of the 3 ideas is, leading the pharmaceutical industry with a clear sense
7. Liposomal Amphotericin B Injection Antibiotics Ready to launch of duty. Dongkwang is committed to be the leading company based on the
values of sincerity, passion and creativity.
The second is, making efforts to realize a welfare society for the public. We
8. Daptomycin(API) Antibiotics Ready to launch Representative
are constantly manufacturing high-quality medicines to make human life
ByungGil Yoo healthy and happy with a sense of duty.
Foundation Date Lastly, enabling the growth of individuals and the company with outstanding
Sep. 1952 creativity. It means all members of the company maximize their abilities to
Research Focus contribute to not only growth of the company, but also national development.
R&D Pipeline
Injectable production line With this philosophy, we have been investing in the production facilities and
Compound Name Code Use Stage of Development focusing on the R&D to supply excellent pharmaceutical products for people.
Total Staff
And Dongkwang has various product line-ups, in total approximately 170
Daptomycin Injection DKF3152 Antibiotics Process validation 365 persons kinds of products. Moreover, we are exporting good-quality medicines to over
Representative Phone 10 countries and fulfilling the values of Dongkwang around the world.
Liposomal doxorubicin DKF3151 Ovarian cancer treatment Formulation
82-2-776-7641 Based on all these mentioned above, we will accomplish the vision of 'first or
Donepezil Depot Injection DKF310 Alzheimer treatment Formulation best' and pioneer the future.
Representative Fax
Aripiprazole Depot Injection DKF002F Major tranquilizer Formulation 82-2-776-1204 Focus Area : Injectables production line
* Equipped with prefilled syringe system
Web * Equipped with freeze-drying line
Dutasteride + Tadalafil Combo DKF331 Protestitis treatment Formulation
www.dkpco.co.kr
Nonsteroidal anti-inflammatory Contact Person
Risedronate + Vit D3 solution DKF335 Formulation
Ulcer treatment drug
Junku Shim
Long acting cross-linked Injectable implant for filling Contact Phone
DKF352 Formulation
hyaluronic acid injection wrinkles and folds in skin 82-2-776-7641 (ext.153)
Contact E-mail
trade@dkpco.co.kr
Financial Figures
Fiscal Year 2015 2016 2017
Sales 83,458 93,194 -
Capital 15,000 15,000 -

Main Products
Product (Ingredient/Formulation)
1.Aragan Injection
DONGWHA PHARM
(sodium hyaluronate 25mg/2.5mL)
Pre-filled
Osteoarthritis 6 countries
syringe
2.Aragan Plus Injection
(sodium hyaluronate 20mg/2mL)
Corticoid reactive skin

3. Silkron Cream
(Betametasone dipropionate 0.64mg,
disease where infection is
2 countries Ointment Company Profile
concerned, bacterial or fungal
Clotrimazole 10mg, Gentamycin sulfate 1mg) DONGWHA PHARM, as Korea’s first and oldest pharmaceutical
infection
company, is pursuing the ultimate goal of pharmaceutical industry,
which is the development of new drugs.
Whal Myung Su, Korea’s first western-style medicine, by integrating
the advantages of Western medicine into the royal court’s secret
recipe in 1897, the first year of The Great Korean Empire.
Furthermore, many pharmaceutical products such as Fucidin ointment
Foundation Date and Pancold A etc., have been developed after DONGWHA PHARM.
1897.09.25 Research Institute was founded in 1973. Since present state-of-the-
art laboratory building was built in 2010, it is now set to become a
Research Focus global hub for new drug development. The DONGWHA Chungju Plant
Antibiotic, Cancer, New Herbal Drug (established in 2009) is equipped with equipment and facilities that
Total Staff satisfy Current Good Manufacturing Practice (cGMP) Regulations of
687 US F. D. A. In addition, the plant has been evaluated as a world-
class pharmaceutical company by the installment of high-tech plant
Representative Phone automation system. Utilizing multi-component resources, DONGWHA
82-2-2021-9300 strategizes to develop numerous superior medicines, the most
Web advanced drugs and new pharmaceutical products.
http://www.dong-wha.co.kr
Contact Person
Yoon Kyung Kim, Director, Global Business
Team
Contact Phone
82-2-2021-9341
Contact E-mail
yoonkyung.kim@dong-wha.co.kr
Financial Figures
Fiscal Year 2015 2016 2017
Sales 223,201 237,470 257,200
R&D Expenditure 13,329 13,717 14,000
Capital 27,931 27,931 27,931

Main Products
Product (Ingredient/Formulation) Use Exporting Countries
Japan, Indonesia, Mexico,

Dong-A ST(Science & Technology)
1. Ambroxol Hydrochloride API
Philippines
2. Pantoprazol Sodium Sesquihydrate API Portugal, Indonesia
3. Levosulpiride API Spain
4. Whal Myung Su Alimentary System USA, Mongolia
5. M-Cobal 500 90C (mecobalamin/Capsule) peripheral neuropathy Vietnam Company Profile
The relief of common cold Dong-A ST focuses on drugs, such as domestically developed new
6. Pan Cold-S(Oral Solution) Mongolia, Cambodia drugs like Stillen, Zydena, and Motilitone, medical devices, diagnosis,
symptoms
and overseas businesses.
7. Silmazin1%Cream (silver sulfadiazine) burn, bedsore, skin ulcers Mongolia
With its optimized research infrastructures such as its world-class,
sophisticated research center completed in 2011, as well as its
excellent researchers, Dong-A ST is furthering its efforts to develop
global new drugs. Also, with the backing of these infrastructures,
R&D Pipeline Representative Dong-A ST vows to positively explore overseas markets, to expand its
Chan-il Park overseas exports, and to establish itself as a global pharmaceutical
0company, operating beyond the domestic market.
Zabofloxacin Acute Exacerbations of Chronic Launched in Korea. Headquarter Address
DW224 Focus Area : Manufacture of ETC drug, overseas business, medical
(Quinolones Antibiotics) Obstructive Pulmonary Disease Signed Agreement in MENA and China. 64, Cheonho-daero, Dongdaemun-gu,
Seoul, Korea equipments and diagnostics
Zabofloxacin
- Community acquired pneumonia Clinical preparation
(Quinolones Antibiotics) Foundation Date
DW1018 DW1018 breast cancer Phase I March. 2013
DW1017 DW1017 AML Candidate Research Focus

New drugs
DW2005 DW2005 Overactive bladder Preclinical completed
Total Staff
DW2007 DW2007 ulcerative colitis Phase II 1,582 persons (R&D Personnel : 212)
DW2008 DW2008 asthma Preclinical completed Representative Phone
DW6008 DW6008 pain Phase I 82-2-920-8114
DW6009 DW6009 antiplatelet Phase I Representative Fax

82-2-926-9400
DW6010 DW6010 dementia Phase I
Web
DW2009 DW2009 Mild cognitive impairment Clinical study http://en.donga-st.com
DW2010 DW2009 Anti-Obesity Clinical study Contact Person
Geunsung Kim
Contact Phone
Contact E-mail
Summary ((1 Billion Won)
New Active Substances e2110576@donga.co.kr
Fiscal Year 2012 2013 2014
Product (Ingredient) Use Approval Date
Sales - 594.6 568.1
Acute Exacerbations of Chronic R&D Expenditure - 525 627
Zabofloxacin 2015.03.20./Korea
Obstructive Pulmonary Disease Capital - 925.7 1,077.9

Main Products Ingredient Code Use Stage of Development
Ph II completed(Korea)
Product (Ingredient/Formulation) Use Exporting Countries Remarks Herbal extract DA-9801 Diabetic neuropathy
Ph II completed(USA)
1. Growtropin II ®inj/AQ/cartridge Brazil, Iran, Peru, Bio- Herbal extract DA-9803 Alzheimer's disease Non-clinical(Korea)
Human growth hormone
(somatropin/injection) Colombia, Mexico pharmaceutical
Herbal extract DA-9805 Parkinson's disease Non-clinical(Korea)
Turkey, Thailand,
Bio- Recombinant Follicle Controlled Ovarian Hyper-stimulation
2. Eporon®inj./PFS (erythropoietin/injection) Renal anemia treatment Chile, vietnam, DA-3801 Launched(Korea)
pharmaceutical Stimulating Hormone in Assisted Reproductive Technology
Pakistan
Recombinant Follicle Ovulation induction in anovulatory
DA-3801 NDA submitted(Korea)
3. Atorvastatin Hyperlipidemia treatment Japan APIs Stimulating Hormone women
Recombinant human
DA-3803 Infertility Ph III completed(Korea)
4. Cycloserine Tuberculosis treatment India APIs Chorionic Gonadotropin
PEG-G-CSF(Pegylated-
5. Terizidone Tuberculosis treatment South Africa APIs Granulocyte-Colony DA-3031 Neutropenia NDA approved(Korea)
Stimulating Factor)
6. Closerin® (Cycloserine/Capsule) Tuberculosis treatment Europe Ethical drug G-CSF(Granulocyte-Colony-
DA-3030 Diabetic neuropathy Ph II completed(Korea)
Stimulating Factor)
Brazil, Turkey,
7. Zydena® (Udenafil/Tablet) Erectile Dysfunction Russia, Malaysia, NCE Interferon- DA-3051 Multiple sclerosis Ph III planned(Brazil)
India Trastuzumab biosimilar DMB-3111 Breast cancer Ph I completde(Japan)
8. Monotaxel®inj. Recombinant Factor
Anti-Malignant tumor Drug EU approval Ethical drug DA-3808 Hemophilia A Non-clinical(Korea)
(Docetaxel anhydrous/Injection) biosimilar
Etanercept biosimila DMB-3853 Rheumatoid arthritis Non-clinical(Korea)
9. Bacchus®
Energy Drink Cambodia -
(Taurine, Royal Jelly and others/Drink) Adalimumab biosimilar DMB-3113 Rheumatoid arthritis Non-clinical completed(UK)
Glyco-engineered
DA-3880 Anemia of chronic renal failure Ph I completde(EU)
Darbepoetin- biosimilar
New anti-VEGF mAb DA-3131 Age-related macular degeneration Non-clinical completed(Korea)
R&D Pipeline
Launched(Korea)
Udenafil DA-8159 Erectile Dysfunction
Ready to NDA(USA)
Udenafil DA-8159 Benign Prostatic Hyperplasia Ph II completed(USA) New Active Substances
Udenafil DA-8159 Pulmonary Arterial Hypertension Ph II (Korea) Product (Ingredient) Use Approval Date/Country
Launched(USA)
Tedizolid DA-7218 Infection: ABSSSI Zydena(Udenafil) Erectile Dysfunction Dec. 2005/Korea
NDA approved (EU)
Tedizolid DA-7218 Pneumonia: HA/VAP Ph III (Global) Jun. 2014/USA
Sivextro(Tedizolid) Infection: ABSSSI
Apr. 2015/Korea
Evogliptin DA-1229 Type2 diabetes NDA submitted(Korea)
5-Hydroxytryptamine4 Irritable Bowel Syndrome-
DA-6886 Ph I completde(Korea)
agonist Constipation
M3 receptor antagonist DA-8010 Overactive bladder Non-clinical(Korea)
SARM(selective androgen
DA-4210 Sarcopenia Non-clinical(Korea)
receptor modulators)
GPR119 agonist DA-1241 Type 2 diabetes Non-clinical(Korea)
Launched(Korea)
Herbal extract DA-9701 Functional dyspepsia
Ph II planned(USA)

Main Products
Dongsung Bio Pharm 1. D

ong Sung Cheong Ro Hwan

(In 1 pill Creosote 44.4mg, Cyperus rhizome powdered 16.6mg, Dyspepsia, watery stool,
U.S.A
Coptidis rhizoma powder 22.2mg, Glycyrrhiza powder 22.2mg, vomiting and diarrhea
Citrus unshii pericarpium 22.2mg)
2. Dong Sung Cheong Ro Hwan (Sugar Coated Tablet)

Dyspepsia, watery stool,
(In 1 tab. Creosote 22.5mg, Pulvis phellondendri corticis 33.75mg, U.S.A
vomiting and diarrhea
Company Profile Pulvis geranil herbae 25mg)
Company introduction Parodontopathy,

3. Teethrol (In 1 tab. Zea mays L. extract 35mg) U.S.A
Gingivitis, Parodontosis
Founded in 1957, Dongsung pharmaceutical has led 60 years to
be a mid-size pharmaceutical. We have taken the lead for the 4. Teethran periodontal disease,
modernization of pharmaceutical industry by establishing KGMP (In 1 cap. Tocopherol acetate 50% 10mg, Carbazochrome 2.0mg, pyorrhea alveolaris
U.S.A
factory and central research center with high end facility in Asan, Lysozyme chloride 30.0mg, Ascorbic acid coated 96% Type SC (erythema, swelling,
Chungnam. We have international competitiveness by producing high 156.3mg ) hemorrhage, pus etc.)
quality medical product through strict quality control and the high
quality hair dye through accumulated new technology. 5. Livermarine
Representative chronic liver disease, fatty
(In 1 cap. Carduus marianus L. seeds extract 200mg, Calcium
Lee Yang-Gu liver, liver cirrhosis, toxic liver U.S.A
Company philosophy pantothenate 8mg, Cyanocobalamin 1.2 , Nicotinamide 12mg,
disease
Headquarter Address Pyridoxine hydrochloride 4mg, Thiamine nitrate 4mg )
'Health from Nature', the health and beauty searched in the nature,
683, Dobong-ro, Dobong-gu, Seoul, means the realization of health and beauty through value discovery Improvement of muscle
Republic of Korea from nature and coexistence with nature. 6. EMG
spasm that runs out of U.S.A
(In 1 cap. Tocopherol acetate 500mg, Magnesium oxide 250mg)
Foundation Date magnesium
Dongsung pharmaceutical are dedicating to nature friendly products
November. 25,1957 development in the various fields of pharmaceuticals, cosmetics, Organic brain dysfunction
Research Focus hair dye and photodynamic therapy under the corporate philosophy accompanying athymia
OTC 'Health from Nature'. symptoms such as tinnitus,
7. GinKolin (In 1 cap. Ginko leaf extract 120mg) headzche, memory U.S.A
Total Staff We will realize the product which can contribute the national health
impairment, attention
342 persons with the vision orienting 100 years corporate and the material impairment, depression,
founded in the nature as a future growth engine. vertigo
82-2-6911-3600 Corporate motto
keratodermia tylodes
Web Dongsung pharmaceutical makes harmony, sincerity and creativity palmaris progressive
as corporate mottos which have been the foundation of corporate (housewife`s eczema),
dongsung-pharm.com 8. You Green F (In 1g, Urea 250mg) U.S.A
management by progressively succeeding them up to now from the keratodermia, ichthyosis,
Contact Person company foundation. senile xeroderma, lichen
Ji Sun Na pilaris, atopic dermatitis
Contact Phone Construction feeling of eye,

82-2-6911-3673 9. Syan Bone defectiveness,
(In 1 Cap. Retinol palmitate 2mg, Ergocalciferol 200IU, Copper Night blindness, U.S.A
Contact E-mail Chlorophyll 0.3mg, Snake oil 296.7mg) Rickets prevention,
jna8911@gmail.com Financial Figures Vitamin A and D supplies
Summary (1 Million Won) Problems with the circulation

Fiscal Year 2015 2016 2017 10. Vaso-Q of the blood : decreasing
(In 1 cap. Crataegus oxyacantha fruit dried extract 50mg, Garlic of memory, enervation, and
Sales 74,660 79,720 84,700 U.S.A
oil 150mg, Ginkgo Biloba Leaf Extract 5mg, Melissa leaf extract concentration becomes
R&D Expenditure 4,078 3,201 4,000 10mg ) worse, dizziness, chronicity
Capital 124,116 125,386 126,000 tiredness

Main Products
Elyson Pharmaceutical Co. Ltd. Product (Ingredient/Formulation)
1. Niferon CR tablet 40mg (Nifedipine)

Use
Hypertension
Exporting Countries
-
Remarks
2. Molsiton tablet 2mg/4mg (Molsidomine) Anti-anginal Drug - -
3. Oxiklorin tablet 100mg/150mg/200mg/300mg Rheumatoid arthritis, Malaria

- -
(Hydroxychloroquine sulfate) and malaria prophylaxis
Company Profile Hypertension, angina,

Treatment of stable chronic
Elyson Pharm was founded in 2011 as thinking patient very first and 4. C onbloc tablet 1.25mg/2.5mg/5mg/10mg
heart failure with reduced - -
conducting research and development for improvement of national (Bisoprolol fumarate)
systolic left ventricular
health and the quality of life. function
Elyson Pharm as a company specialized in cardiovascular disorders, 5. N
ebistol tablet 2.5mg/5mg Essential Hypertension,
strives to develop new global medicine by constant investment to - -
(Nebivolol hydrochloride) Chronic heart failure
R&D, and we do our best for national health with all of one heart of
passion.
Representative
Eul Won Dhong
Headquarter Address R&D Pipeline
2F Kyungpoong building, 18, Nonhyeon-ro
64-gil, Gangnam-gu, Seoul, Korea
Nebivolol+Rosuvastatin EL-1401 Hypertension+Hyperlipidemia phase III
Foundation Date
Oct. 2011
Research Focus
Cardiovascular disease
Total Staff
35 persons
82-2-6342-7001
Web
www.elyson.co.kr
Contact Person
Jae Jin Jung
Contact Phone
82-2-6342-7001
Contact E-mail
elyson@elyson.co.kr Financial Figures
Fiscal Year 2015 2016 2017
Sales 8,601 9,544 14,000
R&D Expenditure 689 870 900
Capital 1,000 1,000 1,000

GC Pharma
Company Profile
GC Pharma (formerly known as Green Cross Corporation) is a 1995 China Growth
biopharmaceutical company that delivers life-saving and life-
sustaining protein therapeutics and vaccines. Headquartered in South GC China is established to support increased demand for albumin and future growth in China.
Korea, GC Pharma is the largest plasma protein product manufacturer 2008 GreenGene Approved
in Asia and has been dedicated to quality healthcare solutions more
GreenGene, GC Pharma’s first recombinant factor VIII product for haemophilia A was granted marketing authorisation in
than half a century. Green Cross Corporation updates its corporate
Korea.
brand as GC Pharma in early 2018. Green Cross Corporation remains
the company's registered, legal name. 2012 Rare Treatment Option
Representative
Eun-Chul Huh 1971 Korea’s First Human Plasma Fractionation The KFDA granted marketing approval for HUNTERASE, the world’s second therapy for the treatment of Hunter syndrome.
Headquarter Address GC Pharma is the first company in Korea to begin fractionating 2014 Another Flu Vaccine Milestone : Green Cross’s manufacturing site in Hwasun, Korea reaches 100 million doses of
107, Ihyeon-ro 30beon-gil, Giheung-gu, plasma proteins from human plasma on an industrial scale. cumulative GCFLU, flujab, production in only five years of operation.
Yongin-si, Gyeonggi-do, Republic of Korea 1974 Pioneering Haematology 2015 Expanding Plasma Business
Foundation Date GC Pharma starts to produce Antihaemophilic factor (AHF) and the To support global demand of plasma products, Green Cross establishes a manufacturing site in Thailand for the Thai Red
1967 resulting therapies are provided free to Korean patients. Cross.
Research Focus 1982 First IV Immunoglobulin New Flu Vaccine
Biological Products
GC pharma launches IV-Globulin in Korea, the county’s first purifies GCFLU QUARDRIVALENT, the only locally produced seasonal influenza vaccine in Korea, achieves MFDS approval.
Total Staff immunoglobulin product for intravenous infusion
2,000 persons 2017 Capacity for the Future
1983 Hepatitis B Triumph
Representative Phone GC Pharma announces major global business expansion plans in Canada. A new biotech facility will help meet future
82-31-260-9300 After a 12 year research and development, GC Pharma launches demand for plasma-derived products.
Hepatitis B vaccine, HEPAVAX.
Web
http://www.globalgreencross.com 1993 New Varicella Vaccine Introduced
http://www.greencross.com SUDUVAX is introduced as the world’s second varicella vaccine
Contact Person option.
Byung Lim Lee
Contact Phone
82-31-260-9300 / 0848
overseas@greencross.com
bllee@greencross.com Summary (1 Million Won)
Fiscal Year 2015 2016 2017
Sales 912,911 1,033,114 1,098,479
R&D Expenditure 92,509 101,893 96,814
Capital 58,433 58,433 58,433

Main Products R&D Pipeline
Product (Ingredient/Formulation) Use Exporting Countries Remarks Compound Name Code Use Stage of Development
· A-/Hypogammaglobulinemia Fibrinogen (Factor I) GC5112A Congenital fibrinogen deficiency Pre-clinical

· Combined therapy with antibiotics
Asia, Middle-East, Plasma-derived Factor VIII GC5111A Hemophilia A Pre-clinical
for severe bacterial or viral infections Plasma
1. Human Intravenous Immunoglobulin Central & South
· Idiopathic thrombocytopenic purpura Derivatives
America Anti-TFPI antibody MG1113A Hemophilia A & B Pre-clinical
· Guillain-Barre syndrome
· Kawasaki syndrome
Tuberculosis vaccine GC3107A Tuberculosis Clinical Phase I
For hypoalbuminemia and shock
Factor Xa inhibitor GC2107 Anti-thrombotics Clinical Phase I
in acute hemorrhage from loss of Asia, Middle-East,
Plasma
2. Human Albumin Solution albumin (burns, nephrotic syndrome, Central & South EGFR target anti-cancer GC1118A Colon Cancer Clinical Phase I
Derivatives
etc.) and low synthesis of albumin America
(hepatic cirrhosis, etc.) Anthrax vaccine GC1109 Anthrax Clnical Phase II
For the treatment of hemophilia A Asia, Middle-East, Tetanus, diphteria and pertussis vaccine GC3111A Tetanus, diphteria and pertussis Clnical Phase II
Plasma
3. Human Blood Coagulation Factor VIII with supplies of blood coagulation Central & South
Derivatives
factor VIII America Hunter Syndrome treatment GC1111B Hunter Syndrome Clnical Phase II
For the prevention and control of Asia, Middle-East, Prevention of HBV recurrence after
Recombinant Hepariris B Immunoglobulin GC1102 Clnical Phase II
4. Recombinant Coagulation Factor VIII bleeding episodes and preoperative Central & South liver transplantation
Product
management in hemophilia A America
Allogenic NK cell MG4101 Hepatocellular Carcinoma Clnical Phase II
· For prophylaxis of hepatitis B after
exposure to HBsAg IVIG GC5101B Severe infection/PID Clinical Phase III
· For prophylaxis of hepatitis B in Asia, Middle-East,
Plasma IVIG GC5107B Severe infection/PID Clinical Phase III
5. Human Hepatitis B Immunoglobulin neonates Central & South
Derivatives
· For prevention of recurrence of America
hepatitis B in patients with liver Seasonal influenza vaccine GC3106A Seasonal influenza Clinical Phase III
transplants
Recombinant Factor VIII GC1101D Hemophilia A Clinical Phase III
For the prophylaxis of tetanus and
Varicella vaccine MG1111 Varicella Clinical Phase III
the reduction of tetanus symptoms Asia, Middle-East,
Plasma
6. Human Tetanus Immunoglobulin by providing passive immunization Central & South Fc-optimized monoclonal antibody MGAH22 Breast cancer Clinical Phase III
Derivatives
against infection caused by America
Clostridium tetani
Asia, Middle-East,
7. Split Virion Inactivated Influenza
For the prophylaxis against influenza Central & South Vaccines
Vaccine
America
Asia, Middle-East,
8. Live Attenuated Varicella Vaccine For the prophylaxis against varicella Central & South Vaccines
America
For treatment (Enzyme Replacement Asia, Middle-East,

Recombinant
9. Idursulfase beta Therapy) of Hunter Syndrome Central & South
Product
(Mucopolysaccharidosis II) America
For decrease the duration of severe

Asia, Middle-East,
neutropenia for patients receiving Recombinant
10. PEG-GCSF Central & South
cytotoxic chemotherapy for solid Product
America
tumor and malignant lymphoma

technology.
Green Cross Cell Corporation

- 2007: Received approval for the HCC immunotherapy “Immuncell-LC” from MFDS.
- 2012: Completed phase III clinical trials for HCC and glioblastoma.
3) Diverse Pipelines of Business
- Build infrastructure through networking with major university hospitals and cancer-related research centers.
- Green Cross - linked synergies expected.
Executives Profile
Company Profile
Duckjoo Lee, President & CEO.
1. Business
• MD, Ph.D.
R&D, manufactures and distributes cell therapy products,
• Studied for Master’s degree from Public Health, University of Minnesota.
licensing business for cell therapy products, research services, cell
• Former Doctor, Ajou University Hospital Family Physician.
cryopreservation, etc.
Joon Hee Han, CFO.
1) Cancer Immunotherapy Business
- The company developed "Immuncell-LC" which is one of the most • MBA.
effective cancer immunotherapy. • Former Managing Director, Green Cross BT, CANADA.
Representative - The products has been approved by KFDA(Korea Food and Drug • Former Director Corporate Strategy, Green Cross Holdings Corp.
Duckjoo Lee, President & CEO Administration) in 2007 for the indication of the reduction in the
Jong Seong Ahn, Director, Operations.
Headquarter Address recurrence of Liver cancer.
153-769, 6th floor, 278, Beotkkot-ro, • Ph.D in Biotechnology.
2) Cell Bank Business
Geumcheon-gu, Seoul, Korea • Former Director, the production sector of Green Cross LabCell.
- Future resource with high potential as a cell therapy.
Foundation Date Gyouchul Jung, Director, R&D.
3) Entrusted Business (CMO service)
Sep. 17, 1992 - Various services based on superior technologies and know-how • MD.
Research Focus as a leader in the cell therapy market. • Former Vice President, Green-Cross Lab. Medical Center.
Manufacture and distribute Anti-Cancer - A company specialized in cell therapies with boundless potential
Kiwon Kang, Director of Commercial Operations.
cell-therapy products in this area.
- Advanced technologies for the development and production of • Former Director, Marketing, Green Cross Corp.
Total Staff cell therapy products. Hee-jung Wang, BOD member.
160 FTE
2. Competitive Edge • MD, Ph.D. Liver Transplantation Specialist.
1) Industry Leader • Current President, Ajou University
82-2-2101-0600
- Cell expansive Technology. Hospital Cancer Center/Transplant Center.
Web - Leader of personalized medicine through the development of safe
http://eng.greencrosscell.com cancer immunotherapy.
- Disastrous medical expenses for serious diseases (2013-2014).
Contact Person Main Products
daehwan kim 2) Continuous R&D Investment, Commercialization
Product (Ingredient/Formulation) Use Remarks
Contact Phone - 2006: Awarded a patent on immune cell cryopreservation
82-2-2101-0702 Clinical Trial Results
Adjuvant therapy for patients Publications of our clinical results in global top-tier
Contact E-mail Financial Figures whose tumor has been removed oncology journals
dhkim@greencrosscell.com after curative resection for
Hepatocellular Carcinoma 1. Liver cancer
Fiscal Year 2015 2016 2017 Immuncell-LC
(Surgical resection, Radio Gastroenterology(May 27, 2015)
Sales 10,418 11,909 19,539 Frequency Ablation, Results of phase 3 clinical trial
Percutaneous Ethanol Injection • Recurrence Free Survival increased by 1.5 times
Therapy) • Risk of recurrence decreased by 37%
Capital $5,400,000 $5,400,000 $5,400,000 • Risk of death decreased by 79%

Product (Ingredient/Formulation) Use Remarks
Adjuvant therapy for patients

2. Brain tumor
Immunotherapy(March 30, 2017) GUJU PHARM. CO. LTD.
Review of phase 3 clinical trial
whose tumor has been removed
• Progression Free Survival increased by 1.5 times
after curative resection for
• Disease control rate increased by 30%
Hepatocellular Carcinoma
Immuncell-LC
(Surgical resection, Radio
3. Pancreatic cancer
Frequency Ablation,
Cancer Immunology, Immunotherapy(Jun 12, 2014)
Percutaneous Ethanol Injection
Results of phase 2 clinical trial led by researchers
Therapy)
• Disease control rate increased by 25% Company Profile
• Improvement of Quality of Life GUJU PHARM. CO. LTD. is a specialized pharmaceutical
manufacturer considering human life the most important value in the
world.
R&D Pipeline Focus Area : Chronic metabolic disease
Compound Name Code (ClinicalTrials.gov Identifier) Use Stage of Development
NCT01890291 Liver cancer Launch
NCT00807027 Glioblastoma Phase III Representative
CIK(Cytokine- NCT02856815 Liver cancer, Mid stage Phase II (IIT) Kim Woo Tae
Induced Killer cell) Headquarter Address
NCT01897610 Liver cancer, Terminal stage Phase II (IIT)
+ aTc(CTL)(Activated
River Tower officetel 12F, 50, Beodeunaru-
Tc cell) - Liver cancer, Liver Transplantation Phase II (IIT)
ro, Yeongdeungpo-gu, Seoul, South Korea
NCT03220984 Colorectal cancer Phase II (IIT)
Foundation Date
NCT01802138 Neuroblastoma Phase I (IIT) 23rd of Dec. 1974
Research Focus
Final Product (Medicine)
New Active Substances Total Staff
270 persons
Immuncell-LC Liver cancer Aug, 2007
82-2-2672-1122
Representative Fax
82-2-2679-7569
Others Web
http://www.gujup.co.kr/
Business Strategy
Contact Person
Kim Jeoung Seob
- Target Indication (Liver cancer)
Contact Phone
• Market Exclusivity -> To maximize Profit & MKT Share
82-2-2672-1122, Ext. 400 Financial Figures
• Fast Track Pathway -> To sustain minimized Payback Period
• CMO Utilization -> Risk mitigation Contact E-mail
kim3548@hanmail.net
Fiscal Year 2012 2013 2014
- Other applications (Various cancers) Sales 56,592 59,253 57,137
• Continuous R&D and Addition of new Indications (Brain tumor, Pancreatic cancer) R&D Expenditure 1,795 1,856 2,091
• Other Collaboration with Partners Capital 13,189 14,788 15,960

Main Products
1. Clif cap.(Cefaclor)
Use
Antibiotics
Exporting Countries
-
Remarks
-
Hana Pharm Co., Ltd
2. Atorix Tab.(Atorvastatin Calcium hydrate) Treatment for Hyperlipidemia - -
3. Unazol cap.(Fluconazole) Antifungal agents - -
4. Bronkid syrup.(Hederae Helix Fluid) Expectorants - -
5. Rabiem Tab. (Rabeprazole Sodium) Proton pump inhibitor - -

Company Profile
Since founded in 1996, Hana Pharmaceutical Company has been
6. Neocatin tab.(Acetyl Carnitine HCl) Cholinergic drugs - -
keeping steady product development and pharmaceutical synthesis,
7. Neotidine tab.150mg(Ranitidine HCl) H2-blocker - - and now it is ready to advance to take-off stage.
With our specialized products such as anesthetics (Propofol,
8. Anicid cap.(Omeprazol) Proton pump inhibitor - -
sevoflurane, isoflurane) and narcotics (Oxycodone, fentanyl,
9. Talimed Tab.(Talniflumate) NSAID - - morphine), we will continue our effort to become as a world-class
global pharmaceutical company.
Representative
10. Diacerhein Cap.(Diacerhein) Treatment of Osteoarthritis - -
Younha Lee
Headquarter Address
16F, 218 Narae B/D, Teheran-ro,
Gangnam-gu, Seoul, Korea
Foundation Date
1996
Research Focus
Synthesis of API, Pharmaceutical Product
Manufacturing, Selling and Exporting
Total Staff
+530
82-2-577-7667
Web
www.hanaph.co.kr
Contact Person
Gemma Kim
Contact Phone
82-2-559-5778
hana.business1996@gmail.com
Fiscal Year 2015 2016 2017
Sales 108,255 125,156 140,155
R&D Expenditure 3,308 4,159 4,164
Capital 35,385 56,923 90,939

Main Products
Thailand, Yemen,
HanAll Bio Pharma
1. Propofol Inj. Anesthetics
Vietnam, Dominican republic
2. Sevoflurane Sol. Anesthetics Yemen, Taiwan, Dominican republic
3. Isoflurane Sol. Anesthetics Yemen, Dominican republic
4. Atracurium Besylate Inj. Muscle relaxants Thailand, Philippines Company Profile

5. Nalbuphine HCl Inj. Analgesics Philippines HanAll is a top 20 Korean-based R&D pharmaceutical company
established in 1973. Our company initially started R&D with the
6. Bupivacaine HCl + Dextrose Inj. Anesthetics Yemen, Philippines
development of over 30 different combinations of cardiology products
7. Midazolam Inj. Benzodiazepines Yemen through its innovative and proprietary XC Hybrid Combination
formulation technology. With the acquisition of Nautilus Biotech and
8. Nitroglycerin Inj. Vasodilators Mongolia strengthened bio-therapeutics pipeline, we are currently developing
engineered protein therapeutics via amino acid replacement
Non-cardioselective beta
9. Labetalol Inj. Chile engineering and mAb fragment via domain engineering which
blockers Representative will provide superior PK/PD profile. We also focus on the treating
Mr. Sung-Wuk Kim / CEO autoimmune disease with bio-therapeutics.
10. Ramosetron HCl Inj. Antiemetics Taiwan
Headquarter Address Not only do we focus on bio-therapeutics, but also strive to develop
Jamshil I-Space 6F, 11-10 Sincheon-dong, new chemical entities for the treatment of cancer due to high global
Songpa-gu, Seoul, Korea needs. It is important to provide effective and safe anti-neoplastic
Foundation Date agents with minimized adverse drug events which can significantly
R&D Pipeline 1973. 11. 20 increase patient's quality of life. Recently, preclinical and clinical data
are emerging for a beneficial effect of Metformin which may affect
Compound Name Code Use Stage of Development Research Focus cancer cell's proliferation and apoptosis. Hence, we are presently
Bio-therapeutics (Biobetter & antibodies), developing new chemical entity of biguanide derivatives as an
- HNP-2001 Anesthetics Phase III
CV Combinations, AMPK activator, Ant- effective and safe anti-neoplastic agent.
- HNP-2006 Contrast media Preclinical Atopic dermatitis.
Total Staff
- HNP-7060 Anti-pain Formulation
446 persons
- HNP-7076 Rheumatoid arthritis Formulation
82-2-2204-1753
Representative Fax
82-2-414-8046
Web
www.hanall.co.kr
Financial Figures
Fiscal Year 2008 2009 2010
Sales 91,900 98,700 106,900
R&D Expenditure 10,831 10,928 10,651
Capital 18,500 18,500 18,500

Main Products
1. Reposporen inj.(Cefazedone)
Use
Antibiotics
Exporting Countries
-
HANDOK Inc.
2. Tomiporan inj.(Cefbuperazoen Sod.) Antibiotics -
3. Normix tab.(Rifaximin) Antibiotics -
4. Hanall Glimepiride tab.(Glimepiride) Antidiabetes Vietnam
5. Glucodown OR tab.(Metformin HCl) Antidiabetes -
Company Profile
6. Hanall tramadol inj.(tramadol HCl) NSAIDS -
HANDOK, a leading innovation-driven pharmaceutical/health-care
7. Levod tab.(Levosulpiride) Prokinetic agent -
company in Korea, develops, manufactures and distributes healthcare
8. Hanall Fluconazole cap.(fluconazole) anti-fungal drug - solutions to improve the health and quality of human life. Handok
9. Lenvard tab.(Rebamipide) antiulcer agent - has a core business focus in diabetes, cardiovascular, muscular
skeletal, psychoneurotic disease, human vaccines, medical devices,
10. Hanall finasteride tab. 5mg(Finasteride) 5alpha-reductase inhibitor Vietnam, Philippines diagnostics and consumer health.Handok, founded in 1954, grew
as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012.
Handok has also established strategic collaborations in several areas
Representative with multiple multinational pharmaceutical companies.
Young-Jin Kim Chairman & CEO
R&D Pipeline Headquarter Address
132, Teheran Street, Gangnam-Gu, Seoul,
135-755, Korea
KOR Phase 2 completed
HL009(Adenosylcobalmin) Atopic dermatitis Foundation Date
US phase 2 IND approved
1954. 4. 27
KOR Phase 1 completed
HL008(amlodipine, losartan) Hypertension
US IND preparation Research Focus
KOR Phase 3 preparation Oncology, Diabetes & Metabolic
HL040(losartan, atorvastatin) Hypertension, Hyperlipidemia
US IND preparation disorders, CNS, CV, Orphan disease, Eye
HL156(Biguanide derivative NCE) Anti-cancer Lead optimization
disorders, Quality of life products
HL032(oral hGH) Growth hormone deficiency KOR Phase 1 ongoing Total Staff
913 persons
HL143(sc IFN) Hepatitis C US Phase 1 on-going
HL036(anti TNF-alpha) Rheumatoid arthritis Lead optimization 82-2-527-5114
HL161(FcRn) Autoimmune disease Lead optimization Web
http://www.handok.co.kr/english/
company/company.asp
Contact Person
So-Hyun Kwon
New Active Substances Contact Phone
Contact E-mail Summary (1 Million Won)
Spelear(Fudostein) antitussive agent 2005-01-19 sohyun.kwon@handok.com Fiscal Year 2015 2016 2017
Sales 358,477 396,253 424,903
R&D Expenditure 18,805 18,149 26,855
Capital 316,424 318,324 319,915

Main Products Others
Product (Ingredient/Formulation) Use Exporting Countries Remarks
We are the best partner to bring your novel drugs to the Korean market.
14 countries Innovation and partnership belong to Handok's core values, and we strive every day to bring Innovative new products to
1. Amaryl M
(Taiwan, Indonesia, The first fixed dose combination of patients, wherever they may have been discovered. With a history as a joint venture, Handok knows how to value partnership
(Glimepiride+Metformin/ Anti-diabetic drug
Philippines, Hungary, glimepiride and metformin HCl in Korea as a way of growing business for both parties involved. Handok offers its partners core competencies in areas that critical for
Tablet)
Russia, Dubai, etc) successful drug development and commercialization.
6 countries
2. Amaryl Mex
(Singapore, Hungary, Applied by DRM technology (Dual Release Excellence in clinical development and management
(Glimepiride+Metformin/ Anti-diabetic drug
Croissy, Philippines, Micro-coating Technology)
Sustanined–release Tablet) Our Clinical Research Center is recognized for performing quality clinical trials, pharmacoeconomic studies, data management
Kazakhstan, etc.)
and biostatistics. The center meets global standards and has been participating in global clinical trials with multinational
3. Tenelia M partners.
Applied by DRM technology (Dual Release
(Teneligliptin+Metformin/ Anti-diabetic drug -
Micro-coating Technology)
Sustanined–release Tablet) Optimized market access through regulatory and pricing expertise
Osteoarthritis, Handok was the first pharmaceutical company in Korea an international pharmacoeconomic team. It has been successful in
arthritis, 5 countries Korea’s No. 1 pain relief OTC product achieving shorter registration and launch timelines, as well as optimizing pricing fir partners' products in the Korean market.
Humeroscapularis (Singapore, Ketotop relieves pain and reduces
4. Ketotop
(Stiff shoulder), Malaysia, Vietnam, inflammation and Ketotop plaster is Maximize returns though strong sales and medical marketing capability
(Ketoprofen/Plaster)
Muscular pain, Kazakhstan, designed to penetrate deeply into the site
Peritendinitis Myanmma, etc.) of pain and works for 12hours We provide maximum return through scientific and ethical marketing practices and top-tier sales force productivity. Handok also
(Tendinitis) has a high reputation among key opinion leaders in Korea.
5. Ready-Q ; Drink and Delicious hangover remedy contains

Chew(Gummy)
Hangover Remedy 1 country (Taiwan)
curcumin, an extract from Tumeric
World-class manufacturing capabilities
Handok offers high-quality manufacturing and QC capability for multiple dosage forms with the highest standard if production
Innovative and best way to consume facilities in Korea to meet partners' manufacturing needs in Korea and other export markets.
Theracurmin, Curcumin made as small
6. Ulgeum Theracurmin - -
particles to be soluble and absorbed well
into body Rigorous company-wide compliance program
Handok believes that adherence to ethical practices is essential for continuous growth and long-term success or the company
and its partners' business. We were the first company to introduce a strict company-wide compliance program in Korea.
Internal research expertise to support your program

R&D Pipeline Handok has expertise in small molecules, biologics, and drug delivery system and is seeking collaborations on innovative early-
Compound Name Code Use Stage of Development stage research programs to build its future pipeline.
- HL2356 Growth Hormone Deficiency Phase II
- HL5101 Cancer Preclinical development
- HL3501 Glaucoma Discovery
- HL1550 Diabetes + Hyperlipidemia Preclinical development
- DENEX Resistant Hypertension Phase I

Main Products
Hankooksinyak Pharm. Co., Ltd. 1. Chunsim

Product (Ingredient/) Use
heart disease, hypotension, etc.

Exporting Countries
2. Keopoongshibodan stroke -
3. Woohwangchongshim-won stroke, atherosclerosis, hypertension, etc. Japan
4. Mankyungdan stroke, sciatica, etc -

Company Profile 5. Mesima gastrointestinal cancer Japan
We have a lot of specialized technologies in the natural medicine
6. Yukmihwan urinary difficulty -
field, such as Korean traditional medicines. Since our modern Korean
traditional medicines, resulting in many accomplishments in the 7. Ickbodan fortifying, kidney-essence -
biotechnology sector. Those accomplishments includes development
of anticancer substances as well. In 1984, we produced and supplied 8. Shinbanwan diabetes -
successfully Korean traditional medicine solutions(i.e., Galgeuntang,
Sipjeondaebotang, Sosihotang etc.) to the market. In 1992, we saw 9. Oakbihwan constipation -
another success for development of the anticancer substance having 10. Chongwidan stomach catarrh, indigestion -
Representative a brand of MESIMA.
Han Sang Wook
Headquarter Address
805-15, Joongsan-Ri, Yangchon-myeon,
Nonsan, Chungnam Prov., Korea R&D Pipeline
Foundation Date Ingredient Use Stage of Development
1961. 2. 27
Korean medicine GST anti-atopic dermatitis Evaluation of GST
Research Focus
Korean traditional herbal medicine
Total Staff
260 persons
Representative Phone New Active Substances
82-41-740-8900
Representative Fax
82-41-740-8849 MESIMA Immuno-stimulating drug 1990.2.28
Web
www.hsp.co.kr
Financial Figures
Fiscal Year 2008 2009 2010
Sales - 20,384 21,687
R&D Expenditure - - 646
Capital - - 2,100

Main Products
HANLIM PHARM. CO., LTD. 1. D

ages Cap.
(Pepsine, Papain, Diastase, Cellulase, Alimentary Drug China

Pancreatin, Pancrelipase, UDCA)
Hemostatics, Anticoagulants
2. Heparin Inj. (Heparin Sod.) Vietnam, Singapore
and related agents
Company Profile 3. Easy-Drops Eye Drops Ophthalmic Drugs USA, Cambodia, Nigeria
With the corporate mission of "Protecting the precious human life 4. N

umaren Eye Drops USA, Myanmar, Cambodia,Vietnam,
Ophthalmic Drugs
from various forms of disease", HANLIM has consistently endeavored (Hydropropylmethyl cellulose, Dextran 70) Hongkong
to manufacture high quality pharmaceutical products. Also, we
5. P osod Eye Drops
continue to make a great investment in new medicine development Ophthalmic Drugs Vietnam, Singapore, Hong Kong, Nigeria
(Potassium Iodide, Sodium Iodide)
and reorganizing manufacturing facilities.
6. Quinovid Ophthalmic Ointment (Ofloxacin) Ophthalmic Drugs Vietnam
7. Quinovid Ear Drops (Ofloxacin) Ophthalmic Drugs Vietnam

Representative
Mr. Jae-Yoon Kim Allergy&ENT Disease
8. Desona Nasal Spray (Budesonide) Cambodia, Vietnam, Mongol, Guatemala
Mr. Jung-Jin Kim Related agent
Headquarter Address 9. P eptazole Inj.

Alimentary Drugs Vietnam
42, Seocho-Daero 52-Gil, Seocho-Gu, (Pantoprazole Sod. Sesquihydrate)
Seoul, Korea
Hemostatics, Anticoagulants
10.Protamine Sulfate Inj. (Protamine Sulfate) Azerbaijan
Foundation Date and related agents
Sep. 1974
Research Focus
Pharmaceutical
R&D Pipeline
Total Staff
635 persons Compound Name Code Use Stage of Development
Representative Phone - HL-MSC Systemic lupus erythematosus Phase 1

82-2-3489-6000
- HL301 Bronchitis Phase 3
Web
http://www.hanlim.com - HL217 AMD Phase 1
Contact Person - HL237 Rheumatoid Arthritis Phase 1

Ms. Jung-Hwa Yang
- HL235 Osteoporosis Lead mol
Contact Phone
82-2-3489-6214 - HL-PIF Mixed hyperlipidemia Phase 3
Contact E-mail Financial Figures - HL151 Allergic rhinitis pruritus Phase 3

yjh0717@hanlim.com
Fiscal Year 2015 2016 2017
Sales 130,702 148,629 169,096
R&D Expenditure 11,148 17,255 14,465
Capital 146,882 171,100 196,100

Main Products
Hanmi Pharm. Co., Ltd Product (Ingredient/Formulation)

1. Amosartan (amlodipine+losartan)
Use
Hypertension
Exporting Countries
Southest Asia 4counties, Latin America 15countries
2. Rosuzet (Rosuvastatin+ezetimibe) Hyperlipidemia WW 16 countries including Brazil
3. Duted (Dutasteride) BPH Japan
4. Amodipin (Amlopidine camsylate) Hypertension Philippines, Mexico
5. Esomezol (Esomeprazole strontium) GERD, Gastric ulcer U.S.A
Company Profile
6. Pidogul (Clopidogrel napadisilate) Antithrombotic Hongkong
Established in 1973, Hanmi Pharmaceutical now is the No.1 R&D
focused pharmaceutical company in Korea with highest R&D
investment for many years. R&D Pipeline
Hanmi Pharm. Co., Ltd. is a Korea-based pharmaceutical company, Compound Name Code Use Stage of Development
fully integrated with strong focus in R&D which is strategically LAPS
GCSF; Eflapegrastim - Neutropenia Phase 3
designed in 3 major fields: 1) Biologics: LAPSCOVERY platform
LAPS
applied long-acting pipelines. Key targeting areas are diabetes, GLP-1; Efpeglenatide - Diabetes, obesity Phase 3
Foundation Date obesity, NASH, and rare diseases / PENTAMBODY platform applied LAPS
hGH; Efpegsomatropin - GHD Phase 2
2010. 7. 5 bispecific antibody pipelines. Key targeting areas are targeted
immuno-oncology and autoimmune disease; 2) NCE: Mainly oncology LAPS HM12460A /
Insulin/ LAPSInsulin Analog Diabetes Phase 1
Research Focus HM12470
and auto-immune disease targeted pipelines; and 3) Fixed-dose
New Biologics, New Chemical Entities combination programs. The company has worked closely with global
LAPS
GLP/GCG HM12525A Diabetes, obesity Phase 1
Total Staff partners on various co-developments and collaborations. Hanmi LAPS
Insulin/ LAPS
GLP-1 combination HM14220 Diabetes Pre-Clinical
2,195 persons continues to further expand through "Open Innovation Strategy" by LAPS
finding potential partners for innovative solutions. Triple Agonist HM15211 Obesity, NASH Pre-Clinical
Representative Phone LAPS
Focus Area : Innovative R&D - Diabetes, Obesity, NASH, Oncology, Glucagon Analog HM15136 Congenital Hyperinsulinism Pre-Clinical
82-2-410-9114 (회사 소개용 사진 배치 ; 주력 제품 or 본사 및 공장 조감도 등 )
Autoimmune diseases, Rare diseases

* 공장 조감도
LAPS
ASB HM15450 Mycopolysaccharidosis Pre-Clinical
Representative Fax
LAPS
82-2-410-9179 GLP-2 Analog HM15910 Short Bowel Syndrome Pre-Clinical
Web Oraxol™; (Paclitaxel+HM30181A) - Breast cancer Phase 3

(회사 소개용 사진 배치 ; 주력 제품 or 본사 및 공장 조감도 등 )
www.hanmipharm.com * 공장 조감도 Olita™ (Olmutinib) - NSCLC Phase 3
Contact Person Poziotinib - Breast cancer, NSCLC Phase 2
Steven Cho
* 주력제품
BTK Inhibitor HM71224 Rheumatoid arthritis Phase 2
Contact Phone
Oratecan™; (Irinotecan+HM30181A) - Solid tumors Phase 1
82-2-410-0462
RAF inhibitor HM95573 Solid tumor Phase 1
Contact E-mail
haamincho@hanmi.co.kr Src kinase/tubulin dual inhibitor KX2-391 Solid tumor Phase 1
FLT3 Inhibitor HM43239 AML Pre-Clinical
GMB Stem Cell Therapy HM21001 Glioblastoma Pre-Clinical
Financial Figures PENTAMBODY - Solid tumor Pre-Clinical
* 주력제품 Summary (1 Million Won)
Fiscal Year 2015 2016 2017
New Active Substances
Sales 1,317,535 882,725 916,586
Product (Ingredient) Use Approval Date/Country
R&D Expenditure 187,159 162,594 170,676
Capital 25,577 26,088 27,909 Olita tab(Olmutinib) NSCNC 2017 NOV. /South KOREA

Main Products
Han Wha Pharma Co., Ltd. Product (Ingredient/Formulation)
1. Antibio
Use
Probiotics
Exporting Countries
Vietnam
Remarks
2. Ramnos Probiotics Malaysia -
3. Muteran Mucolytics - -
4. Wingli-M Anti-diabetics Indonesia Under registration

Company Profile 5. Winexge Anti-hypertension Indonesia Under registration
Han Wha Pharma(HWP) is a pharmaceutical company based in
6. Telmiam Anti-hypertension - -
Seoul, Korea. HWP is well established in development, manufacture,
distribution, marketing/sales and export of pharmaceutical and
healthcare products. HWP is recognized to doctors and pharmacists
as a specialized company that has ethical products in certain
therapeutic areas such as alimentary, cardiovascular, obstetrics/
gynecology, neuro-muscular, and respiratory system. Aiming to R&D Pipeline
become a global enterprise, HWP has introduced global marketing Compound Name Code Use Stage of Development
Representative techniques through an organic partnership with several overseas - YJP-14 Cardiovascular agent Phase 2
Kyoungrak Kim companies. As a result, HWP has continued making record growth in
Headquarter Address sales by successfully launching new products in the domestic market - YJP-40 Respiratory agent Phase 3
76 Hwarang-ro 32-gil, Seongbuk-gu, to meet customer needs based on market research. In sales activities,
HWP has grown into a most trusted company among customers - YJC-50018 Anti-rheumatoid arthritis Preclinical
Seoul, 02789, KOREA
by successfully supplying high-quality and superior medicines to
Foundation Date hospitals and clinics. HWP has expanded its business area to dietary
July 4, 1976 supplements. HWP family consists of NaturaLife focused on nutrition
Research Focus supplements for domestic market and NaturaLife Asia for exporting
Respiratory diseases etc. business to Asian territory.
Total Staff Focus Area : Gastro-intestinal system, Respiratory system, Obstetrics/
300 persons Gynecology etc.
82-2-959-3161
Representative Fax
82-2.959-3621
Web
www.hwpharm.com
Contact Person
Jinbo Kim
Contact Phone
Contact E-mail
hw@hwpharm.com
Fiscal Year 2015 2016 2017
Sales 57,887 65,146 62,719
Capital 3,436 3,436 3,436

Main Products
Hawon Pharmaceutical Corporation Product (Ingredient/Formulation)

1. F azidone Inj. 1g,2g
Use
- urinary tract infection, cholangitis, intrauterine
Exporting Countries
-
(Cefazedone sodium 1g,2g) infection, adnexitis
- pneumonia, bronchitis and breathing device nfection
- ear, nose and throat nfection
- nephritis and urinary tract infection
2. H
awon Ceftriaxone Inj. 1g,2g - sepsis
Mongolia
(Ceftriaxone Na 1g,2g) - bone and joint infection
Company Profile - skin, laceration and soft tissue infection
- peritonitis, cholecystitis, cholangitis
Hawon believes that "To contribute to the health and happiness of
- meningitis
people through developing good medicines". We will keep the level
of global standards of competition and place high priority on R&D for - Respiratory Infections
3. Ciploxacin Inj. 200mg (Ciprofloxacin 2mg) - ENT infections, Oral, Teeth, jaw infections -
devised out new products and raw materials of new brand.
- kidneys, urinary tract infection
Focus Area : Antibiotic Drug etc 4. Myal Inj. (Sodium hyaluronate/10mg) - Osteoarthritis of the knee, shoulder treatment -
- perceived exercise barrier
5. Coxicam Cap. (Meloxicam 7.5mg) - Symptomatic treatment of rheumatoid arthritis Vietnam
Representative - Symptomatic treatment of poker back
Kooh, Dae-ho - upper airway infection : otitis media, tonsillitis,
Headquarter Address pharyngitis
#135-080, 2~4F Time bldg, 312 Nonhyun- 6. Furoxetil Tab.(Cefuroxime axetil 300.72mg - lower respiratory tract : acute bronchitis and chronic
-
ro, Kangnam-gu, Seoul, Korea (cefuroxime axetil(as cefuroxime) 250mg)) bronchitis, pneumonia
- urogenital system infection : nephropyelitis, cystitis,
Foundation Date urethritis
4th May 1981 - Ulcer
Research Focus - Gastric mucosal lesions in the following diseases
Natural Medicine 7. Remist Tab. (Rebamipide 100mg) (erosion, bleeding , redness, swelling) improvement of -
acute gastritis, acute exacerbation of chronic gastritis
Total Staff group
158 persons - Acute or recurrent vaginal candidiasis
Representative Phone - Hand, nail fungus, athlete's foot (foot ringworm),
8. Fronan Cap. (Fluconazole 50mg) -
tinea corpus, wanseon (groin ringworm), Skin and skin
82-70-8260-6030
fungal infections, including candida eorureogi
Representative Fax - Reduced risk of myocardial infarction
82-2-554-4557 - Reduced risk of stroke
9. Lipitrol Tab. (Atorvastatin calcium 10.35mg) -
Web - Vascular regeneration and reduce the risk of chronic
stable angina
http://www.hawonpharm.co.kr
- Functional due to poor digestion digestive symptoms
Contact Person 10. Mosadin Tab. (Mosapride citrate 5.29mg) -
(heartburn, nausea, vomiting)
R&D Department
Contact Phone
82-70-8260-6030(#3) Financial Figures
Contact E-mail
hawon342@hawonpharm.co.kr
Fiscal Year 2012 2013 2014
Sales 6,190,651 5,865,021 5,320,896
R&D Expenditure 78,894 35,727 49,028
Capital 5,777,685 5,254,988 5,915,659

Main Products
Humedix Co., Ltd Product (Ingredient/Formulation)
1. S odium Hyaluronate
Remedies for Arthritis Worldwide

(Sodium Hyaluronate/Powder)
2. H
igh Hyal Plus Inj.
(Sodium Hyaluronate/Injection)
3. H
igh Hyal Inj.
Company Profile (Sodium Hyaluronate/Injection)
We, humedix, have platform technology for application of 4. High Eye Inj. (Sodium Hyaluronate/Injection) Ophthalmological surgical aids Worldwide
biocompatible polymers just like hyaluronic acid and PEG.
And then, we are trying to research and develop the improvement of
drugs with biocompatible polymers.
We've rapidly grown up recently due to our products developed
with hyaluronic acid and have been listed in korean stock R&D Pipeline
market(KOSDAQ), Compound Name Use Stage of Development
Representative
Chung, Bong-Yeol Focus Area : application of biocompatible polymer as hyaluronic acid cross-linked hyaluronic acid improvement of osteoarthritis pre-clinical
and PEG etc.
Headquarter Address conjugated Vit. D derivative whitenning pre-clinical
Unit 603 Mega Valley, 268, Hagui-ro,
Dongan-gu, Anyang-si, Gyeonggi-do, scFv macular degeneration pre-clinical
Korea
Foundation Date
2003
Research Focus
Biomaterials & Applications
Total Staff
79 persons
82-70-7492-5618
Representative Fax
82-31-421-5623
Web
www.humedix.com
Contact Person
Lee, Jong-Oh
82-70-7492-5609
Contact E-mail
jolee@humedix.com Fiscal Year 2012 2013 2014
Sales 11,704 23,544 29,200
R&D Expenditure 1,916 1,832 2,602
Capital 2,042 2,304 3,158

Main Products
HUONS CO., LTD. Product (Ingredient/Formulation) Use

Temporary improvement of
1. Hutox Inj. 100units (Botulinum Toxin Type A) moderate to severe glabellar Worldwide -
wrinkles
2. Elraive premier (Sodium hyaluronate + Lidocaine) HA Dermal Filler Worldwide -
3. High Hyal Plus Inj. (Sodium Hyaluronate) Osteoarthritis treatment Worldwide -
4. Lidocaine / Articaine with Epinephrine Inj. Dental Anesthetics Worldwide -
Company Profile
5. Dermashine Balance Skin hydro-lifting Worldwide -
Huons has existed for more than 50 years, and grown to a competent
global company, producing original and effective essential medicine 6. Derma Akne Acne treatment Worldwide -
and medical products, through continual challenges and innovations Treatment and Prevention of
7. Vitamin D Inj. (Chloecalciferol 200,000IU) Worldwide -
over 50 years. Vitamin D deficiency
Huons is putting a ceaseless effort for human healthy life based on ANDA
the advanced manufacturing technologies and production facilities. 8. Sodium chloride inj. Diluent Worldwide Approval in
US FDA
Our goal is to achieve 1 billion USD in 2020 and aiming to be the
TOP TEN global company in the industry. Huons is trying to develop 4 9. Honey bush Inner beauty Worldwide -
Representative
KEY AN, UM cores businesses in order to be the successful model of cooperation
case. Our 4 main values are research and development, management
Headquarter Address of distribution, manufacturing production and developing a global
902-c, 253 Pangyo-ro, Bundang-gu, business.
R&D Pipeline
Seongnam-si, Gyeonggi-do, Korea Compound Name Code Use Stage of Development
Foundation Date - HU007 Dry eye syndrome Phase II

July 30, 1965
- HU002 Fatty liver Phase II
Research Focus
- HU014 Glabellar wrinkle Phase I/II
NCEs, Biologics and Generics
- HU024 Dry eye syndrome Pre-Clinical
Total Staff
570 persons - HU036 Auto-immune disease Discovery
Representative Phone - HU035 Atopy Discovery

82-2-854-4700 - HU017 Inflammatory bowel disease Discovery
Web
www.huons.com
Contact Person
Han Seok, Ko
Contact Phone
82-2-854-4700 March, 2015/ Korea
Clacier Eye drop (Cyclosprine 0.05%) Dry eye Syndromes
(Modified generic)
Contact E-mail
intbiz@huons.com Financial Figures
Others
Fiscal Year 2015 2016 2017
Sales - 167,572 - We, Huons are a new company separated from the former Huons established in 1965. The former Huons split into Huons Global
R&D Expenditure - 14,003 - (a holding company) and the new Huons (operations). In assuming that Huons has not split, the sales was 21.5b(KRW) in 2015 &
Capital - 95,051 - 24.5b(KRW) in 2016 based in separated income statement.

Main Products
Hyundai Pharm Product (Ingredient/Formulation) Use
Acute, chronic respiratory disease,

1. S urfolase Capsule acute, chronic bronchitis, bronchial

China IND submission
(Acebrophylline 100mg) asthma, paranasal sinustis, dried
rhinitis
Preparation
2. M
inoxyl solution 5% Hong Kong, Vietnam, Approval
Main pattern baldness
Company Profile (Minoxidil 5g/100mL) Cambodia, Myanmar Submission
Approval
We, Hyundai Pharm. with corporate philosophy in "Contribute to
public health promotion" which embodies humanistic philosophy Approval
3. Hyundai Moolpas-F Solution Hong Kong, USA,
in improving public health and quality of life and CEO's philosophy (Methyl salicylate, dl-camphor, etc)
Antiinflammatory analgesic, pernio
Mongolia
Registration
focused in transparent enterprise spirit, implements organization's Approval
vision and value and actively handle fast changing business are in
4. B umooly-S Solution Eczema, dermatitis, erosion, miliaria,
order to have a new leap forward in 21st century.
(Diphenhydramine HCl, Dibucaine rhus dermatitis, pruritus, pernio, USA Approval
Focus Area : Caridovascular, CNS, Oncology support, Women's Health HCl, etc) insect bite, hives
Representative Care, Respiratory
5. V arosc Tablet Approval
Lee, Han Koo Hypertension, coronary artery disease Vietnam, Cambodia
(Amlodipine besylate 5mg) Approval
Headquarter Address
6. O
lanpin Tablet Treatment of schizophrenia, bipolar Approval
Hyundaipharm Bldg, Bongeunsa St 135, Hong Kong, Macao
(Olanzapine 5mg, 10mg) disorder Preparation
Gangnam-Gu, Seoul, Korea
Treatment of episodes of major Approval
Foundation Date 7. Mirtapin Tablet (Mirtazapine 15mg) Hong Kong, Macao
depression Preparation
1965
Research Focus 8. Mirap SR tablet (Pramipexole HCl) Idiopathic parkinson's disease Thailand Submission
Pharmaceutical products, Health food
drinks, Medical equipment & device
Total Staff
over 400
82-2-2600-3951
Representative Fax
82-2-2693-7628
Web
www.hyundaipharm.co.kr/english
Contact Person
Yuna Chae
82-2-2600-3883
Contact E-mail
yuna.chae@hdpharm.co.kr Fiscal Year 2012 2013 2014
Sales 101,116 106,627 107,837
R&D Expenditure 8,083 8,368 8,243
Capital 14,000 14,000 14,000

Main Products
ICURE Pharmaceutical Inc Product (Ingredient/Formulation) Use
Treatment of mild to
moderate dementia of the

1. Rivaderm Patch (Rivastigmine) - -
Alzheimer and Parkinson`
disease
2. Exoderm Patch (Nicotine) Nicotine replacement therapy - -
Company Profile 3. N
SAIDs Plaster
(Ketoprofen/ Diclofenac Sodium,
Icure Pharmaceutical Inc. is a privately held specialty drugs company Relief for Rheumatic arthritis Russia, Hong Kong,
diethylammonium/ Flurbiprofen/ -
pain Bolivia, India
with its HQ located in Seoul, R&D Center in Pyeongtack-si and KGMP Indomethacin /Felbinac/
approved manufacturing facility in Anseong-si in Korea. Icure's Loxoprofen)
business strategy is to develop innovative transdermal drug delivery
systems for local, systemic and device aided delivery of drugs. Icure 4. Lidogesic Cataplasma (Lidocaine) Local anesthetics - -
is developing the transdermal formulations that enhance therapeutic Treatment of bronchial
value of the drugs by reducing side effects, enhancing efficacy and asthma and chronic
promoting patient compliance. 5. Tulobuterol Patch (Tulobuterol) - -
obstructive pulmonary
Representative disease (COPD)
Young Kweon Choi The company has successfully developed and commercialized several
pharmaceutical plasters and patches for the treatment dementia 6. T eeth whitening strips
Headquarter Address associated with Alzheimer Disease, rheumatic arthritis pain, nicotine Teeth whitening treatment Taiwan, Finland -
(Hydrogen perxide)
7, Saimdang-ro 1-gil, Seocho-gu, Seoul replacement therapy.
137-87, Korea Anti wrinkles, Whitening,
These products have been licensed to several leading Korean 7. Cosmetics Patch and Facial mask -
Moisturizing
Foundation Date Pharmaceutical firms for sales in Korea. Several countries
May 29, 2000 Anti wrinkles, Whitening,
Focus Area : Central nervous system, Respiratory, Nicotine 8. Skin care Product -
Research Focus Moisturizing
Replacement Therapy, Pain management, Skin care
TDDS(Transdermal Drug Delivery System)
Total Staff
93 persons
R&D Pipeline
82-2-6959-6909 Compound Name Code Use Stage of Development
Representative Fax Donepezil Patch - Treatment of mild to moderate Clinical study phase 1
82-2-6959-8509 dementia associated with
Alzheimer`s disease and
Ropinirole Patch - Formulation phase
Web Parkinson`s disease
www.icure.co.kr
Fentanyl Patch - Relief for Severe cancer pain BE Study phase
Contact Person
Tom Chung Prevention for nausea and
Granisetron Patch - vomiting caused by cancer -
Contact Phone chemotherapy
Contact E-mail
global@icure.co.kr
joebu@icure.co.kr Fiscal Year 2012 2013 2014
Sales 9,122 9,347 14,930
R&D Expenditure 309(3%) 372(4%) 305(2%)
Capital 10,111 12,930 14,997

Main Products
IKSU PHARMACEUTICAL CO., LTD. Product (Ingredient/Formulation) Use
valetudinarianism, asthenia, reduced stamina,

Achieved the first

1. Iksu gongjindan pill/liquid dizziness by aggravated liver functions, - liquid production in
headache, chronic fatigue, emmeniopathy the world
Cerebral apoplexy (total paralysis, hemiplegia,

2. Y ongpyo wonbang speech defect, coma, lethargy condition,
woohwang chungsimwon facial paralysis), hypertension, palpitation, - -
Company Profile pill/liquid anxiety neurosis, acute & chronic convulsion,
autonomic imbalance, insensibility
With 50-year history Iksu Pharm. Co., Ltd. has made continuous
growth on herb medicine in a half century history. Iksu Pharm. which Cerebral apoplexy (total paralysis, hemiplegia,
has developed ‘Gohowhan’, a neuralgia, arthritis treatment medicine, 3. Yongpyo speech defect, coma, lethargy condition,
Korean wonder drug ‘Woowhangchungshimwon.’, and ‘Gongjindan’ woohwangchungsim won facial paralysis), hypertension, palpitation, Vietnam -
known as the best royal tonic medicine with its distinguished Korean pill/liquid anxiety neurosis, acute & chronic convulsion,
herbal medication technology, is raising its public trust such as autonomic imbalance, insensibility
receiving license of Gongjindan, Banhasashimtang and Cheers liquid Following symptom of the person with
released by its technology knowhow. stuffiness of epigastrium, nausea, anorexia,
Representative Achieved the first
By releasing various products through dosage form change with soft stools or diarrhea : acute&chronic gastric
Yong-Jin Chung 4. Iksu banhasasimtang liquid - liquid production in
securing of GMP and quality management system for excellent catarrh, fermental diarrhea, dyspepsia, gastric
the world
Headquarter Address ptosis, gastraneuria, weak stomach, hangover,
medical suplies manufacturing we continue development of high
2~4F, Iksu Building., 315, Gucheonmyeon- heartburn, stomatitis, nervousness
quality liquid herb medication medicine. Iksu Pharm. also completed
ro, Gangdong-gu, Seoul, 134-050, Korea license registration of Gongsjindan liquid, fresh blood peritomy liquid, Maldigestion, vomiturition, thirst, headache
Banhasashimthag liquid, Engyosan liquid and Daesenggi liquid first in 5. Cheers liquid - -
Foundation Date caused by heavy drinking
1970 domestic.
Common cold, coryza, headache, pain of
6. Iksu galgeuntang liquid - -
Research Focus shoulder and hands
Herbal medicine
Insomnia, unrest, anxiety, thirst, palpitation,
Total Staff 7. Yongpyo ansin pill/liquid - -
neurasthenia, shortness of breath, amnesia
121 persons
8. Iksu gohohwan pill Neuralgia, arthralgia, myalgia - -
82-2-416-1116~7 9. Iksu samsoeum liquid Headache, fever, cough caused by cold - -
Web valetudinarianism, asthenia, reduced stamina,
www.iksu.co.kr 10. Hwangjinhwan gold pill dizziness by aggravated liver functions, - -
Contact Person headache, chronic fatigue, emmeniopathy
Yong Kim valetudinarianism, asthenia, reduced stamina,
Contact Phone 11. Hwangjejinsangbo liquid dizziness by aggravated liver functions, - -
82-2-416-1115 headache, chronic fatigue, emmeniopathy
Contact E-mail loss of appetite, stomach swelling,

a02580124@naver.com 12. Wisokchung Q indigestion, overeating, dyspepsia, nausea, - -
Financial Figures vomiting
Fiscal Year 2015 2016 2017
Sales 14,300 17,800 21,100
Capital - - -

R&D Pipeline
Compound Name
Antlers and 5 other ingredients

Code
IK-101
Use
Improve Liver Function

Stage of Development
Under registration
ILDONG Pharmaceutical
Corni and 5 other ingredients IK-102 Improve Liver Function Under registration
Rehmannia glutinosa and 5 other

IK-103 Improve Liver Function Under registration
ingredients
Angelica root and 5 other ingredients IK-104 Improve Liver Function Under registration
Company Profile
Ginseng and 5 other ingredients IK-105 Improve Liver Function Preclinical
ILDONG Pharmaceutical, as one of the leading pharmaceutical
Peony and 1 other ingredients IK-106 Pain relief Formulation companies in Korea, strives to create a healthier and happier future
for mankind with developing, manufacturing and distributing the
Asparagus tuber and 15 other finest pharmaceutical products.
IK-301 Atopic Dermatitis Phase II
ingredients
With latest research facilities and passionate professionals, we have
Antlers and 2 other ingredients IK-401 Immunity Improvement Formulation concentrated on new drug development project targeted at resistant
bacteria, malignant tumor, and Alzheimer’s disease, and pushed
Foundation Date forward our production of outstanding quality APIs, generic drugs,
Mar. 14th, 1941 IMDs, OTC(Over-The-Counter) products as well as nutraceuticals.
ILDONG Pharmaceutical has been successful for a few decades in
Research Focus OTC Market with several power brands. Representatively, ILDONG’s
prescribed drugs, OTC, probiotics, nutrient Multi-vitamin brand ARONAMIN ranked no.1 sales OTC brand in
food Korean OTC market in 2016.
Total Staff ILDONG succeeded in developing a chronic hepatitis B treatment
1,401 persons BESIVO in 2017 and it has been approved as a new drug from
Representative Phone MFDS(KFDA). ILDONG also has strengthen the competitiveness
82-2-526-3114 in Ethical market with many original brand-name drugs through
technical and marketing partnership with global pharmaceutical
Web companies and outstanding quality generic drugs by own synthetic
https://www.ildong.com technology.
Contact Person
Nathan Ahn(Sales) / Sungsang Seo(IR)
Contact Phone
82-2-526-3500(Sales)
82-2-526-3500(IR)
Contact E-mail
export@ildong.com(Sales)
diplomat@ildong.com(IR)
Financial Figures
Fiscal Year 2015 2016 2017
Sales 458,600 479,900 461,200
R&D Expenditure 50,900 53,800 50,000
Capital 25,068 17,845 19,629

Main Products
Asia / Central
Remarks
Ilsung Pharmaceuticals
1. Biovita Probiotics FDF
America
2. Aronamin series Vitamin complex Asia FDF
3. Capecitabine Anti-cancer Asia / Pakistan FDF
4. Pemetrexede Anti-cancer Asia / CIS FDF Company Profile

5. Fursultiamine Active vitamin Japan / Asia API ILSUNG Pharmaceuticals is one of the well-known pharmaceutical
companies in Korea. ILSUNG has been focused on antibiotics,
Asia / CIS / Central
6. Levofloxacin Antibiotics FDF anesthetics and contrast media and is expanding to GI, CV, CNS and
America
other areas. ILSUNG is famous for its in-licensing activities with
7. Ceftriaxone Antibiotics Asia / CIS FDF global partners such as GSK (UK), Bracco (Italy), Abbott / Baxter (USA),
Ono / Teijin (Japan). ILSUNG is selling various kinds of the branded
8. Besifovir Hepatitis B Asia FDF products such as Augmentin, Suprane, and Rytmonorm. In addition
to this, ILSUNG is interested in exporting business for contrast media
9. Telmisartan/Rosuvastatin Cardiovascular Asia FDC Representative and CMO business for antibiotics based on well organized KGMP
Suk Keun Yoon manufacturing facilities approved by PMDA for contrast media and
10. Rosuvastatin/Ezetimibe Cardiovascular Asia FDC
Foundation Date antibiotics.
FEB 15th 1061 Focus Area : Antibiotics, Anesthesia, Contrast Media, GI, CV, CNS
Research Focus
R&D Pipeline Antibiotics, Anesthesia, Contrast Media
Compound Name Code Use Stage of Development Total Staff
245 persons
Toosendanin (botanical drug) ID 1201 Alzheimer's disease Phase 2
PARP inhibitor (compound name has not anticancer (target indication Phase 1 82-2-3271-8705
IDX 1197
been disclosed) will be determined after P1) (Single Ascending dose)
Representative Fax
HIF modulator(compound name has not
IDF-11774
anticancer (target indication
Preclinical
82-2-718-7239
been disclosed) will be determined after P1)
Web
Lucentis bio-betters IDB0062 Macular Degeneration Preclinical www.ilsung-ph.co.kr
Avastin bio-betters IDB0072 anticancer Preclinical Contact Person

Ji Young Lee
Contact Phone
82-2-3271-8824
New Active Substances Contact E-mail
jiyounglee@ilsung-ph.co.kr
Financial Figures
Besivo (Besifovir) Hepatitis B virus Nov. 1, 17 / S.Korea
Fiscal Year 2012 2013 2014
Sales 77,161 62,807 62,829
R&D Expenditure 1,903 1,402 1,213
Capital 318,059 322,744 328,683

Main Products
1. Raypam Injection(Iopamidol)
Use
CT Contrast Media
Exporting Countries
-
Remarks
-
IL-YANG PHARM. CO., LTD.
2. Sevoprane Inhalation (Sevoflurane) Anesthesia - -
3. Augmentin
Antibiotics - -
(Amoxicillin + Clavulnate)
Company Profile
With the company`s slogan, 'Respect humanity', 'Promote human's
health' and 'Improve welfare', IL-YANG PHARM. CO., LTD., has
R&D Pipeline tried its utmost to manufacture superior medicines for the last
half a century. In addition, IL-YANG has put forth its strength for
the construction of the country with healthy people under the
Iohexol - CT Contrast Media - banner of "Challenging the limitations of the medical practice and
pharmaceutical dispensing for one hundred years". On the basis of
Iopromide - CT Contrast Media -
the most advanced medical practice and pharmaceutical dispending
Representative and a solid business footing in the Korean market, IL-YANG has
Ioversol - CT Contrast Media -
Dong Yeon KIM, Ph.D exported a variety of pharmaceuticals to approximately 30 countries
Iomeprol - CT Contrast Media - Headquarter Address in the world including the USA and Europe. And also IL-YANG has
110, Hagal-ro, Giheung-gu, Yongin-si, opened an era of local production, by establishing 2 Joint Ventures in
Meglumine Gadoterate - MRI Contrast Media - China; YangZhou-IlYang and TongHua-IlYang.
Gyeonggi-do, 17096, Republic of Korea
Gadobutrol - MRI Contrast Media - Foundation Date
July 1st , 1946
Research Focus
Gastroenterology, Oncology, Virology,
Vaccine
Total Staff
621 persons
82-31-281-7851 (Headquarter)
82-2-570-3700~7 (Seoul)
Web
www.ilyang.co.kr
Contact Person
Young Hwi KO
Contact Phone
82-2-570-3804
Financial Figures
Contact E-mail
yhko@ilyang.co.kr Summary (1 Million Won)
Fiscal Year 2015 2016 2017
Sales 186,285 261,614 290,000
R&D Expenditure 15,007 14,646 16,000
Capital 48,727 48,727 48,727

Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks

26. Alvorin Tab / Levocetirizine Antihistamine - Generic
New 27. Epinastine Tab / Epinastine HCI Antihistamine, Antiallergy - Generic
1. Supect Cap / Radotinib 1st and 2nd line of CML-CP -
Drug 28. Kukuratum Syrup / Pelagonium
Gastric Ulcer, Duodenal Ulcer, Acute laryngitis - Generic
New sidoides
2. Noltec Tab / Ilaprazole Erosive Esophagitis, H.pylori Ecuador, Cambodia
Drug 29. Ambosol Inj / Amino acid Amino acid - Generic
Eradication
3. Il Yang Flu Vaccine Pre-filled 30. Ibandronsan Tab / Ibandronic Acid Osteoporosis - Generic
Syringe inj / Trivalent purified Influenza Vaccine - Generic CVA, Cardiac infarction,
inactivated influenza virus antigen 31. Clopidogrel Tab / Clopidogrel - Generic
Peripheral artery disease
4. Teratect Pre-filled Syringe inj / Non-insulin dependent
Quadrivalent purified inactivated Influenza Vaccine - Generic 32. Glimed Tab / Glimepiride - Generic
diabetes, mellitus
influenza virus antigen Neurogenic bladde,r Nervous
33. Finasterid Tab / Finasteride - Generic
5. Rosatan Tab / Losartan potassium Hypertetion - Generic pollakiuria
6. Nizaractine Cap / Nizatidine H2-blockers - Generic Pyelonephritis, Cystitis,
34. Cefadroxil Cap / Cefadroxil - Generic
Urethritis
7. Neusilin A Tab / Magnesium
Antacid, Absorbent - Generic 35. Nofaxin Tab / Levofloxacin Antibiotic - Generic
Aluminum Silcate
8. Andilac-S Cap / Lactobcillus 36. Aldrin Tab, Susp / Almagate Antacid action Vietnam, Cambodia, Mongolia, Etc Generic
Digestive - Generic
Acidophillus 37. N
oigel Susp / Aluminium
Habitual constipation, Antacid action Vietnam, Cambodia, Mongolia, Etc Generic
9. Mutacil Powder / Psyllium husk - Generic magnesium silicate
irritable bowel syndrome
38. Norumo Susp / Boehmite Antacid action Cambodia, Etc Generic
10. Motive Tab / Mosapride Cirtate Anticonvulsive - Generic
39. Shumecton Susp / Dioctahedral
Antidiarrhotica Cambodia, Etc Generic
11. Etive Tab / Itopride HCI Anticonvulsive - Generic smectite
12. Montidin Tab / Levosulpiride Anticonvulsive - Generic 40.Alluphose Plus Susp / Colloidal
Antacid action Cambodia, Etc Generic
Aluminum phosphate
12. Telmisartan Tab / Telmisartan ARB - Generic Symptoms due to insufficient
41. Azintal Forte Tab / Azintamide Vietnam Generic
13. Betaprol Tab / Bisoprolol -blockers - Generic bile secretion
42. G
inkgo Biloba Leaf Ex Cap /
14. AmBP Tab / Amlodipine Mesylate Circulatory Improvement Vietnam Generic
CCB - Generic Ginkgo biloba leaf extract
Monohydrate
43. Alled Tab / Cetirizine HCI Allergin rhinitis Mongolia Generic
15. Furix Tab / Furosemide Diuretics - Generic
44. Alcom Tab / Flubendazole Anthelmintics Mongolia Generic
16. Indapam Tab / Indapamide Diuretics - Generic
45. E piderm Cream / Triamcinolone
17. Atrovastatin Tab / Atorvastatin Hyperlipidaemic - Generic Dermatologicals Cambodia, Singapore Generic
Acetonide
18. Pista Tab / Pitavastatin Hyperlipidaemic - Generic 46. Aminopi Tab / Thiamine Vitamin, Mineral & Nutrition - Generic
19. Actigli Tab / Piolitazone HCI Hypoglycemic agent - Generic 47. J ointap Plus Cap / Sodium
Vitamin, Mineral & Nutrition - Generic
20. Hinechol Tab / Bethanechol chondrotin sulfate
Autonomic nervous system - Generic
Chloride 48. Poweramin Softcap / L-leucine Vitamin, Mineral & Nutrition - Generic
genitourinary, Urinary 49. Wonbi-D / White Ginseng Extract Health Drink Malaysia, Mauritius -
21. Poverin Tab / Propiverine HCI frequency, urinary - Generic
incontinence 50. S ol+(Ginseng energy) / Guarana Afghanistan, Mongolia, USA,
Energy Drink -
powder Pakistan, Etc
22. Sildenafil Tab / Sildenafil citrate Erectile dysfunction - Generic
Guatemala, Singapore, South Africa,
23. Arthalgyl Inj / Aspirin lysine Fever reducer, Pain reliever - Generic Taiwan, Malaysia, USA, Bangladesh,
Improvement of brain Vietnam, Spain, Syria, Iran, Egypt,
24. Nutrix Tab / Acetly-L-Carnitine - Generic 51. D
.A.H.G (API) / Dried Aluminum
metabolism Antacid Raw Material India Ney Oh, China, Cambodia, -
Hydroxide Gel
Costa Rica, Colombia, Thailand,
Motion sickness, Vomiting,
25. Bonaring A Tab / Dimenhydrinate - Generic Tunisia, Pakistan, the Philippines,
Nausea, Meniere’s disease
Australia, Hong Kong

52. Magnesium Hydroxide Gel (API) Antacid Raw Material

Taiwan, Malaysia, the US, Spain,
Singapore, Indonesia, Thailand,
Pakistan, Australia, Hong Kong, -
ISU Abxis Co., Ltd.
Bangladesh, Guatemala, New
Zealand, Syria, Egypt,
53. Almagate (API) / Aluminum
Antacid Raw Material China -
Magnesium Hydroxide Carbonate
Taiwan, Malaysia, the US, Spain,
Singapore, Indonesia, Thailand,
54. Magnesium Aluminum
Antacid Raw Material Pakistan, Australia, Hong Kong, - Company Profile
Metasilicate (API)
Bangladesh, Guatemala, New Since 2001, ISU Abxis has established its own platform technologies
Zealand, Syria, Egypt,
and product pipelines with a desire of being an axis of all therapeutic
Bangladesh, Bolivia, Switzerland, antibody industry as its name stands (ABXIS=AntiBody + aXIS).
55. Magaldrate (API) Antacid Raw Material Taiwan, Spain, Ecuador, Egypt, India, -
Beginning with the successful development and market-launch of
Chile, Pakistan
Korean first therapeutic antibody in 2006. Consequently in 2013 and
Vietnam, Taiwan, United States,
56. Dried Aluminium Phosphate (API) Antacid Raw Material - 2014, ISU Abxis launched two biotherapeutics for orphan diseases of
Singapore, China
Gaucher and Fabry disease. ISU’s three products, supplied to over 30
57. Hydrotalite (API) / Aluminum
Antacid Raw Material Germany, Indonesia - countries including Turkey, Iran, Mexico and Algeria, are available as
Magnesium Hydroxycarbonate Representative the only alternative against the reference drugs worldwide. Moreover,
Mr. Seok Joo Lee ISU ABXIS GMP which is for drug substance has been inspected
Headquarter Address under PIC/S guideline and successfully registered, and application of
R&D Pipeline variation for DS manufacturing site addition were approved by MFDS
Global R&D Center C-5F, 22
Compound Name Code Use Stage of Development Daewangpangyo-ro, 712 beon-gil, (Ministry of Food and Drug Safety). ISU Abxis will grow its advanced
Ilaprazole - N.E.R.D Phase III Bundang-gu, Seongnam-si, Gyeonggi-do, technology based business for difficult-to-treat and orphandisease
13488, Korea market both domestically and worldwide.
Radotinib - Chronic Myeloid Leukemia Phase III
- IY-7640 Anti-viral Phase I Foundation Date
March 28, 2001
Flu Vaccine - Pediatric Quadrivalent Flu Vaccine Phase III
Research Focus
Oncology, Metabolic disorder
New Active Substances Total Staff
Product (Ingredient) Use Approval Date/Country 150 persons
Dec. 2007 / China, Oct. 2008 / Korea, Representative Phone
Noltec (Ilaprazole) Anti-Ulcer Agent
Oct. 2016 / Ecuador, Jan. 2017 / Cambodia 82-31-696-4700
Supect (Radotinib) Anti-CML Agent Jan. 2012 / Korea Web
http://www.abxis.com
Others Contact Person

Mira PARK
OUT-LICENSING BUSINESS Contact Phone
IL-YANG PHARM CO., LTD. is seeking for a partner in every continent to License out new chemical entity developed by IL-YANG's 82-31-696-4645
very own technology and R&D. IL-YANG is fully focusd on promoting "ILAPRAZOLE (Proton Pump Inhibitor)" and "RADOTINIB (Tyrosine Financial Figures
Kinase Inhibitor)" as well as "INFLUENZA VACCINE (Trivalent/Quadvalent)" with other biological products globally with mutual Contact E-mail
business relationships. mira.park@isu.co.kr Summary (1 Million Won)
IN-LICENSING BUSINESS Fiscal Year 2015 2016 2017

IL-YANG PHARM CO., LTD. is dedicated to realize the true value of the products which compliance to IL-YANG's own vision and Sales 11,471 19,055 30,051
strategy. IL-YANG is actively engaged in the In-Licensing business to introduce innovative products from all nations to Korea. R&D Expenditure 5,339 5,344 4,831
ILYANG and Licensor will synergistically maximize the effect of registration, marketing, distribution and sales regarding the product. Capital 9,791 9,875 9,875

Main Products
12 countries
Remarks
The first therapeutic

JEIL Pharmaceutical Co., Ltd.
Adjunct to Percutaneous including Algery, antibody developed in
1. Clotinab®(Abciximab)
Coronary Intervention (PCI) Turkey, Columbia, Korea and the world’s
Venezuela and etc. second Abciximab
20 countries The first drug for GD

Enzyme Replacement Therapy
including Mexico, Sri developed in Korea
2. Abcertin®(Imiglucerase) (ERT) for Gaucher disease
(GD)
Lanka, Iran, Russia and the world’s second Company Profile
and etc. Imiglucerase
We, Jeil pharma have started global business by supplying Penicillin
The first drug for FD APIs to a Japanese renowned company and also wide range of
3. Fabagal®(Agalsidase beta)
Enzyme Replacement Therapy Launched only in developed in Korea plaster products to South East Asian countries in the late 1990s.
(ERT) for Fabry disease (FD) Korea in 2014 and the world’s second
Agalsidase beta Our factory has passed the strict standard of PMDA, Japan and
also has PICS GMP as Korea has enrolled a member of PICS. As for
API facilities, we have 5 dedicated factories such as Cephalosporin
injection, Cephalosporin Oral, Caba-penem, Cytotoxic anti-cancer
Representative and General APIs.
R&D Pipeline Suk Je Sung In finished dosage as well, we have installed dedicated production
Headquarter Address lines such as Caba-penem injection and Cytotoxic Anti-cancer
343, Sapyeong-daero, Seocho-gu, Seoul, products. Besides these, we produce many kinds of generics to meet
Recombinant Factor IX ISU304 Hemophilia B Phase I the need of our customers around the world. In 2016, our overseas
06543, Korea
sales turnover exceeds 60 million US dollarsand more than 50
Novel drug (mAb) ISU104 Solid tumor Phase I Foundation Date countries, we are supplying our products.
1959
Paroxysmal nocturnal We, Jeil pharma will keep expanding our market with best quality
Eculizumab ISU305 Phase I (2018)
hemoglobinuria (PNH) Research Focus of products and contribute to the enhancement of global citizens'
Cardiovascular, Gastrointestinal, but no health.
Non Small Cell Lung Cancer,
Nivolumab ISU106 Non-clinical study (ready) limitation
Melanoma
Total Staff
Trastuzumab ISU103 Breast cancer Non-clinical study (ready) 945 persons
82-8-529-7451~65 (546)
Web
www.jeilpharm.co.kr
Contact Person
Pil Joong Kim
Contact Phone
82-2-529-7451~65 (520)
pjkim@jeilpharm.co.kr
Fiscal Year 2015 2016 2017
Sales 594,716 617,280 640,000
R&D Expenditure 20,299 22,313 23,000
Capital 7,425 7,425 7,425

Main Products
1. Cefditoren (Ingredient)
Use
Antibitotics
Exporting Countries
Japan
Remarks
-
JINYANG PHARM. Co., Ltd.
2. Cefcapene (Ingredient) Antibitotics Japan -
3. Epinastine (Ingredient) Allergy Japan -
4. Meropenem (Ingredient) Antibitotics Japan -
Vitenam,Thailand,
5. Meropenem (Formulation) Antibitotics -
Azerbaijan Company Profile
6. Imipenem (Formulation) Antibitotics Vietnam, Thailand - Since Jin Yang Pharm. Co., Ltd. was established in 1971, we have
7. Entecavir (Formulation) Anti Viral Japan, Hong Kong - been trying to stay ahead of the pharmaceutical industry in Korea
with our full automatic production system in the most modern and up-
to-date manufacturing facility.
In 2017, new manufacturing facility which is designed to export our
products to advanced countries including U.S. & Europe (cGMP/
R&D Pipeline EU-GMP standard) was completed and PIC/s GMP was approved.
Representative It is capable of manufacturing oral formulations over 500 million
JPI-289 JPI-289 Stroke Phase 2A Jae-Joon, Choi Tablets(Capsules) per year by using state-of-the-art technologies &
equipments.
JPI-547 JPI-547 Cancer Phase 1 Headquarter Address
231, Hyoryeong-ro, Seocho-gu, Seoul, We have also been leading the development of the pharmaceutical
JP-1366 JP-1366 GERD Phase 1
Korea industry in Korea through cooperation with the global pharmaceutical
JP-2266 JP-2266 Type 1 Diabetes Mellitus Pre-clinical companies.
Foundation Date
JCT1-PD JCT1-PD Parkinson’s disease, AMD Pre-clinical July 01, 1971 For more than forty years, based on the principle of honesty and
Fixed dose combination drug sincerity, all the staffs and employees of our company have been
Tamsulosin/Solifenacin JLP-1207 Phase 3 Research Focus putting all their efforts into building a better world with the aim of
for BPH
Capsule, Tablet, Dry Syrup developing good quality drugs for health and happy life of the people
Fixed dose combination drug
Metformin/Rosuvastatin JLP-1310 Phase 3 Total Staff and with the faith of managing the company in a profound respect
for diabetes / dyslipidemia
217 Employee for humanity. We promise to be a company that keeps on doing
Fixed dose combination
research and development for the improvement of life quality of the
Telmisartan/Amlodipine/Rosuvastatin JLP-1401 drug for hypertension / NDA Representative Phone
dyslipidemia
people and clients can give their confidence to our company. We will
82-2-3470-0372 contribute to healthy life of the people by bending over backwards to
New salt form drug for
Varenicline JLP-1603 NDA Web help you not to lose your healthy body and happy life.
smoking cessation aid
http://www.jinyangpharm.com/
Clinical trial study
UNI-DEB (Medical Device) JLM-1401 Liver Cancer (TACE)
(Pivotal study) Contact Person
Chang Hwan, Lim
Contact Phone
82-2-3470-0361
Others Contact E-mail
chlim@jyp.co.kr Financial Figures
Jeil is partnered with many multinational companies like Pfizer, Takeda, Daiichi Sankyo and etc.
We are currently promoting Pfizer's Lipitor, Takeda‘s Nesian, and Daiichi Sankyo's Cravit in Korea, so we have a very good Summary (1 Million Won)
understanding of various market and plenty of sales marketing experience. Fiscal Year 2015 2016 2017
We seek new opportunities through in licensing as well as co-promotion. If you are interested in entering the Korean market, Sales 40,100 36,100 46,000
partnering with us will be a great opportunity to both of us. R&D Expenditure 2,172 1,390 1,600
Capital 6,000 6,000 6,000

Main Products
1. CLIVIX (Clopidogrel bisulfate/Tab.)
Use
Anti-coagulants
Exporting Countries
-
Remarks
-
JW Pharmaceutical Corporation
2. ESZOL (Esomeprazole/Cap.) GERD - -
3. ATORAN (Atorvastatin/Tab.) Hyperlipidemia - -
4. Acechol (Choline Alfoscerate/Soft Cap.) Neuropsychiatric system - -
5. ELBUNAL (Erdosteine/Cap.) Respiratory system - -
Company Profile
6. BESDIPINE (Amlodipine besylate/Tab.) Anti-hypertensives - -
Since its foundation, JW Group has led the hospital market based on
7. HYALLON (Hyaluronate sodium/Inj.) Osteoarthritis - -
respect for life and the pioneering spirit, and is now being reborn as a
8. ALBIJIN (Pot.bismuth citrate, Ranitidine global healthcare company to lead the industry into the 21st century.
Digestive system - -
hydrochloride,Sucralfate hydrate/Tab.)
Based on leading competitiveness in the ethical drug market, JW
9. MOGATON (Itopride HCl/Tab.) GI-regulator - -
Pharmaceutical has built up strong sales network across the country
10. RAMISTA (Rebamipide 100mg/Tab.) Digestive system - - and superior pipelines in I.V solutions, antibiotic, cardiovascular,
gastrointestinal, nephrology, anticancer and neuropsychiatry. And
11. ROSUVATIN 10mg (Rosuvastatin Ca./Tab.) Anti-hyperlipidemics - -
Representative now, it is pioneering the rapidly growing new field such as diabetes
12. JINFLAG (Sarpogrelate HCl/Tab.) Anti-coagulants - - and so on. It has been striving to produce and provide innovative new
Mr. Kyung Ha Lee / CEO
13. OCTIRAN 40mg (Octylonium bromide/Tab.) Digestive system - - technologies and services heading for healthy lives of human beings
Headquarter Address on the basis of its founding spirit of "Respect for life".
14. DAPID (Indapamide/Tab.) Anti-hypertensives - - 698, Shindaebang-dong, Dongjak-gu,
15. KAZATAN (Losartan potassium/Tab.) Anti-hypertensives - - Seoul, 156-757
16. MIARYL (Glimepiride/Tab.) Anti-diabetics - - Foundation Date

1945.
17. BANDRON
Osteoporosis treatment - -
(Ibandronate sodium monohydrate/Inj.) Research Focus
18. ACTOGREEN (Pioglitazone HCl/Tab.) Anti-diabetics - - Anti cancer, Formulation research
19. SIMECOPAN Total Staff
Digestive system - - 1,872 persons
(Simethicone, Alverine citrate/Soft Cap.)
20. TRIMA (Trimebutine maleate 200mg/Tab.) Digestive system - - Representative Phone
82-2-8406-777
Representative Fax
82-2-841-1213
Web
R&D Pipeline http://www.jw-pharma.co.kr/
Atrovastatin Calcium - Antilipidemic Agents BE study
Choline Alfoscerate - Nootropics % Neurotonics Formulation Study
Antithrombotics & Antiplatelet Financial Figures
Clopidogrel bisulfate / Aspirin - Formulation Study
Agents
Linagliptin - DPP-4 Inhibitors Formulation Study Fiscal Year 2008 2009 2010
Sitagliptin - DPP-4 Inhibitors Formulation Study Sales 437,648 455,147 443,276
Empagliflozin - SGLT Formulation Study R&D Expenditure 19,942 22,173 24,231
Capital 23,033 23,774 24,487

Main Products
Japan, China
KMS Pharm Co., Ltd.
EU (Spain, Germany)
South-East Asia (Hongkong, Indonesia, Malaysia,
1. Carbenem Antibiotics Infection by Gram
Mongol, Parkistan, Philippines, Syria, Thailand,
(Imipenem/Cilastin) - positive bacteria
Vietnam, Yemen, Nigeria, India, Bangladesh etc.)
CIS (Russia, Kazahstahn, Belarus, etc.)
Latin America (Brazil, Mexico, Argentina etc.)
Company Profile
Supply electrolytes and trace
2. I.V Solutions South-East Asia (Vietnam, Cambodia, etc.) Future oriented pharmaceutical manufacturer producing and
elements
distributing finished medicines such as tablets and capsules to the
3. Antifungal Agents
Infection by fungi
Japan domestic and overseas hospitals, pharmacies, etc. under KGMP
(Itraconazole,ketoconazole) South-East Asia (Indonesia, Parkistan etc.) based on PIC/S GMP guidelines.
4. Other antibiotics Japan
Various infection
(Cefmetazole, amikacin) South-East Asia (Vietnam etc.)
Care for various cancer

5. Anticancer drugs South-East Asia Foundation Date
including hematological
(Cytarabine,Alkyloxan,5-FU) (Turkey, Malaysia, Bangladesh etc.) July 1997
cancer
Research Focus
Finished medicines
Total Staff
R&D Pipeline 60 persons
Compound Name Code Use Stage of Development Representative Phone
82-31-215-5456
Phase I clinical trial approved by FDA in April,
WnT - Hematological Malignancy
2011 Web
www.kmspharm.com
Lucentis bio-betters - Metastatic Colorectal Cancer Pre-clinical study for IND application
Contact Person
Montelukast - Anti-Asthma
BUSH-Tab® Tech (Formulation research) Jong Ho, Kim
To be launched in January, 2012
Contact Phone
82-31-215-5456(ext. 403)
Contact E-mail
kjh2198159@naver.com
100mg: 6th, May, 1993

Q-ROXIN (Balofloxacin) Antibiotics
200mg: 7th, Jul., 1995
Financial Figures
Zepeed (Avanafil) Erectile Dysfunction 17th, Aug., 2011
Fiscal Year 2015 2016 2017
Sales 9,500 11,000 12,900
Capital 1,200 1,200 1,200

Main Products
Cambodia, Myanmar
Remarks
Kolmar Korea Co.,Ltd.
1. Levocetirizine dihydrated 5mg Tab Anti-histamines -
Hongkong, Mongolia
2. Tramadol hci 37.5mg / Vietnam, Cambodia

Anti-inflammatory -
Acetaminophen 325mg Tab Hongkong
Vietnam, Cambodia
3. Levosulpiride 25mg Tab Indigestion -
Hongkong Company Profile
4. Losartan potassium 50mg Tab Hypertension Vietnam - Since founded in 1990 as a joint venture company with Nihon(Japan)
Kolmar, Kolmar has grown to the biggest Korean Pharmaceutical
5. Rebamipide 100mg Tab Gastric ulcer Vietnam - contract manufacturer.
6. Felodipine 5mg Tab Hypertension Cambodia - Kolmar Korea has extended our business to pharmaceutical business
from 2002. And provide specialized production system with total
7. Levodropropizine 60mg Tab Antitussives & Expectorants Hongkong -
outsourcing service on development and production of pharmaceutical
8. Streptokinase / and quasi-drug.
Enzymes Ecuador -
Streptodornase 10mg Tab Representative Kolmar Korea has provided customized contract manufacturing
Cho Hong Koo service with customers who want to outsource their pharmaceutical
Headquarter Address products, cosmetics and healthcare foods to be more competitive and
245 Sandan-gil, Jeonui-myeon, Sejong to develop new formulations feasible in the market.
city, Korea Focus Area : CMO (Contract Manufacturing Organization), Generic
Foundation Date drug.
1990.05.15
Research Focus
42 (Pharmaceutical division)
Total Staff
650 persons
82-2-3485-0497
Representative Fax
82-2-515-1532
Web
http://www.kolmarpharm.co.kr
Contact Person
Mr.M.S.Pyo
Contact Phone
Contact E-mail
mspyo@kolmar.co.kr
Fiscal Year 2012 2013 2014
Sales 177,779 267,881 439,080
R&D Expenditure 7,418 11,997 17,200
Capital 9,742 9,742 10,550

Main Products
1. Painless Tablet
Use
Anti inflammatory
Exporting Countries
Philippines
Remarks
EU-GMP 추진품목
Kolon Pharma
2. Hiforge Tablet Hypertensive Ajerbaijan -
3. Cerephone Dry Syrup Anti-biotic Vietnam -
4. Azithrobiotic Dry Syrup Anti-biotic Vietnam -
5. Romaryl Cream Anti-fungi HongKong -

Company Profile
KOLON Pharma is focusing on developing and distributing high-
6. Levocetirizine HCl Tab. Anti-histamine The Philippines -
quality over the counter pharmaceuticals, prescription medications
7. Minoxidil solution Male pattern alopecia Japan - (mainly respiratory and dermatology) and sports nutrition products in
Korean market with a vision of expanding globally.
KOLON PHARMA is now working on expanding our business through
the open R&D process in Oncology, CNS and Hepatology areas as
well as focusing on developing of new drugs by using Incrementally
Representative Modified Drug(IMD) technique.
R&D Pipeline Woosok Lee
Headquarter Address
Tadalafil - Eretile dysfunction BE 13 Kolon-ro, Gwacheon, Gyeonggi, Korea
Amlodipine + Olmesartan - Hypertension BE Foundation Date
September, 1958
Celecoxib - Antiinflammatory BE
Research Focus
Atorvastatin Calcium - Hyperlipidemia BE Respiratory, Dermatology
Entecavir - Treatment of HBV BE Total Staff

453 persons
82-2-2120-8300
Web
http://www.kolonpharma.co.kr
Contact Person
Narae Song
Contact Phone
82-2-2120-8533
Contact E-mail
narsong@kolon.com
Financial Figures
Fiscal Year 2015 2016 2017
Sales 73,500 81,600 100,200
R&D Expenditure 1,478 1,494 1,600
Capital 6,000 6,000 6,000

Main Products
1. Foster HFA
Korea Arlico Pharm Co.,Ltd.
(Beclomethasone Dipropionate, Asthma, COPD - No.1 in MDI Market
Formoterol Fumarate / inhalation)
2. Topisol Milk Lotion
(Methyl Prednisolone aceponate/ Topical Corticosteroids - No.1 in Topical Steroid Market
Topical Lotion)
World’s No.1 Surfactant
3. Curosurf Neonatal Distress One of the leading product s in
Company Profile
-
(Poractant Alfa/Oral Solution) Respiratory syndrome hospital -Accounting for 63% of the About 20 years, we Korea Arlico Pharm have been poured our energy
Korean market into helping people to live healthier and happier based on the belief
4. COMY Syrup that life is precious and nature is the source of all life.
Nasal & Sinus -Ranked No.1 in pediatric
(Pseudoephedrine, -
Congestion decongestion and rhinitis market We value our quality through KGMP validation for better
Chlorphenylephrine/Oral Solution)
circumstance.
5. INVOSSA-K Inj. The World's first cell-mediated
Osteoarthritis -
(1: hChon J, 2: hChonJb#7) gene therapy In the year 2010, we had 30% increase from 2009 and keep growing
Disposable sachet its sale record in 2011 and exports to 4 Countries as for April. 2011.
5. APNIBEN Q Soln Representative
Cold sores/ Stomatitis - The only mouthwash type Ranked We Awarded a million dollars "Export top" by Korea International
(Diclofenac/Gargle Solution) Hang Gu Lee
No 1. in Somatitis Tx Market
Trade Association in 2013.
6. BICOGREEN S Tab Headquarter Address
Ranked No 1. in Constipation And we went public on February 12, 2018.
(Bisacodyl, Sennoside, Sod. Constipation - Korea Arlico B/D, 7-21,Baumoe-ro
Market
Docusate) 27-gil, Seocho-gu, Seoul, 06752, Republic In the near Future, we hope to find more countries to have a strong
of Korea partnership.
Foundation Date
R&D Pipeline OCT. 01, 1992
Compound Name Code Use Stage of Development Research Focus
beclomethasone dipropionate + Tablets, Ointments, Creams, Gels
KPC-7001 Asthma COPD Pre-registration
formoterol + CHF-5992 Total Staff
beclomethasone dipropionate + 200 persons
KPC-7002 Asthma COPD Pre-registration
formoterol high dose
Oseltamivir Capsule/Dry Powder for
KPC-1023 Influenza Launched 82-2-585-0004
suspension
Bepotastine Dry Syrup/SR tablet KPC-2003/2004 Rhinitis Phase 1 Web
www.arlico.co.kr
Bepotastine + Montelukase KPC-2007 Rhinitis Phase 1
Contact Person
Undisclosed KPC-9007 Psoriasis registration SEUNG CHAN HAN
Sinecatechins KPC-7104 Warts Pre-registration Contact Phone
82-2-520-6945
New Active Substances schan@arlico.co.kr
Fiscal Year 2015 2016 2017
Morniflu Tab(Monriflumate) NSAIDs 2004.06.09. / Italy
Sales 32,985 48,214 71,346
Remicut Cap(Emedastine Difumarate) Anti histamine, For allergic Rhinitis 1994.04.31. / Japan
R&D Expenditure 1,770 1,358 1,925
Brexin Tab (Piroxicam beta cyclodextrine) NSAIDs 1992.01.22. / Italy Capital 1,112 1,216 3,211

Main Products
1. Thioct HR Tab.
Use
Relief and treatment of

Korea Otsuka Pharmaceutical Co.,Ltd.
Vietnam, Mongol -
(Thioctic Acid 600mg / Solid oral) diabetic multiple neuritis
2. Acrasone Cream 10g

(Betamethasone Dipropionate Anti-inflammatory action and Vietnam, Tanzania,
-
0.64mg, Clotrimazole 10mg, good antifungal action Hongkong
Gentamicin Sulfate 1mg)
Company Profile
Hypertension Renal disease
3. Cozasartan Tab. Established in 1982, Korea Otsuka Pharmaceutical Co.,Ltd. is a joint-
in diabetic patient with - -
(losartan potassium 50mg)
hypertension stock company that provides excellent and innovative medicines as
part of its mission of contributing to the Korea healthcare industry.
Duodenal ulcer, gastric ulcer, We have large-scales production facilities in Korea for the consistent
4. Curazol Cap. (Omeprazole 20mg) Ecuador -
reflux esophagitis etc., production of finished goods from synthesis of life. Moreover our
products have help treat patients in Korea and improve quality of
life. Moreover our products been exported Europe, Asia and the
Middle East contributing to the taken an active part in international
Representative clinical studies, and strived to expand our business starting with the
Others Moon Sungho healthcare business in 2012.
Headquarter Address Focus Area : CNS, Neurology, Cardiology, Gastroenterology
Our ultimate goal is to become a global pharmaceutical company competing against current multi-national companies.
226 Yeoksam-ro, Gangnam-gu, Seoul,
We will vigorously continue to improve our products.
Korea
Foundation Date
July 9,1982
Total Staff
340 persons
82-2-3287-9000
Representative Fax
82-2-3287-9019
Web
http://www.otsuka.co.kr
Contact Person
Kim Taejin
Contact Phone
82-2-3287-9124
Contact E-mail
paran2010@otsuka.co.kr Financial Figures
Fiscal Year 2012 2013 2014
Sales 11,517,041 12,124,578 12,100,153
R&D Expenditure 402,665 213,818 177,080
Capital 17,356,368 17,457,246 18,287,237

Main Products
Hong-Kong, Philippines,
Remarks
KOREA PHARMA CO., LTD.
1. ABILIFY Tab. Anti-psychotic agent -
Thailand, Indonesia
2. ABILIFY ODT Anti-psychotic agent OPEL(Europe) -
Hong-Kong, Philippines,
3. PLETAAL Tab. Anti-platelet agent -
Thailand, Vietnam, Malaysia
Company Profile
4. PLETAAL SR Cap Anti-platelet agent - -
Korea Pharma Co., Ltd.(KP) established in 1974, have acquired KGMP
Philippines, Thailand, as we have safe and stabilized production systems. KP maintain the
5. MUCOSTA Tab. Anti-ulcer agent -
vietnam, Cambodia, Malaysia production process to assure the efficacy, safety and stability of all
6. SAMSCA Tab. Aquaretic agent Philippines, Thailand - our products such as oral solid forms, oral liquid forms, topical liquid
forms, ointment etc. We have built up perfect Q.C. systems, and we
7. Meptin Tab. Anti-asthmatic agent - - are supplying our products to the domestic markets, and exporting
to over 16 countries to be widely recognized the manufacturing and
8. Meptin swinghaler Anti-asthmatic agent Philippines, Indonesia - technological achievements in the world.
Representative
Anti-asthmatic agent Philippines, Thailand, Jae Don Park Focus Area : CNS Drug, Colon Cleansing Agent, Alimentary
9. OBUCORT swinghaler -
(Inhalation) Indonesia Preparation etc.
Headquarter Address
10. Mikelan Tab. Anti-arrhythmic agents - - 87, Jeyakgongdan 3-gil, Hyangnam-eup,
Hwaseong-si, Gyeonggi-do, Korea
HSCT (hematopoietic stem cell
11. Busulfex IV transplantation)Conditioning - - Foundation Date
agent Sep. 03, 1974
12. Lorelco Tab. Anti-hyperlipidemic agent - - Research Focus
Developing innovative new medicines
Total Staff
242 persons
82-2-558-1277
Representative Fax
82-2-558 1678
Web
www.koreapharma.co.kr
Contact Person
Jin Wook Lee
Contact Phone
Contact E-mail
koreapharma@hanmail.net
jinwook.lee@koreapharma.co.kr Fiscal Year 2012 2013 2014
Sales 44,744 50,046 54,829
R&D Expenditure 1,010 1,350 1,453
Capital 3,300 4,200 4,200

Main Products
1. VASTIA Tab. 5mg/10mg

Korea Prime Pharm. Co., Ltd.
Central nervous system agent Hong Kong -
(Donepezil HCl 5mg, 10mg)
2. ALBIX Tab. 10mg

Central nervous system agent Hong Kong -
(Memantine HCl 10mg)
3. KOTASE Tab.
Anti-tumefacient enzyme
(Bromelaine 40mg & Crystalline
preparation
Myanmar, Vietnam - Company Profile
Trypsin 1mg)
KOREA PRIME PHARM. CO., LTD. is specializes in manufactures and
4. BAB Chewable Tab. sales of pharmaceutical drugs(ETC) and Hospital doctors prescribe
(Hydrous dibasic calcium phosphate medications, and going to achieve higher growth rate of 30% per year
Alimentary preparation Myanmar -
100mg, Calcium lactate 25mg, rather than the average growth rate of the pharmaceutical industry.
Vitamins, etc.)
Furthermore, domestic pharmaceutical companies are noticed
5. AMOROLFINE Nail Lacquer Topical antifungal agent for to a big change by Korea-US FTA agreement recently. Therefore,
- -
(Amorolfine HCl 5g) onychomycosis Our c35,145ompany cope with the policy changes of the domestic
Representative pharmaceutical industry and the opening of the global pharmaceutical
6. CRICOLON Tab.
(Dibasic Sodium phosphate Kim Dae Ik market, and we think to develop new products as a top priority
Tablet type colon cleansing in order to grow as a global company, and are focusing on doing
anhydrous 398mg, Monobasic - -
agent Headquarter Address business making new drugs(improved new drugs, Biomedicine, drug
Sodium phosphate
monohydrate1,102mg) 8F, Daein B/D, 158-3, Daein-dong, Dong- formulation development, and so on) by R&D cooperation.
gu, Gwangju, Korea
7. RISDON Tab. 1mg/2mg In particular, our company awarded "2009, Korea Health Industry
Central nervous system agent - - Foundation Date Award", and "Grand Prize"in the part of independent medium venture
(Risperidone 1mg, 2mg)
1995. 5. 31 company. With this opportunity, we will increasingly continue to
8. PAROXETINE Tab. 20mg Research Focus work hard with the responsibility of the development of domestic
Central nervous system agent - -
(Paroxetine HCl 22.8mg) pharmaceutical health industry.
Medicine
Total Staff
253 persons
82-2-848-8487
Representative Fax
82-2-848-8489
Web
http://www.koreaprime.co.kr/english/
main.htm
Financial Figures
Fiscal Year 2008 2009 2010
Sales 35,145 43,544 60,233
Capital 1,950 2,150 2,150

Main Products
1. Denical Tab.
KOREA UNITED PHARM.INC.
(Calcium lactate pentahydrate
271.8mg, Calcium Glluconate
In case of calcium shortage/supply Vietnam, Cambodia -
240mg, Precipitated Calcium
Carbonate 240mg, Dried
Crgocalciferol 0.118mg)
Pharyngolaryngitis, acute bronchitis, tonsillitis,
2. Throgin Tab. Company Profile
bacterial pneumonia, otitis media, sinusitis, Vietnam, Cambodia -
(Roxithromycin 150mg)
periodontitis, etc.
· Establishment Date : Dec. 3, 1987
Respiratory tract infection, infections in ear, nose,
3. Rocin Tab. · B usiness Activities : Manufacture, Marketing & Sales of
throat, mouth and tooth, renal and urinary tract Vietnam, Cambodia -
(Ciprofloxacin 250mg) Pharmaceuticals and Other Healthcare Products
infection, etc.
4. Anflaim Tab. respiratory tract infections, urinary tract infections, · Number of registered products : about 307 items
Vietnam, Cambodia -
(Ofloxacin 100mg) dermatological infections, gynecological infections
· Number of employees : 810 (Feb. 28, 2017)
hyperlipidemia, prophylactic use in
5. Simbidan Tab.
hypercholesterolaemic patients with ischaemic Vietnam - · Investment in R&D : 12.8% of net sales (2016)
(Simvastatin 20mg)
heart disease Representative
· Sales : $160M (2016)
1. Anti-inflammation and analgesia in the Duk-young Kang
following diseases and symptoms : Chronic Headquarter Address
· Growth Rate from 2015 to 2016 : 9.2%
rheumatoid arthritis, osteoarthritis, low back pain,
25-23, Nojanggongdan-Gil, Jeondong- · Incrementally Modified Drug : Clanza®CR, Clavixin®Duo Cap,
scapulohumeral periarthritis and neck-shoulder-arm
6. Loxorofen Tab. syndrome.
Myeon, Sejong, Korea Cilostan®CR, Kalomin®Tab, Losasc®Tab5/50, Losasc®Tab5/100,
(Loxoprofen sodium 68.1mg) 2. Anti-inflammation and analgesia after operation, Vietnam, Cambodia - Foundation Date
Gastiin®CR, Levotics®CR
(60mg as anhydrous) trauma or tooth extraction. Dec. 03, 1987 KUP is an export-oriented company. KUP is aiming to be not only
3. Anti-pyresis and analgesia in the following a local leader but also global leading company by offering wide range of
diseases : Acute upper respiratory tract Research Focus
generics as well as differentiated products, incrementally modified drugs.
inflammation(including acute upper respiratory tract Drug delivery system
inflammation accompanied by acute bronchitis) - Novel Controlled Release Formulation KUP has broad and well balanced portfolio of 307 products and
Rheumatoid arthritis, osteoarthritis, (degenerative - Novel Fixed Dose Combination exports 416 different items to 32 countries through global marketing,
arthritic disease), sciatic neuralgia, amenorrhoeic Total Staff
and overseas manufacturing facilities in USA, Vietnam, and has
7. Talpain Tab.
pain, pain caused by trauma, inflammation and Vietnam, Cambodia - business alliances with oversea companies. Especially, KUP
(Talniflumate 370mg) 810 persons
pain after surgery, tendosynovitis, sprain, adnexitis, established manufacturing facility in Alabama, US for manufacturing
pharyngitis, tonsillitis, otitis, sinusitis Representative Phone and distrubuting drugs and health functional foods in 2003. This
Duodenal ulcer, gastric ulcer, Gastric oesophageal 82-2-512-9982 facility have allowed KUP to expand markets in US, Japan, and
8. Exad Cap. (Nizatidine 150mg) Vietnam, Cambodia -
reflux disease
Web Europe with know-hows of FDA regulatory processes.
Alleviation of the following symptoms due to http://www.kup.co.kr
functional dyspepsia: abdominal fullness, epigastric
9. Borad Tab. (levosulpiride 25mg) Vietnam, Cambodia - Contact Person
discomfort, and stomach soreness, belching,
nausea and vomiting Jihyun Ahn
10. Apepsia-m Tab. Following diseases and dyspepsia in case of Contact Phone
(Domperidone maleate drug administration nausea, vomiting, anorexia, 82-2-558-8612
Vietnam, Cambodia -
12.72mg) abdminal Distension, abdominal pains, flatulence, Financial Figures
(10mg as Domperidone) etc. Contact E-mail
jihyun@kup.co.kr Summary (1 Million Won)
Fiscal Year 2015 2016 2017
R&D Pipeline Sales 162,039 176,905 -
Ingredient Use Stage of Development R&D Expenditure 16,434 17,456 -
Sildenafil citrate Treatment for erectile dysfunction. Bioquivalence Test completion Capital 227,804 234,220 -

Korea Vaccine
KUP invested in Research&Development. KUP invested about 12%
of net sales and 10% of total employees in R&D continuously. KUP is
successful developing innovative drugs and commercializing them. As
a result, KUP has launched several IMDs including Clanza®CR Tab.,
Calvixin®Duo Cap., Cilostan®CR Tab., Kalomin®Tab., Losasc®Tab5/50,
Losasc®Tab5/100, Gastiin®CR Tab., Levotics®CR Tab.. In addition, KUP
has well balanced R&D portfolio including differentiated products of anti-
neoplastic, Anti-hypertensive, and Antithrombotic Drugs.
KUP has been acknowledged at home and abroad. KUP was Company Profile
nominated as Forbes’ ‘Asia’s 200 Best Under A Billion’ over two
Specializing in production of infectious disease preventive
consecutive years. KUP is one and only pharmaceutical company in Korea
medicine(Vaccine) and disposable medical devices, Korea Vaccine
nominated by the Forbes magazine as one of the ‘Asia’s 200 Best Under
has contributed to people's health since 1954.
A Billion’ over two consecutive years (2009~2010). KUP was awarded the
Best Drug Research Award in Korea for Cilostan®CR Tab in 2015. Focus Area : Pediatric vaccine and disposable medical supply.
Main Products Representative

Product (Ingredient/Formulation) Use Exporting Countries Remarks Deok-Ho Choi
· Improved dosing Headquarter Address
1. Clanza®CR Tab. Pain caused by rheumatism regimen from b.i.d. to 128, Mongnae-ro, Danwon-gu, Ansan-si,
Ukraine, Vietnam,
(Aceclofenac 200mg / Controlled (Antiinflammatory Analgesic q.d. Gyeonggi-do, South Korea
Philippines
Release Formulation) drug) · Less side effects of
gastrointestinal Foundation Date
· Improved dosing 1956.01
2.Cilostan®CR Tab. Ischemic symptoms, regimen from b.i.d to Research Focus
(Cilostazol 200mg / Controlled Thrombosis (Antithrombotic - q.d.
Vaccines
Release Formulation) drugs) · Reduced side effects of
headache & tachycardia Total Staff
3. Clavixin®Duo Cap. 260 persons
Acute coronary syndrome · Improved patient
(Clopidogrel 75mg and Aspirin -
(Antithrombotic drugs) compliance Representative Phone
100mg / Fixed Dose Combination)
4. Kalomin® Tab.
82-31-495-6397~8
(Pelargonium Sidoides(as dry Upper respiratory tract · Improved patient 82-2-443-1961~5
-
extract) 20mg / New Dosage infections (Antitussive) compliance for adults Representative Fax
Formulation) 82-2-2249-0363
5. Losasc® Tab5/50, 5/100
(Amlodipine 5mg and Losartan · CCB+ARB in ONE tablet Web
Hypertension www.koreavaccine.com
50mg / Amlodipine 5mg and - · Patent protected unique
(Anti-hypertensive drugs)
Losartan 100mg, Dual Layer Anti- formulation
Contact Person
Oxidant)
Sungbae Ha
Gastrointestinal symptoms
6. Gastiin®CR Tab · Improved dosing
associated with functional Contact Phone Financial Figures
(Mosapride 15mg / Controlled - regimen from t.i.d. to
Release Formulation)
dyspepsia(brash, nausea,
q.d.
82-2-443-2008
vomiting) Summary (1 Million Won)
Contact E-mail
· Just one tablet, twice a Fiscal Year 2012 2013 2014
daily sbha@koreavaccine.com
7. Levotics®CR Tab. Sales 115,774 100,700 133,200
Antitussive - · Performed clinical trial
(Levodropropizine 90mg) R&D Expenditure 179 236 206
lll phase of 8 university
hospitals Capital 46,790 55,646 63,256

Main Products
1. Freeze-dried BCG
KOREAN DRUG CO., LTD.
Prevention of Tuberculosis - Global distributorship
vaccine(percutaneous)
2. Kovax Polio PF. Prevention of Poliomyelitis - -
Prevention of Thphoid
3. Typhoid Kovax Inj. - -
bacillus
Company Profile
4. Kovax Influ PF (Influenza Vaccine) Prevention of Influenza - -
We manufacture, distribute, export and import more than 180
5. IL-YANG Flu Vaccine (Influenza medicines, health functional foods and cosmetics. Also, do contract
Prevention of Influenza - Global distributorship
Vaccine) manufacturer of specific dosage forms, supplies medicines and
6. Vari-L Vaccine Inj. Prevention of Varicella - Global distributorship diverse products.
We have always been eager to be the most reliable and trustworthy
Prevention of
pharmaceutical company that can bring the highest value to the
7. CD.JEVAX Inj. Japanese - Global distributorship
Encephalitis Virus
society, clients and employees since our establishment in 1980.
Representative We started the progressive sales of our OTC products and we become
Sang Hun, Park a famous local brand in Korea with the launch of our brand Haben®,
Headquarter Address a common cold remedies. Also, another brand called Santamon®,
34, 28 Gil, Nonheyon-ro, Gangnam-gu, an anti-anemic, had a very good reception in the market. These
Seoul, Korea achievements made us an important place in the OTC market and we
earned the affection and respect of the Korean society.
Foundation Date
January, 1980. Later on, after continuously developing and researching new drugs
day and night and start the incrementation of our sales in the ETC
Research Focus market with notorious and innovative products.
Central Nervous System drugs
Nowadays, we are developing and doing research in Lifestyle
Total Staff modification products, such as Vitamins, Omega 3 and nutrients,
255 persons essentials for patients and human’s healthy lifestyles.
82-2-529-6100
Web
www.nicepharma.com
Contact Person
Eun Young, Park
Contact Phone
82-2-529-6100 (Ext. 313)
Contact E-mail
eypark@nicepharma.com Financial Figures
Fiscal Year 2015 2016 2017
Sales 47,390 55,308 59,000
R&D Expenditure 2,405 3,278 3,600
Capital 5,500 5,500 5,500

Main Products
1. Neuromed
KUKBO SCIENCE
Alzheimer's dementia China -
(Oxiracetam/Tablet, Syrup, Injection)
2. Gabatin Vietnam, Myanmar,
Epilepsy, Neuropathic pain -
(Gabapentin/Tablet, Capsule) Cambodia
3. Neurocept (Donepezil/Tablet) Alzheimer's dementia Vietnam -
4. Lukema
Asthma, Allergic rhinitis Vietnam -
(Montelukast/Tablet, Chewable tablet) Company Profile
Schizophrenia, Bipolar We, KUKBO SCIENCE LTD., have produced public health insecticides
5. Zypeace OD (Olanzapin/OD Tablet) Vietnam -
disorder and rodenticides and made effort to make eco-friendly products over
Singapore, Vietnam, 47 years under 'Human Living, Human Environment' as company
6. Allertec (Cetrizine/Tablet) Allergic rhinitis, Skin itching -
Cambodia philosopy.
7. Isotren (Isotretinoin/Soft capsule) Severe acne Vietnam, Cambodia - KUKBO SCIENCE. LTD is the biggest pest control company in South of
8. Plamed (Clopigorel/Tablet) Atherosclerotic symptoms Vietnam - Korea. We have exported our products about 20 countries around the
world.
Representative
R&D Pipeline HO-YOUNG AHN
Compound Name Code Use Stage of Development Headquarter Address

49, SANDAN-RO, HEUNG DEOK-GU,
Crude extract KDC14-1 Osteoporosis Phase I
CHEONGJU-SI, SOUTH OF KOREA
Crude extract KDC14-2 Anti-thrombosis Research
Foundation Date
Crude extract KDC14-3 Brain disease Research 1983.02.10
Crude extract KDC14-4 Inflammatory bowel disease Pre-clinical Research Focus
Crude extract KDC14-6 Atopy treatment Pre-clinical MANUFACTURING
Total Staff
73 persons
New Active Substances Representative Phone
010-6844-1527
Web
Neuromed Tablets (Oxiracetam) Alzheimer's dementia 1992-03-11/Korea
WWW.KUKBOSCIENC.CO.KR
Ribecca Cream (Difluprednate) Eczema, dermatitis 1995-01-05/Korea
Contact Person
SOPHIA KIM
Contact Phone
Other
010-3845-0842
Contact E-mail
kukbo@kukboscience.co.kr Financial Figures
Fiscal Year 2015 2016 2017
Sales 9,517 9,713 9,192
Capital 2,300 2,300 2,300

Main Products
Thailand, Oman,
Remarks
Kukje Pharma Co., Ltd.
1. Cleanbait power 35g
Pest control Qatar, Russia, Hong -
(Hydramethylnon 2%)
kong etc
2. Coumafen Jordan, Philippine

Pest control -
(Flocoumafen 0.005%) etc
3. Delta zone MC
Vietnam, Chile, Company Profile
Pest control Spain, South Africa, -
(Deltamethrin 2.5%) Kukje took its first step as a prescription drug manufacturer 57 years
UAE etc
ago. It is now Korea’s representative pharmaceutical company and
continues further growth in becoming a global leader that will help
render people around the world healthier. Kukje is committed to its
vision of developing prescription drugs to prevent diseases as well as
render your lives more meaningful and beautiful.
Representative
Mr. Nam Tae-Hoon
Headquarter Address
96-8, Yatap-ro, Bundang-gu, Seongnam-
si, Gyeonggi-do, Republic of Korea
Foundation Date
Jul. 27, 1959
Total Staff
500 persons
82-31-781-9081
Web
www.kukjepharm.co.kr
Contact Person
Mr. H. J. Lee
Contact Phone
82-70-7461-7314
Contact E-mail
trading@kukjepharm.co.kr
Financial Figures
Fiscal Year 2015 2016 2017
Sales 111,651 114,992 122,291
R&D Expenditure 3,438 4,424 6,511
Capital 16,607 16,607 17,397

Main Products
1. Cefminox Sod. Inj. 1g/0.5g

Use
Antibiotics
Exporting Countries
China
Remarks
-
Kwang Dong Pharmaceutical Co.,Ltd.
2. Ceftazidime Inj. 1g Antibiotics Vietnam -
3. Lincomycin Hcl. Inj.600mg Antibiotics Vietnam -
4. Spectinomycin Hcl Inj. 2g Antibiotics Iran -
5. Amlodipine Tab.5mg Hypertension Cambodia - Primary Logo

Company
Secondary Logo
Profile
Kwang Dong Pharmaceutical Co., Ltd. has tried its utmost to
6. Cefotetan Inj. Antibiotics UAE -
manufacture superior medicines for the last half a century since it
took the first step to supply medicines in Korea,abarrenlandforth
emedicalindustryin1960’s. Kwang Dong has been advancing in to
a top-ranking pharmaceutical company in the world through thee
establishment of the most advanced factories in Pyungtaek City.
R&D Pipeline Primary Signature
WeSecondary
have Signature
been enjoying an excellent reputation in technology over
forty years because of the goods quality and dependability of our
Compound Name Code Use Stage of Development Representative goods. We are one of leading pharmaceutical manufacturer in Korea
Nizatidine&Irsogladine Cap. - Gastritis Phase 3 is completed
Soo Boo Choi having GMP factory for ETC, OTC, drink and nutrition supplement.
Headquarter Address So, we have been exporting to our pharmaceutical products (Finished
Cyclosporin eye-drop - Dry Eye syndrome Phase 3 is ongoing 1577-4, Seocho-dong, Seocho-gu, Seoul, products) to sell all over the world.
Rebamipide eye-drop - Dry Eye syndrome nonclinical trial is ongoing Korea
Foundation Date
October. 16, 2012
Research Focus
Pharmaceutical
Other
Total Staff
Our product line with certified PIC/s GMP is fully equipped with high performance modern technology such as high-quality lyophilizer 749 persons
for producing Cephalosporin Injections. Approximately 150 kinds of medicines including ophthalmic products, antibiotics, GI products, Representative Phone
CV products, NSAIDs and etc. are produced and sold as of now and, at the same time, we are constantly expanding the CMO
82-2-6006-7258~9
business.
Representative Fax
82-2-6006-7024
Web
www.ekdp.com
Financial Figures
Fiscal Year 2008 2009 2010
Sales 276,173 276,585 289,435
R&D Expenditure 6,500 6,630 6,150
Capital 52,400 52,400 52,400

Main Products
Product (Ingredient/Formulation) Use
Advanced prostate cancer in combination with LHRH
Exporting Countries
Kyongbo Pharmaceutical Co., Ltd.
1. Bicalude Tablet (Bicalutamide 50mg) Vietnam, Nigeria
analogue therapy or surgical castration
2. Lenara Tablet (Letrozole 2.5mg) Breast cancer -
3. Kwangdong Woohwang
Stroke, Hypertension, Palpitation, Mental anxiety, Acute. Vietnam
Chungsimwon
4. Sedera ODF (Sildenafil citrate 50mg) Treatment of erectile dysfunction -
5. Cool strip ODF (Cetylpyridinium Preventive treatment of pharyngitis, amygdalitis, Company Profile
-
chloride 1.5mg) stomatitis Kyongbo Pharm. has committed Contract Manufacturing
Analgesia, anti-inflammatory : arthrosis deformans, Organization(CMO) business with sufficient technical and marketing
6. KD-Fen Plaster(Diclofenac
tenontothecitis, tennis elbow, myalgia, post traumatic Hong Kong resources. As one of major manufacturers of APIs and finished
Diethylammonium 120.0mg)
pain dosages in Korea, we will put utmost efforts along with the best
7. Clisia Solution(Clindamycin staff of R&D and quality assurance to be a global pharmaceutical
phosphate 1.188g/100mL ( 1g as acne vulgaris Hong Kong, Cambodia manufacturer. Our modern facilities and infrastructure guarantee
Clindamycin) that our products meet superior quality in accordance with cGMP
8. Beaurasen Injection(placenta 100mg, standards.
menopausal disorder Malaysia, Hong Kong Representative
Benzyl Alcohol 0.03mg)
Taewon Kang Focus Area : General API, Anti-Cancer API, Cephalosporins API,
9. Kwangdong Ceftriaxone Sodium Inj. Treatment of community-acquired or mild to moderate Carbapenem API
Afghanistan, Vietnam
(Ceftriaxone Sodium1g) health care-associated pneumonia Headquarter Address
1. after 5-FU therapy recurrent, progressive metastatic 174, SIROK-RO, ASAN-SI,
rectal cancer, colon carcinoma CHUNGCHEONGNAM-DO, 336-020,
2. combined treatment with 5-FU or Leucovorin, KOREA
progressive metastatic rectal cancer, colon carcinoma
10. Iritesin Injection(Irinotecan 20mg) Georgia Foundation Date
without other therapy
3. gastric cancer (incapable surgery or requrrent) Mar., 31, 1987
4. small cell lung cancer
Research Focus
5. progressive small cell lung cancer
GENERIC
Total Staff
352 persons
R&D Pipeline
Category Product Name Development Phases Indicant dosage form Development Type
82-2-365-2301
License in from
Representative Fax
KD501 Clinical test Phase II dementia oral Elcomscience (Kor)
Central Self developed 82-2-2175-2388
Nervous Web
System dementia,
www.kbpharma.co.kr
KD103 Developing Alzheimer's considering Self developed
disease Contact Person
Richard Kim
Metabolic
KD101 Pre clinical obesity oral Self developed
disease Contact Phone Financial Figures
82-2-2175-2387
License in from Summary (1 Million Won)
Endocrine Contact E-mail
KD802 Pre clinical short stature Injection Genexine (Kor) /
System Fiscal Year 2012 2013 2014
joint research skarajjang@kbpharma.co.kr
Sales 152,822 162,238 170,278
Digestive antinauseant R&D Expenditure 4,408 4,724 5,357
Ramosetron ODF IND oral / film Self developed
trouble medicine
Capital 10,758 10,758 10,758

Main Products
1. ATORVASTATIN
Use
Hypolipidemic
Exporting Countries
Japan
Remarks
-
Kyowa Hakko Kirin Korea Co., Ltd.
China, Japan, South
2. CEFTIZOXIME Anti-Biotic -
east Asia(SEA)
EU, Japan, SEA,

3. CEFTRIAXONE Anti-Biotic -
Russia etc
Company Profile
4. CLARITHROMYCIN Anti-Biotic Japan -
Korean affiliate of Kyowa Hakko Kirin Co., Ltd., Japan
5. PRANLUKAST Anti-asthmatic Japan -
A global specialty pharmaceutical company mainly focused on
6. Loxoprofen Anti-inflammatory Turkey - Hemato-oncology, Nephrology, Immunology and CNS area with world
leading high technology on antibody.
7. SULBACTAM -lactamase inhibitor Japan, Russia -
Focus Area : Hemato-oncology, Nephrology, Immunology and CNS
8. Cefroxadine Anti-Biotic Japan - area
9. Cefotaxime Anti-Biotic Russia, SEA etc - Headquarter Address
5th Floor, Samwon Tower, Yeoksam-dong,
10. Clopidogrel Anti-platelet Japan -
124, Teheran-ro, Gangnam-gu, Seoul,
Korea
Foundation Date
May 24th, 1991
Research Focus
R&D Pipeline
Hemato-oncology, Nephrology,
Compound Name Code Use Stage of Development Immunology, CNS
Tenofovir Disoproxil - HBV Pilot scale Total Staff
74 persons
Duloxetine HCl - Antidepressant Pilot scale
Ezetimibe - Hyperlipidemia Pilot scale 82-2-3471-4321
Cinacalcet HCl - Hyperlipidemia Completed Process validation Representative Fax
82-2-3471-4322
Dabigatran Etexilate - Anticoagulant Pilot scale
Web
Vildagliptin - Diabetes Pilot scale www.kyowa-kirin-korea.com
Sitagliptin Phosphate - Diabetes Pilot scale Contact Person
Mr. Sang Heon Lee
Memantine HCl - Alzheimer'S Disease Completed Process validation
Contact Phone
82-2-2181-2926
Financial Figures
Contact E-mail
sheon@kyowa-kirin-korea.com Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 41,919 47,768 50,528
R&D Expenditure 1,097 1,925 3,623
Capital 2,000 2,000 2,000

Main Products Compound Name Code Use Stage of Development
Product (Ingredient/Formulation) Use Exporting Countries Remarks - KHK4577 Atopic Dermatitis PII
1. Neulasta (Peg filgrastim) Neutropenia - - - KHK7580 Secondary Hyperparathyroidism PII
2. Grasin (Filgrastim) Neutropenia - - Bardoxolone Methyl RTA402 CKD in Patients with Type 2 Diabetes PII
3. Nesp (Darbepoetin alfa) Anemia - - X-linked Hypophosphatemic

Rickets(XLH)inpediatricpatients PII
4. Regpara (Cinacalcet HCl) Secondary Hyperparathyroidism - - X-linked Hypophosphatemic
- KRN23
Rickets/Osteomalacia(XLH)inadultpatients PI
5. Renagel (Sevelamer HCl) Hyperphosphatamia - - X-linked Hypophosphatemic
Rickets/Osteomalacia(XLH)inadultpatients PI
6. Nplate (Romiplostim) Idiopathic Thrombocytopenic Purpura - -
- KHK2823 Cancer PI
7. Mitomycin-C (Mitomycin) Cancer - -
- KHK2898 Cancer PI
8. Leunase (L-asparaginase) Cancer - -
- KHK4083 Autoimmune diseases PI
KHK2804
- Cancer PI
CEP37250
- KHK6640 Alzheimer's Disease PI

R&D Pipeline
Tivozanib KRN951 Cancer PI
Idiopathic Thrombocytopenic Purpura Launched

Romiplostim AMG531
Aplastic anemia PII
Leukemia/Lymphoma Launched
Cutaneous T-cell Lymphoma PIII
Peripheral T-cellLymphoma PII
Mogamulizumab KW0761
Adult T-cell Leukemia/Lymphoma PII
Solid Tumor PI
Asthma PI
Disseminated Intravascular Coagulation, Congenital

Antithrombin Deficiency Launched
Antithrombin Gamma KW3357
Disseminated Intravascular Coagulation, PI
Congenital Antithrombin PI
Granisetron - Chemotheraphy induced Nausea and Vomiting Launched
Tivantinib ARQ197 Hepatocellular Cancer PIII
Benralizumab KHK4563 Asthma PIII
Brodalumab KHK4827 Psoriasis PIII
Istradefylline KW6002 Parkinson's Disease PIII
Mesalazine Z206 Ulcerative Colitis PIII
- ASKP1240 Organ Transplant Rejection PII
- BIW8962 Cancer PII

Main Products
Kyung Dong Pharm. Co., Ltd. Product (Ingredient/Formulation)
1. Clopidogrel bisulfate (API)

Use
-
Exporting Countries
Japan
Remarks
2. Roxatidine acetate HCl (API) - Japan, China -
3. Aclovir Inj (Acyclovir) - Pakistan, Chile -
Pakistan, Yemen, Vietnam,

4. Ceftisone Inj.(Ceftriaxone sodium) - -
Company Profile Philippines, Afghanistan
Kyung Dong Pharm. Co., Ltd. established a GMP factory in 1987 to 5. Ducas Tab. (Tripotassium bismuth dicitrate) - Vietnam -
manufacture medical products with good quality.
6. Rebamide Tab.(Rebamipide) - Philippines -
Since we were approved as a designated KGMP company in 1991,
we have been producing more than 80 items including tablets, 7. Cozoltec Tab. (Cetrizine HCl) - Pakistan, Vietnam, Cambodia -
capsules, injections, and solutions.
We have approved BGMP manufacturer since 2001 and also have the
cGMP and EU-GMP grade facilities for general finished product and R&D Pipeline
Representative API. Compound Name Code Use Stage of Development
Ryu Deokhee
Bucillamine (API) - Antirheumatic Process Validation
Headquarter Address
9F, Kyungdong B/D, 1926 Imidafenacin (API) - Urinary antispasmodic Process Validation
Nambusunhwan-ro, Gwanak-gu, Seoul,
Risperidone (API) - Antipsychotic Process Validation
Korea
Foundation Date Escitalopram (API) - Antidepressant R&D
Sep. 1975
Ambrisentan (API) - Pulmonary hypertension R&D
Research Focus
Circulatory system, Digestive system Pilsicainide (API) - Antiarrhythmic R&D
Total Staff Istradefylline (API) - Antiparkinson R&D

618 persons
Suplatast (API) - Antiallergic R&D
82-2-570-6135 Clopidogrel Camsylate (Finished Product) - Antiplatelet KFDA Approved
Web Esomeprazole base (Finished Product) - Anti-peptic ulcer KFDA Approved

www.kdpharma.co.kr
(Finished Product) KD3003 Anti-rheumatic Preclinical Research
Contact Person
Nam, Gwi Hyun (Finished Product) KD4001 Anti-diabetic Preclinical Research
Contact Phone Amlodipine+Valsartan+Rosuvastatin Anti-hypertensive and Anti-
82-2-570-6168 KD5001 Clinical Research
(Finished Product) hyperlipidemic
Contact E-mail Financial Figures Varenicline Besylate (Finished Product) KD8001 Smoking cessation treatment Clinical Research
gwihyun.nam@kdpharma.co.kr
Fiscal Year 2015 2016 2017
Other
Sales 151,893 158,599 175,500
R&D Expenditure 4,390 4,580 5,600 Competitive strong power of Products and Good profit structure by 1st generic development through R&D and patent research.
Capital 13,575 13,575 13,575

Main Products
Kyung Nam Pharm. Co, Ltd Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Lemona pulvis (vitamin B,C) vitamin America, Hong Kong, Mongolia -
2. KN vitamin C Tab. (vitamin B,C) vitamin - -
3. Lemo vita C Tab. (vitamin B,C) vitamin America, Hong Kong, Mongolia -
Company Profile 4. Jahasaengryeok (Human Placenta) Tonic nutrition Hong Kong, Mongolia -
KyungNam Pharmaceutical has been representing the domestic
vitamin C market by its steady seller ‘Lemona’ which has been relieve menopausal
5. Plagensia inj. (Human Placenta) - -
receiving constant love for 28 years since the first release in 1983. As symptoms
proving its popularity, it has been awarded “Brand Award of the Year
for four consecutive years hosted by the Korean Consumers’ Forum 6. PM Solution (Salicylic Acid) athlete's foot treatments - -
and shown 73 percent of overwhelming public support in vitamin C
product field in 2011. In addition, KyungNam has been occupying the 7. M
inol troche relieve Throat
unrivaled No.1 title in the Human placenta market, which is the origin - -
(Cetypyridinium Chloride) inflammation
Representative of the life energy.
Mr. Hee-Cheul Lee / CEO
Moreover, KyungNam has been leading the general medicines market
Headquarter Address through its product such as PM, a typical athlete‘s foot medicine, and
17F, Keumkang Tower B/D, 889-13, Dachi- Minol Troche, a sore throat drug.
dong, Gangnam-gu, Seoul, 135-918
Foundation Date
Jun 1, 1957
Research Focus
Vitamin & Human Placenta
Total Staff
244 persons
82-2-3490-5105
Representative Fax
82-2-3490-5129
Web
http://www.kyungnampharm.co.kr
http://www.lemona.co.kr
Financial Figures
Fiscal Year 2008 2009 2010
Sales 43,701 46,869 45,983
R&D Expenditure - - 337
Capital 11,192 14,692 15,350

Main Products
Medica Korea Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries
Singapore,
Remarks
1. N
imegen Soft Cap.10/20mg Cystic acne and acne
Hong kong, Myanma, -
(Isotretinoin 10,20mg) conglobata treatment
Vietnam
2. G
REEN PAM Cap. Supplementary treatment of
Vietnam -
(Thymomodulin 80mg) bacterial and viral infections.
Company Profile 3. POINTY Cap. (Diacerhein 50mg)

Treatment of osteoarthritis
Vietnam -
disease
Established Doing-IlPharmaceutical Co., Ltd., in 1976. Acquired and
renamed Medica Korea in 2000 4. A
llutec Tab. Rhinitis, Conjunctivitis, Hong kong,
-
(Cetirizine Hydrochloride 10mg) Eczema, Dermatitis, etc Cambodia
Manufacturing one hundredand twenty pharmaceutical products
under the control of KGMP (Korea Good ManufacturePractice).
Focus Area : Skin Diseases
Target country : Philippines, Vietnam, Cambodia, Hongkong,
Representative Singapore, Myanma, etc. R&D Pipeline
Chani Jeong Compound Name Code Use Stage of Development
Headquarter Address Nimegen Soft Cap. 10mg Cystic acne and acne
- Approved
7F, Diplomatic center 2558, (Isotretinoin 10mg) conglobata treatment
Nambusunhwan-ro, Seocho-gu, Seoul,
Asthmatic bronchitis, Chronic
Republic of Korea SALBUTRON SR Cap.4mg
- bronchitis, emphysema Approved
(Salbutamol sulfate 8mg)
Foundation Date disease
May 20th, 1976
Hypertension, Meniere’s
Research Focus disease, Buerger’s disease,
NEWBORN Tab. 25 I.U.
ETC, OTC Drugs - menopausal disorder, Approved
(Kallidinogenase 25 I.U.)
circulatory disturbance of
Total Staff
chorioretinal disease
165 persons
Representative Phone MUCOSTEN INJ. 10% Acute Chronic & Asthmatic
- Approved
(Acetylcysteine 100mg/mL) bronchiti disease
82-70-4018-8000
Representative Fax CALDIOL Soft Cap.20 Chronic renal failure,
- Approved
82-2-585-9689 (Calcifediol 20 ) Metabolic bone disease
Web
http://www.medicakorea.com/
Contact Person
Lee Won Jung
82-2-70-4018-8052
82-2-70-4018-8053 Summary (1 Million Won)
Contact E-mail Fiscal Year 2015 2016 2017

overseas@medicakorea.com Sales 30,637 36,858 36,858
Trade@medicakorea.com R&D Expenditure 696 612 463
Capital 3,560 3,560 3,560

Main Products
MG Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks
Under registration in Iran,

1. MG TNA inj. IVH for NPO inpatients Vietnam Kazahstan, Syria, Thailand,
Malaysia and Kenya
Mongolia, Vietnam, Under registration in Iran,

2. MG TNA-peri inj. IVH for NPO inpatients Philippines, Kazahstan, Syria, Thailand,
Myanmar Malaysia and Kenya
Company Profile
Under registration in Syria,
MG Co., Ltd. is a pharmaceutical company that specializes in 3. MG Combi-peri inj. IVH for NPO inpatients Mongolia
Kazahstan
manufacturing parenteral & enteral nutrition solution to play a big
role in nutrition infusion therapy and its related areas. 4. Lipid LCT inj. 10% / 20% Supply EFA & Calory Mongolia Under registration in Iran
It is mandatory for patients to provide proper nutrition to treat the Under registration in overseas
5. FOMS TNA inj. IVH for NPO inpatients -
disease and recover their health, especially for: surgical patients who countries
are incapable of taking nutrition, patients with hypoproteinemia and
malnutrition, patients with wasting disease caused by burn or gash, Under registration in overseas
6. FOMS TNA-peri inj. IVH for NPO inpatients -
countries
Representative and patients with immunosuppression.
Chul-Soo, Shin (Mr.) With a long-term experience and accumulated technology, for the 7. FOMS Lipid inj. 20% Supply EFA & Calory -
Under registration in overseas
first time in Korea, we succeeded in localization of a 3-chamber bag countries
Headquarter Address
27, Yongso 2-gil, Gwanghyewon-myeon, product, MG TNA with 2-chamber bag products, MG COMBI, and
Jincheon-gun, Chungcheongbuk-do, South Lipid LCT etc. Furthermore, we recently developed the new products,
Korea FOMS TNA and FOMS Lipid, which are the combination of fish oil,
olive oil, MCT oil and soybean oil. R&D Pipeline
Foundation Date
September 16, 2003 We, MG Co., Ltd., promise our effort and endeavor to provide the best Compound Name Code Use Stage of Development
quality products in nutrition therapy and always hold an outstanding Selenium for injection - Supply for Selenium Formulation
Research Focus position to take care of human health in the 21st century.
Nutrition infusion therapy products Zinc for injection - Supply for Zinc Formulation
Total Staff
IVH for NPO pediatric
87 employees TPN solution for pediatric patients -
inpatients
Review the formular
82-2-2057-1002 Dextrose, Amino acids, Lipid
- IVH for NPO inpatients Review the formular
(New formular for 3-chamber bag)
Web
www.medi-green.co.kr Dextrose, Amino acids, Lipid, Vitamins,
Elements etc. - IVH for NPO inpatients Review the formular
Contact Person (The first 4-chamber bag product)
Seong-Un, Jeong (Mr.)
Contact Phone
82-2-2057-1002
kasabian@medi-green.co.kr
Fiscal Year 2015 2016 2017
Sales 14,480 17,623 20,220
Capital 9,873 11,111 18,670

Main Products
MOTHER'S PHARMACEUTICAL CO., LTD. Product (Ingredient/Formulation)

1. R AYBON Tab. (Angelica·Chaenomeles·Ledebouriella·Dipsac
Use Remarks
Relaxation on Golgwan Georgian ETC

us·etc Soft Ext. 405.4mg)
2. S TOEM Tab. (Artemisia Asiatica 95% Ethanol ext. 60mg) Chronic gastritis, acute gastritis improvement ETC
The above-mentioned · duodenal ulcer, gastritis,
3. RACETINEM Tab. (Ranatidine hydrochloride 84mg, Sol drip-Ellison syndrome, reflux esophagitis, pre-
Tripotassium dicitrato bismuthate 100mg, sucralfate anesthesia medication (prevention of Mendelson's ETC
Company Profile hydrate 300mg) syndrome), postoperative ulcer, nonsteroidal anti-
inflammatory analgesia (NSAID)
MOTHER'S PHARMACEUTICAL CO., LTD. is a manufacturing plant 4. ITANDOL Tab.(Titrated extract of zea mays L. Unsaponifiable Gingivitis after periodontal treatment, secondary
of tablets, hard capsules authorized from Korea Food & Drug OTC
fraction 35mg) treatment of moderate periodontitis
Administration. We took over a pharmaceutical company, which had
5. URUQBAC Tab.(Anhydrous dibasic calcium phosphate
manufactured oriental medicine more than 35 years. We have even 100mg, Coated ascorbic acid 10 4.17mg, Benfotiamine
expanded our business areas to chemical medicine based on natural 50mg, Biotin 0.2mg, Calcium pantothenate 30mg,
product research experience. We have been rapidly developing to Cholecalciferol granule 4mg, Choline bitartrate 50mg, 0.1%
become the best pharmaceutical company. 1. Supply of vitamin (D, B1, B2, B6, C) OTC
Cyanocobalamin 50mg, Folic acid 0.4mg, inositol 50mg,
Magnesium oxide 100mg, Nicotinamide 50mg, Pyridoxine
Representative hydrochloride 50mg, Riboflavin 50mg, Ubidecarenone
Jwa-Jin Kim 10mg, Ursodeoxycholic acid 30mg, y-oryzanol 5mg)
Headquarter Address Gingivitis after periodontal treatment,
6. E tantan-Plus Cap. (Ascrobic acid 150mg, Carbazochrome
703-ho, 1-dong, (Lotte Itcastle,) 98, Gasan adjuvant treatment of gingivitis and moderate OTC
2mg, Dried vitamin E 50% 10mg, Lysozyme chloride 30mg)
digital 2-ro, Geumcheon-gu, Seoul, Korea periodontitis
7. KERASIDIL Cap. (Calcium pantothenate 60mg, Keratin
Foundation Date 1. Damaged hair, poor growth of infectious nails
20mg, L-cystine 20mg, Medicinal yeast 100mg, OTC
July 20th, 2011 2. Assistive treatment of hair loss
p-aminobenzoic acid 20mg, Thiamine nitrate 60mg)
Research Focus - Constipation
Novel drug 8. B icarine-M EntericCoated Tab. (Bisacodyl 7mg, Docusate
- Relieving the following symptoms of
constipation: loss of appetite (loss of appetite), OTC
Total Staff sodium 20mg, Sennae folium Powder 100mg)
abdominal distension, intestinal fermentation,
99 persons hemorrhoids
Representative Phone 9. R anitis Tab. (Aluminum magnesium hydroxide 100mg,
82-2-2026-8890 Aluminium magnesium silicate 125mg, Magnesium oxide Stomach pain, heartburn, indigestion, nausea OTC
50mg, Ranitidine hydrochloride 31.5mg)
Web
10. UruqbacClassic Tab. (Anhydrous dibasic calcium
www.mtspharm.com
phosphate 100mg, Coated ascorbic acid 10 4.17mg,
Contact Person Benfotiamine 50mg, Biotin 0.2mg, Calcium pantothenate
Ye Rin Kim 30mg, Cholecalciferol granule mg, Choline bitartrate
1. Supply of vitamin D, B1, B2, B6, C
50mg, Cyanocobalamin(1000) 50mg, Folic acid 0.4mg, OTC
Contact Phone 2. Supply of zinc
Magnesium oxide 100mg, Nicotinamide 50mg, Pyridoxine
82-70-7457-8812 hydrochloride 50mg, Riboflavin 50mg, Ubidecarenone
10mg, Ursodeoxycholic acid 10mg, Zine oxide 21.2mg,
Contact E-mail
y-oryzanol 5mg)
yelinkim0921@motherspharm.com Financial Figures
R&D Pipeline
Fiscal Year 2015 2016 2017
Sales 16,898 24,234 33,000
R&D Expenditure 500 600 1,000 - MTS-F1 - Candidate
Capital 2,000 2,000 2,000 - MTS-N1 - Candidate

Main Products
Myung In Pharm. Co., Ltd. Product (Ingredient/Formulation)
1. Igatan-F Cap.
Use
Gum disease
Exporting Countries
-
Remarks
2. Disgren Cap. Anti-thrombosis China -
3. Silvercept Tab./OD Tab. Dementia - -
4. Q-Rokel Tab./XR Tab. Schizophrenia Peru -

Company Profile 5. Rispen Tab./OD Tab. Anti-psychotic - -
Established in 1985, Myung In is a distributor as well as a contract
6. Superpirin Cap. Anti-thrombosis - -
manufacturer with exceptional expertise in the development of small
molecule, conventional and specialized solid dosage forms including 7. Newpram Tab. Depression&Bipolar disorder - -
pellets and bi-layer tablets, and sterile products including liquid/
lyophilized vial and liquid ampoule. 8. Zanapam Tab. Tranquilizer - -
A research-driven pharmaceutical company, Myung In has ranked 9. Proctin Cap. Depression&Bipolar disorder Singapore -
first among locals in the field of central nervous system in Korea.
Myung In also collaborates with many global partners to successfully 10. Q-Pam Tab./Oral soln./Inj. Epilepsy - -
Representative
Hang Myung Lee launched their products in Korea, getting them to be blockbusters.
Headquarter Address Myung In will continue to expand and invest in facilities to provide
Myung-In Bldg, 95, Banpo-daero, Seocho- high quality medicines to patients as well as to meet the growing
gu, Seoul, Korea 06657 market demand.
Focus Area : anti-thrombotic, anti-hypertensive, anti-psychotic, anti- R&D Pipeline
Foundation Date
April.1.1985 depressant&bipolar disorder, anti-insomnia, ADHD, anti-convulsant, Compound Name Code Use Stage of Development
anti-parkinson, anti-dementia
Research Focus Mirtazapine 7.5mg - Depression Approved
New Drugs Introduction, Incrementally
Betahistine HCl - Vertigo(Off-label:Obesity) Approved
Modified Drugs development, New
technology export, Overseas CMO Levetiracetam Inj. - Epilepsy Approved
business
Waiting for approval from
Total Staff Paliperidone - Schizophrenia
MFDS
430 persons
Waiting for approval from
Representative Phone Aspirin/Clopidogrel (75mg/75mg) - Anti-thrombosis
MFDS
82-2-587-9060
Representative Fax
82-2-585-0352
Web
http://www.myunginph.co.kr New Active Substances
Contact Person Product (Ingredient) Use Approval Date/Country
Hee Soo Kim Financial Figures
Disgren(Triflusal) Anti-thrombosis 1993.12.13
Contact Phone Summary (1 Million Won)
82-2-587-9060 Fiscal Year 2015 2016 2017 Narcaricin Tab.(Benzbromarone) Anti-gout 1995.03.27
Contact E-mail Sales 140,000 148,000 159,000

hskim@myunginph.co.kr R&D Expenditure 5,400 6,500 9,000
Capital 5,600 5,600 5,600

Main Products
Myung Moon Pharm. Co., Ltd. Product (Ingredient/Formulation)
1. Kimite Patch (Scopolamine 1.5mg)

Use
Motion sickness
Exporting Countries
Vitenam, China, Hong-Kong

Remarks
2. Dobutamine Inj.
Cardiac stimulants Vietnam, Pakistan, Nigeria -
(Dobutamine HCl 280.3mg/5ml)
3. Inopan Inj.
Cardiovascular drug Vietnam, Pakistan, Nigeria -
(Dopamine HCl 200mg/5ml)
Company Profile
4. Ketocin Inj. Nonsteoidal Anti- Vietnam, Philippines, Rep. of
-
In 1983, Myungmoon Pharm. Co., Ltd. was established for the (Ketorolac tromethamine 30mg/1ml) inflammatory drug Dominica
improvement of national health. It is achieving remarkable
development via research and development, production, and sales 5. B upivacaine HCL Heavy Inj. 0.5% Vietnam, Nigeria, Rep. of
Local Anesthetics -
(Bupivacaine HCL 21.12mg/4ml) Dominica
based on its founding principle: Advancement, Harmony, and
Creation. 6. Pyrinol Tab.
Parasympathomimetics Chile, Malaysia -
Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to (Pyridostigmine Bromide 60mg)
produce the finished medicines; Injection, Tablet, Capsule, Patches, 7. L evonia Tab.
Solution and Creams. Contraceptive Vietnam, Mexico -
Representative (Levonorgestrel 1.5mg)
Mr. Lee, Kyu Huok / CEO Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250
8. Tipem Inj.
Headquarter Address specialized and general medicines and has more than 400 specialized Antibiotics Vietnam -
(Imipenem 500mg, Cilastatin 500mg)
Myungmoon B/D, 946-18 Dogok-dong, and generalmedicine licenses to be able to manufacture. Myungmoon
Gangnam-gu, Seoul Pharm. Co., Ltd. is focusing on our research and development efforts 9. E sgen Vaginal Cream
Hormons Guatemala -
so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new (Estropipate 1.5mg/g)
Foundation Date products every year.
September, 1983 10. N
eocoline Inj. 500mg
Myungmoon Pharm. Co., Ltd. established the new plant for API in parkinson diease Uzbekistan, Vietnam -
(Citicoline 500mg/2ml)
Research Focus 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the
Medicines, Bio-Product other 8 API products now, however, Myungmoon Pharm. Co., Ltd.
Total Staff would have many new API products in the foreseeable future.
450 persons To gain a foothold on biomedicine products, outsourcing strategies
Representative Phone are preceding the use of trusted clinical agency CRO and production R&D Pipeline
82-2-6711-2000 agency CMO, and Myungmoon Pharm. Co., Ltd has already started to
develop human growth hormones through a bio-venture corporation.
Representative Fax Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching Sonatropin-PEG conjugate (Bio-Product) GROWTH Hormone Finished Process(Lab Scale)
82-2-572-5137 bio-similar, including EPO and the processing of the complement
of plants for biomedical products as well as the development of Erythropoietin(Bio-Product) Erythrogenesis Finished Process(Lab Scale)
Web
www.mmpharm.co.kr advanced medical bioethics, including monoclonal antibodies.
Flumanzenil Inj. 0.5mg Antidote for Midazolam Launching on April, 2012
Myungmoon Pharm. Co., Ltd. is sharply developing to be a
professional and global treatment company in the world. Valsartan 160mg, 80mg Hypertension Launching on April, 2012
Lansoprazole 30mg Antipeptic ulcer drug Launching on August, 2012
Financial Figures Sildenafil 100mg Erectile dysfunction Launching on August, 2012
Summary (1 Million Won) Raloxifene 60mg Osteoporosis Launching on July, 2013

Fiscal Year 2008 2009 2010
Sales 77,390 92,246 100,914
R&D Expenditure 1,401 1,741 1,789
Capital 5,100 5,293 5,500

Main Products
Pharmbio Korea Co., Ltd Product (Ingredient/Formulation)
1. Picolight
(Sodium Picosulfate, Magnesium Discussing out-licensing

Pre-colonoscopic preparation -
Oxide(light), Citric Acid(anhydrous)/ in Vietnam, etc.
Powder)
2. Urocitra-K Discussing out-licensing

Uric acid lithiasis Myanmar
(Potassium citrate/Tablet) in Vietnam, etc.
Company Profile
3. Urocitra-C
Pharmbio Korea Co., Ltd. is an emerging, innovative company Discussing out-licensing
(Potassium Citrate, Citric Acid Uric acid lithiasis -
in Cambodia, etc.
established in 1999, specializing in registration, ex/importing, Hydrate/Powder)
manufacturing, and marketing of innovative pharmaceutical products
in Korea. It is one of the most influential companies in many 4. Endonse (Pronase B/Powder) Pre-endoscopic preparation - -
therapeutic areas. 5. Ribon Discussing out-licensing
Postmenopausal
Focus Area : Urology, gastroenterology, neurosurgery, orthopedics, (Risedronate Sodium Hydrate / - in Singapore, Hong Kong,
osteoporosis
general surgery, immunology, etc. Tablet) etc.
Representative 6. Gagron
Bong Kil, Nam (Pentasan Polysulfate Sodium / Interstitial Cystitis - -
Calsule)
Headquarter Address
A-7F, Samho Bldg, 83 Nonheyon-ro, 7. Movilax
Seocho-gu, Seoul 137-940, South Korea (Polyethylene Glycol3350, Chronic constipation - -
Electrolytes/Powder)
Foundation Date
May 1st, 1999 8. Zinkistin
Zinc deficiency - -
Research Focus (Zinc Histidine Dihydrate / Capsule)
25 9. Acupan casule Discussing out-licensing
pain controller -
Total Staff (Nefopam Hydrochloride / Capsule) in Nigeria, etc.
170 persons
82-2-587-2551~4
Representative Fax
82-2-529-7454
Web
www.pharmbio.co.kr
Contact Person
Jun Sang, Nam
Contact Phone
Contact E-mail
bd@pharmbio.co.kr
Fiscal Year 2012 2013 2014
Sales 32,700 39,300 44,200
R&D Expenditure 1,500 2,700 3,300
Capital 20,680 34,065 40,020

Main Products
PMG Pharm Product (Ingredient/Formulation)
1. Layla Tab (12 Herbal extracts 405.4mg)

Use
Osteoarthritis
Exporting Countries
-
Remarks
2. Rudia Cap 50mg (Diacerein) Osteoarthritis - -
3. D
uroc Tab 100, 200, 300 400mg
Rheumatoid arthritis - -
(Hydroxychloroquine sulfate)
Company Profile 4. Tarsin Cap 0.5, 1mg (Tacrolimus) Rheumatoid arthritis - -
PMG Pharm has been a leading pharm in the market for treatments 5. Rheumakin Tab 10, 20mg (Leflunomide) Rheumatoid arthritis - -
of rheumatoid arthritis, osteoarthritis, anti-osteoporosis and related
6. A
dmin Forte Tab
diseases and its main business has been focused on the development VitD deficiency - -
(Cholecalciferol, VitD 1000IU)
of DMARDS, DMOADS and NSAIDs etc. At 13 Mar 2012, a Layla
Tab has been registered as a new treatment for the osteoarthritis. 7. Indometa Cap 25mg (Indomethacin) NSAID - -
Layla is consisted of 12 medicinal plants which has been recognised
as traditional herbal medicines for arthrosis. PMG Pharm is ready to 8. S ynflexSafe Tab
NSAID - -
expand its business by licensing out Layla. (Naproxen/Esomeprazole 500/20mg)
Representative
Mr. Young Chin Chun 9. Morix Cap 7.5mg (Meloxicam) NSAID - -
Headquarter Address 10. Laxib Cap 100, 200mg (Celecoxib) NSAID - -

21 Sinangbukro 4-gil, Sangnok-gu, Ansan-
11. Droban Tab 150mg (Ibandronate) anti-osteoporosis - -
si, Gyeonggi-do, South Korea
Foundation Date 12. Risena Tab 35, 150mg
anti-osteoporosis - -
Dec, 2001 (Risedronate Na)
Research Focus
DMARDS, DMOADS, NSAIDS
Total Staff
89 persons
R&D Pipeline
82-31-439-5470
PMG1001 - Osteoarthritis In-vitro test
Web
www.pmgpharm.co.kr
Contact Person
Ki-Tae Han
Contact Phone New Active Substances
82-31-439-5470
Contact E-mail
kthan@pmgpharm.co.kr Layla Tab(12 Herbal extracts 405.4mg) Osteoarthritis 2012.03.13/Korea
Financial Figures
Fiscal Year 2015 2016 2017
Sales 29,131 32,695 38,000
R&D Expenditure 1,147 1,335 1,500
Capital 2,319 2,636 2,636

Main Products
Richwood Pharmaceutical Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks
1.Acetracet Tab. (acetaminophen, tramadol HCl) Pain relief - -
2. Ebaco SR Cap. (pseudoephedrine, ebastin) Allergic rhinitis - -
3. Gli-M Tab. 2/500mg (glimepiride, metformin) Type II diabetes - -
Company Profile Buerger's disease, acquired

4. Limaprost 0.17mg (limaprost) - -
Richwood Pharmaceutical Co., Ltd., a reliable CMO company with spinal canal stenosis
global standards in pharmaceutical manufacturing, has competitive
advantages such as holding specialized formulation technologies 5. Cetirizine Tab. (cetirizine) Allergic rhinitis - -
using a 3-layer tablet machine and a GPCG series, a strategic
partnership with CRO, and development pipelines of herbal medicine. 6. Livaduet Tab. (atrovastatine,amlodipine besylate) Hypertension - -
Representative
Mr. JeongSuk Lee / CEO R&D Pipeline
Headquarter Address Ingredient Use Stage of Development
Danam B/D 22F, 120 Namdaemoonno
5-ga, Jung-gu, Seoul Oxycodone hydrochloride Opioid analgesic Clinical trial
Foundation Date
March, 1974
Research Focus
Finished drug, Herbal medicine
Total Staff
146 persons
82-2-778-2351
Representative Fax
82-2-756-5402
Web
www.richwood.net
Financial Figures
Fiscal Year 2008 2009 2010
Sales 25,192 32,744 41,414
Capital 500 500 500

Main Products
RP Bio Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Ginsatine
Korea Ginseng Multivitamin Vietnam, Cambodia Soft gels
(Korea Ginseng 100mg and multivitamins etc.)
2. Caldiol (Calcifediol hydrate 20mg) Vitamins Vietnam, Pakistan Soft gels
3. Ursa (Ursodeoxycholic acid 100mg) Hepatics China Soft gels

Company Profile
- RP Bio. is CMO by OEM/ODM specializing in Soft Gelatine Capsules 4. Provimin (Korea Ginseng 100mg, etc.) Vitamins Cambodia Soft gels
for pharmaceutical and health functional food formulations since
1983. Initially founded as a J/V between R.P. Scherer USA and 5. Livergold-F (Milk Thistle 100mg, etc.) Hepatics Myanmar Soft gels
Daewoong Pharmaceutical Co., Ltd. Korea. RP Corp. boasts high
quality production as a Korean company to pass international audits. 6. Valix Vaginal (Nystatin 100kIU, etc.) Pessary Vietnam Soft gels
7. Nimegen (Isotretinoin 20mg) Acne Vietnam, Cambodia Soft gels

* Infra
Representative
Seung-ho Han, Nam-gi Kim · K GMP approved Pharmaceutical Mfg. facility (finished dosage: Soft 8. Tak-Sen (Naproxen 250mg) Pain Reliever - Soft gels
capsules)
Headquarter Address
· T wo KGMP approved Health Functional Food Mfg. facilities (one for 9. Whituben Q (Acetaminophen 180mg, etc.) Cold Medicine - Soft gels
315 Yeongdong-daero, Gangnam-gu,
Seoul, Korea soft capsules and another for tablets, powders and granules)
10. Tobicom-S (L-Citrulline, etc.) Eye - Soft gels
Foundation Date
Oct.1983
Research Focus
Pharmaceuticals, health functional food
Total Staff
330 persons
82-2-2002-9800
Web
http://www.rpskorea.com
Contact Person
Hee Jeong Jang
Contact Phone
82-2-2002-9819
Contact E-mail
heej09@rpcorp.co.kr Financial Figures
Fiscal Year 2015 2016 2017
Sales - 26,013 70,000
R&D Expenditure - 250 300
Capital - 34,144 40,690

Main Products
SamChunDang Pharm. Co., Ltd. Product (Ingredient/Formulation)
1. Sodium Hyaluronate 0.1% Eye Drops

Use
Artificial Tears
Exporting Countries
Vietnam, Myanmar
Remarks
Myanmar, Panama,
2. Tobramycin 0.3% Dexamethasone 0.1%
Antibacterial Cambodia, Hong -
Eye Drops
Kong, Yemen
Myanmar, Panama,
Company Profile 3. Fluorometholone 0.1% Eye Drops Anti-Inflammatory
Vietnam, Cambodia,
-
China, Costa Rica,
SamChunDang(SCD) Pharm. Co., Ltd. is the leading pharmaceutical Hong Kong
company specialized in ophthalmic fields. We have acquired EU
GMP certificate for sterile eye drops from UK MHRA(Medicines & Hong Kong,
Healthcare products Regulatory Agency). Since established in 1943, 4. Mometasone furoate 0.05% Nasal Spray Nasal Spray Myanmar, Vietnam, -
we have been providing a high quality pharmaceutical product for the Ecuador, Cambodia
purpose of providing healthier and happier lives for everyone.
We provide safety and convenience and also offer a wide range of
Headquarter Address choices with multi-dose and preservative-free single dose eye drops.
351, Hyoryeong-Ro, Seocho-gu,Seoul 137- We have been exporting pharmaceutical products to more than 25
overseas countries for more than 20 years and have been seeking to R&D Pipeline
877, Korea
expand in to the global market with EU GMP certificated techology. Compound Name Code Use Stage of Development
Foundation Date
in 1943 Confidential SCD311 Artificial Tears Formulation development
Total Staff Confidential SCD212 analgesics DDI (Phase I complete)

384 Employees
Confidential SCD313 Artificial Tears Formulation development
82-2-2046-1100
Web
www.scd.co.kr
Other
Contact Person
Mr. Brian Kim Submission of EU CTD (Decentralised Procedure) UK-MHRA has confirmed the dates for submission of Dossier and allocated the DCP
Contact Phone number.
82-2-2046-1250 Allocated DCP number(s) together with the PL numbers : UK/H/5793/01/DC - Olopatadineeye drops 1mg/ml, PL 43063/0002
DECENTRALISED
Contact E-mail
After submission of EU CTD Dossierin Aug. 2014, MHRA (UK) inspection was successfully done in 1st week of Jan. 2015.
silluet75@scd.co.kr
EU GMP Certificate from MHRA, U.K was generated on Mar. 9th,2015.
(Certificate No. : UK GMP 43778 Insp GMP 43778/10951938-0001)
Financial Figures
Fiscal Year 2015 2016 2017
Sales 100,514 111,521 120,422
R&D Expenditure 4,357 5,158 9,480
Capital 10,619 11,000 11,053

Main Products
SAMA PHARM CO.,LTD. Product (Ingredient/Formulation) Use

NSAIDs
1. S ETOPHENTM (Acetaminophen/ tablets ER

(Fever, Pains, Headache, - -
tablets & Dry syrup & suspension)
Menstrual pain etc.)
2. CODENAL®
Cough, sputum Hong Kong -
(Dihydrocodeine, etc. / tablets & syrup)
3. ATOCK® Acute & chronic, bronchitis,
- -
(Formoterol fumarate / tablets & dry syrup) Bronchial asthma
Company Profile
4. LIDOMEX®
SAMA is Korea’s top leading company in Respiratory, ENT, Eczema, Dermatitis, Prurigo,
(Prednisolone valeroacetate / topical lotion & - -
Psoriasis, etc.
Dermatology, and Pediatrics. Founded in 1945, it is one of the most cream)
financially sound companies with a long history of achievements 5. CITUSTM
and recognitions by the Korean government. It has a GMP-certified Bronchial asthma, Perennial
(Pranlukast hydrate / tablets, ispersible tablets & - -
manufacturing plant, and it has been accredited by Japan’s allergic rhinitis
dry syrup)
Regulatory Authority (PMDA: Pharmaceuticals and Medical Agency) Gingivitis glossitis,
as an “Accredited Foreign Manufacturers”. SAMA has a central R&D 6. TANTUM®
Pharyngitis, Laryngitis, - -
center and nation-wide sales force. (Benzydamine HCl / gargle solution & nebulizer)
Tonsillitis etc.
Representative
Jun Hur SAMA has a strong track record of new business development and Chronic inflammatory
partnership with multinational companies, with some having lasted bronchial disease, acute
7. HEBRON® (Ivy leaves extract / tablets & syrup) - -
Headquarter Address over 30 years. It has demonstrated capabilities in branding and inflammation of respiratory
49 Dongwha gongdan-ro, Munmak-eup, marketing to achieve #1 brand recognition and equity. tract
Wonju-si, Gangwon-do 8. BEPORIN® (Bepotastin salicylate / tablets) Anti-histamines - -
SAMA is also active in its own in-house R&D activities, especially
Foundation Date in Respiratory and GI fields. SAMA’s CitusTM(pranlukast) tablet for Gastric ulcer, duodenal
Oct. 04, 1945 adults was developed with its proprietary patent technology, which 9. GERD® (Sodium alginate / solution) ulcer, improvement of gastro - -
dramatically lowered the dosage (112.5mg * 2cap. -> 50mg * 1tab.) esophageal reflux disease
Research Focus
Respiratory, ENT, Dermatology, Pediatrics, SAMA also successfully completed a Phase II clinical trial for the new 10. NOMA Growth promotion, nutritional
4th generation LTRAs drug in collaboration with Mitsubishi Tanabe. (Multivitamins, Minerals / gummies & deficiency, supply for - -
GI, and Orphan Diseases
chewable tablets) vitamins & minerals
Total Staff SAMA plans to expand into other fast growing therapeutic areas via
320 persons licensing deals and its own R&D.
Representative Phone Focus Area : Respiratory, ENT, Dermatology, Pediatrics, GI, and
82-2-2056-7200 Orphan diseases
Representative Fax R&D Pipeline

82-2-2056-7210
Web
www.samapharm.co.kr SLIP SLIP Erectile dysfunction Launch
Contact Person TDIQ TDIQ Erectile dysfunction Launch

Soojin Lee Bronchial asthma,
PRIT PRIT Launch
Allergic rhinitis
82-2-2056-7283 Bronchial Asthma,
SA09012 SA09012 Phase 2
Allergic rhinitis
Contact E-mail
Fiscal Year 2015 2016 2017 DRIT SA15001 Gastric ulcer, GERD Non-clinical study
sjlee@samapharm.co.kr
Sales 59,658 65,876 61,800 Bronchial Asthma,
PRIC SA16001 Phase 1
R&D Expenditure 4,898 4,236 4,400 Allergic rhinitis
Capital 140,077 148,916 156,100 HLIM SA16002 Bronchitis Phase 1

Main Products
Samik Pharm. Co., Ltd. Product (Ingredient/Formulation)
1. CEZAR TAB. (Losartan potassium 50/100mg)

Use
Hypertension
Exporting Countries
-
Remarks
2. CEZAR PLUS TAB.

(Losartan potassium 50mg, Hydrochlorothiazide Hypertension - -
12.5mg)
3. TAMITRA TAB.
Cambodia, Myanmar,
Company Profile (Acetaminophen 325mg, Tramadol Hydrochloride NSAIDs
Vietnam
-
37.5mg)
Since founded in 1973, Samik has focused on our ability to improve
public health through the R&D and manufacture of a number of the 4. N
EWSOVOMIN SYR.
Dizziness, vomiting, headache
over-the-counter drugs famous for excellent efficacy and good quality (Dimenhydrinate 20mg, Anhydrous Caffeine Mongolia -
caused by motion sickness.
under the banner of "systemic approach to natural drugs". 10mg, Pyridoxine Hydrochloride 2.5mg)
“Aiming for the best technical capability in the field of solid 5. TMD CAP. (Thymomodulin 80mg) Bacterial and viral infections.
Cambodia, Myanmar,
-
dosage form” Vietnam
Now, Samik will establish as Total Health Company in fact as well 6. B ROJE TAB.
Representative Inflammation Cambodia, Vietnam -
as in name by devoting itself to the development of new natural (Bromelain 40mg, Crystallized trypsin 1mg)
Lee, Sae Young drugs, modified drug and to supplementing biomedicine pipeline,
marketing its own best medicines globally in R&D and management 7. BONOMAX TAB. (Alendronate 70mg) Osteoporosis Myanmar, Vietnam -
Headquarter Address
15F, A Tower, 11, Beobwon-ro 11-gil, as well as by continuing in development and manufacture of the 8. AMORIA CAP. (Meloxicam 7.5/15mg) NSAIDs Bolivia, Hong Kong -
Songpa-gu, Seoul, 05836, Republic of therapeutic prescription only medicine based on excellent technology
Korea accumulated in the natural drug manufacture industry in the mean-
time.
Foundation Date
1973 “Realizing Health improvement in harmony with nature”
Please give us your help and encouragement with interest and
Research Focus
support continuously to us who are devoting ourselves to establish
R&D Pipeline
Circulatory System
a welfare society in spite of our poor ability in contributing to Health Compound Name Code Use Stage of Development
Total Staff of mankind under the banner of "realizing health improvement in
135 persons Chong Myung Tang - Brain Function Formulation Development
harmony with nature."
Representative Phone SIP-1101 SIP-1101 Liver Function Research
82–2-928–0661~4
SIP-1102 SIP-1102 Allergic Rhinitis Formulation Development
Web
www.samik.co.kr SIP-1103 SIP-1103 Dementia, Brain Function Formulation Development
Contact Person SIP-1104 SIP-1104 Hypertension Formulation Development

Kim, Yu Li
Contact Phone
82-2-928-0661
web@samik.co.kr
Fiscal Year 2015 2016 2017
Sales 33,053 38,367 40,689
Capital 34,781 38,831 42,000

Main Products
Samil Pharm. Co., Ltd. Product (Ingredient/Formulation)

1. O
floxacin 3mg/mL Ophthalmic Soln.
Use
Susceptible strains of the
under registration
Asia, Mid-East
& Oint. microorganisms (Asia, Mid-East, Europe)
2. T obramycin 3mg/mL Ophthalmic Susceptible strains of the under registration
Asia, Mid-East
Solution & Ointment microorganisms (Asia, Mid-East)
3. Polymyxin B sulfate 6,000IU,
Neomycin sulfate 3mg (potency), conjunctivitis, blepharitis, and
Asia, Mid-East under registration (Asia)
Dexamethasone 1mg / Ophthalmic keratitis
Company Profile Suspension & Ointment
Company overview 4. Levofloxacin 5mg/mL Ophthalmic Susceptible strains of the under registration
Asia
Solution microorganisms (Asia, Mid-East)
· 1947 - The establishment of Samil Pharm. Co., Ltd.
Sjogren's syndrome, Stevens-
· 1969 - Technical alliance with Boots Co. of the UK for Brufen 5. Sodium Hyaluronate 1mg/mL Johnson Syndrome, dry eye under registration
Asia
· 1985 - Korea stock exchange IPO (000520) Ophthalmic Solution syndrome, drug-induced, injury, (Asia, Mid-East)
contact lenses
· 1985 - Completion of KGMP (Korean Good Manufacturing Practice) 6. Diclofenac sodium 1mg/mL a nonsteroidal anti-inflammatory under registration
in Ansan Asia, Mid-East
Ophthalmic Solution product (Mid-East)
Representative
· 1987 - Establishment of Central R&D Center / Set up ophthalmic 7. P ovidone 20mg/mL Ophthalmic under registration
Kang Huh a lubricant alleviating dry eyes Asia
business division Solution (Mid-East)
Headquarter Address 8. A
cyclovir 30mg/g Ophthalmic keratitis caused by herpes simplex under registration
· 2003 - Newly established Thea business division Asia
155, Hyoryeong-ro, Seocho-gu, Seoul, Ointment virus (Asia, Mid-East)
Korea · 2008 - Joint Venture contract with Allergan Inc, of USA corticosteroid-responsive
9. F luorometholone 1mg/mL Ophthalmic under registration
Foundation Date · 2011 - Joint Venture contract with Mon-samil LLC of Mongolia inflammation of outer and anterior Asia
suspension (Asia, Mid-East)
07 OCT. 1947 segments of the globe
· 2014 - $9 Million export contract with Iran
10. Losartan Potassium, HCTZ 50mg,
Research Focus hypertension Asia -
Export country : Hong Kong, Japan, Myanmar, Mongolia, 50/12.5mg, 100/12.5mg Tablets
Ophthalmology, Gastro-intestinal,
Philippines, USA, Vietnam, Yemen
Respiratory, Circulatory, Cardiovascular,
Dermatology Subsidiary company : Samil H&T Co., Ltd., Samil Medical Co., Ltd.
(detistry, medical device)
Total Staff
396 persons Focus Area : Ophthalmology, Gastro-intestinal, Respiratory, R&D Pipeline
Circulatory, Cardiovascular, Dermatology Compound Name Code Use Stage of Development
82-2-520-0300 Stable pharmaceutical composition
Trimebutine 1020100002507 12 JAN. 2010
comprising Trimebutine and prokinetic agent
Representative Fax
82-2-588-5924 Pharmaceutical composition in tablet form
Limaprost alfadex 1020100068304 15 JUL. 2010
for oral administration comprising Limaprost
Web
Multi layer pharmaceutical tablet with
www.samil-pharm.com improved stability comprising Sulglycotide
Sulglycotide 1020110013635 16 FEB. 2011
Contact Person and H2 antagonitsts and preparation method
Shin-ku Kang thereof
Financial Figures Pharmaceutical composition comprising
Contact Phone Telmisartan 1020120079809 Telmisartan with improved stability and 23 JUL. 2012
preparation method thereof
Contact E-mail Fiscal Year 2015 2016 2017 Pharmaceutical composition comprising
Sales - - - Telmisartan & Hydrochlorothiazide 1020120114062 15 OCT. 2012
skkang@samil-pharm.com Telmisartan and HCTZ
Capital - - -

Main Products
Samjin Pharmaceutical Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries
Singapore,
Remarks
1. PLATLESS (Clopidogrel / Tablet) Antithrombotics, Antiplatelet Cambodia, -

Philippines
Philippines,
Vietnam, Cambodia,
2. GEWORIN Tablet Analgesics & Antipyretics OTC
Mongolia,
Company Profile Uzbekistan
All human beings have the right to enjoy a healthy and happy life. 3. NEUSTATIN-A (Atorvastatin / Tablet) Antilipidemic Agents Philippines -
However, the complicated social structure of modern society and 4. TRESTAN Capsule Appetite Stimulants - OTC
the development of material civilization cause the advent of new
diseases. 5. NEUTOIN (Donepezil / Tablet) Nootropics & Neurotonics - -
In order to protect human health from these diseases and Hong Kong,
fundamentally get rid of diseases, Samjin Pharm Co., Ltd secures 6.NEUSTATIN-R (Rosuvastatin /Tablet) Antilipidemic Agents Philippines, -
excellent personnel and latest equipment and continues to challenge Myanmar
Representative the development of excellent pharmaceutical drug by utilizing
Sung-Woo Lee advanced pharmaceutical information and technology. 7. BAMEDIN (Rebamipide/Tablet) Antiulcerants
Cambodia,
-
Guatemala
Headquarter Address Samjin pharm Co., Ltd always strives for a better future on the basis
121 Wausan-Ro(Seogyo-dong), Mapo-Gu, of dignity of human life and company philosophy. 8. MAROBIVEN-A Inj. Antiinflammatory Enzymes - -
Seoul, Korea
The company pioneering a healthy life of people and challenging the 9. SYNERJET (Acetaminophen, Tramadol / Tablet) Analgesics & Antipyretics Philippines, Vietnam -
Foundation Date prosperous future with mind of creation.
Apr. 18. 1970 10.ARB-XG (Amlodipine, Valsartan / Tablet) Antihypertensive Agents Philippines, Vietnam -
Focus Area : Cardiovascular system drugs, Analgesics & Antipyretics,
Research Focus etc.
AIDS, Dry eye, etc.
Total Staff
R&D Pipeline
688 persons
82-2-3140-0700 - SJ-3366 AIDS Phase1/Preclinical
Web Dry eye syndrome, Oral

Rebamipide Prodrug SA001 Phase II
www.samjinpharm.co.kr treatment
Contact Person Dry eye syndrome, Eye drop
Bum-Kyu Shin - SJP002 Phase II
solution
Contact Phone
- SJP1601 Cancer Preclinical
82-2-3140-0673
Contact E-mail - SJP1602 Cancer Biological test
bk72@samjinpharm.co.kr Financial Figures Aptamer-drug conjugate SJP1604 Cancer Preclinical
Summary (1 Million Won) - SJP1610 Cancer Biological test

Fiscal Year 2015 2016 2017
Alzheimer's disease,
Sales 216,511 239,312 245,272 - SJP1701 Biological test
Parkinson's disease
R&D Expenditure 15,748 17,437 19,932
Capital 13,900 13,900 13,900

Main Products
Samyang Biopharmaceuticals Corporation Product (Ingredient/Formulation) Use Exporting Countries
Asia, Europe,
Remarks
1. Genexol® Inj. (Paclitaxel) Anti-Cancer -

Middle East
2. Genexol-PM® Inj. (Paclitaxel) Anti-Cancer Africa, Asia -
3. Nanoxel®-M Inj. (Docetaxel) Anti-Cancer - -
Company Profile 4. Pemed® Inj. (Pemetrexed) Anti-Cancer Europe, Middle East -
Samyang Biopharmaceuticals Corporation is focusing its efforts on 5. Protezomib® Inj. (Bortezomib) Anti-Cancer - -
healthcare as its core strategic business of the 21st century. Samyang
6. Lenalid® Tab. (Lenalidomide) Anti-Cancer - -
Biopharmaceuticals Corporation is developing proprietary and unique
core technologies for the development of world class novel drug 7. Palseron® Inj. (Palonosetron) Nausea and vomiting - -
delivery systems.
8. Zolenic® Inj. (Zoledronic Acid) Bone metastasis Europe -
Focus Area : Oncology, GMP Manufacturing(APIs, Injections, Patches),
DDS Technology 9. R heumastop® Transdermal Patch
Rheumatoid arthritis Africa, Middle East -
Representative (Diclofenac Diethylamine)
Taeung Eom
10. Tulobuterol Transdermal Patch Asthma acute bronchitis - -
Headquarter Address
295 Pangyo-ro, Bundang-gu, Seongnam- 11. Fentaderm® Transdermal Patch (Fentanyl) Severe Pain - -
si, Gyeonggi-do 13488, Korea 12. Rivastigmine Transdermal Patch Anti-Alzheimer - -
Foundation Date
Asia, Europe, Japan,
2011. 11. 01 13. Paclitaxel (API) Anti-Cancer -
South America
Research Focus
novel drug delivery systems and medical
devices
Total Staff
R&D Pipeline
276 persons Compound Name Code Use Stage of Development
Representative Phone Paclitaxel - Market

PM
82-2-2157-9857 (Polymeric Docetaxel - Cancer Market
Web Micelle)
Temsirolimus - Preclinical
www.samyangbiopharm.com
PNP Docetaxel - Clinical
Contact Person (Polymeric Nano- Cancer
Mr. Sung-Seup Shin Particle) Sirolimus - Preclinical
Contact Phone Oral_CSDS Prednisolone - Ulcerative colitis Research

82-2-2157-9857 Oral_FDT Ramosetron - Vomiting Registration
Contact E-mail Financial Figures Oral_BA - SYO-1644 Cancer Preclinical
sungseup.shin@samyang.com
Summary (1 Million Won) siRNA
Fiscal Year 2015 2016 2017 SENS mRNA - Cancer Research

Sales 62,634 70,300 80,500 pDNA
R&D Expenditure 7,700 8,400 8,890
Capital 208,939 220,788 230,000

Main Products
Seoul Pharma Co.,Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks

Lauched as Viagra L
1. VULTIS® (Sildenafil citrate/ ODF) Erectile dysfunction -
in Korea
2. VULTEUM® (Tadalafil / ODF) Erectile dysfunction - -
3. ARTPEZIL® (Donepezil HCl / ODF) Dermentia - -
4. Diflu cap. (Fluconazole/capsule) Antifungal - -
Company Profile 5. Aliver susp. (I-leucine,I-isoleucine,I-valine) Hypoalbuminemia - -
Seoul Pharma Co., Ltd., (the “SPC”) has engaged in manufacturing 6. Sebron cap./syrup (acetylcystein/cap./syrup) Mycolytics - -
and distribution of pharmaceuticals since its establishment in 1976 7. S eoul Amlodipine Besylate tab.
Anti-Hypertension - -
and established the Centralized R&D Centre in 1997 for the purpose (amlodipine besylate/tablet)
of R&D on new drug delivery technology.
SPC has produced more than 50 oral solid products mainly as Rx with
such therapeutic categories as respiratory, infective, cardio-vascular,
gastro-intestinal, endocrinal, anti-obesity, and so on. R&D Pipeline
Representative In order to become a world-class pharmaceutical company, SPC has Compound Name Code Use Stage of Development
Mr. Jungho Kim focused its R&D on the innovative and creative DDS technology such
COPD agent
Headquarter Address as special formulations development and as its result, SPC developed - SPC-702 Preclinical
(W-peptide derivative)
21, Banpo-daero, Secho-gu, Seoul, 06710, a new Platform technology, named as “SmartFilm® Technology”, to
produce Orally Disintegrating Film(ODF) products. SPC has planned to - SPX-601 prevention and curing arthritis Phase II a Clinical
Korea
penetrate the global market through SmartFilm® Technology with a Sildenafil citrate Vultis erectile dysfunction Launched May 2012
Foundation Date new cGMP/EU-GMP plant was built in Osong city, especially targeting
1976 Aug. A Domestic Patent
to the US, EU, and other regulatory markets. Through SmartFilm® Donepezil HCl Artpezil Dermentia
Registration
Research Focus Technology, SPC is willing to enter the global challenge for the market
and be a Hidden Champion in the global pharmaceutical industry. - Aripiprazole ODF Schizophrenia MA completed
NCE, IMD, ODF
Tadalafil Vulteum Erectile dysfunction Launched Sep 2015
Total Staff
218 persons - SPO-1107 Anti-emetic Formulation Research
Representative Phone - SPO-1304 Antiviral Formulation Research

82-2-3470-2300 - SPO-1405 Obesity Formulation Research
Web - SPO-1401 Anti-emetic Formulation Research
www.seoulpharma.com
- SPO-1406 Overactive bladder Formulation Research
Contact Person
Yongnam Jang
Contact Phone
82-2-3470-2385
Other
Contact E-mail
overseas@seoulpharma.com Our SmartFilm® technology, which is a DDS technology to produce Orally Disintegrating Film (ODF), results from our effort and
Financial Figures
yongnam.jang@seoulpharma.com devotion to develop the new technology under our confidence since 2009 that our future depends on how to secure platform
Summary (1 Million Won) technology and strengthen core competence.
The SmartFilm® technology is differentiated from the existing platform one, because it is the globally leading technology to enable
Fiscal Year 2015 2016 2017
to load the higher dose of active pharmaceutical ingredients, secure the optimal manufacturing process of ODF and mask the bitter
Sales 44,731 45,920 46,652 taste of medicines.
R&D Expenditure 2,505 2,127 2,526 We appreciate you for your continuous support and encouragement to us until our company becomes one of the global leading
pharmaceutical companies through SmartFilm® technology.
Capital 33,528 42,070 54,090

Main Products
SHIN POONG PHARM. CO., LTD. Product (Ingredient/Formulation) Use Exporting Countries Remarks
Medical device with

1. Medicurtain Inj. Surgical adhesion barrier -
novel mode of action
2. Candeamlo Tab. Hypertension treatment - IMD, FDC
3. Ezerosu Tab. Hyperlipidemia treatment - IMD, FDC
Company Profile 4. Hyal Forte Inj. Osteoarthritis treatment - Leading product in Korea
Shin Poong Pharm. Co., Ltd is a R&D oriented multinational

pharmaceutical company headquartered in Seoul, South Korea,
with 7 manufacturing site worldwide with global partners in over 59
countries. Main focusing areas are CV, CNS, surgical wound care,
musculoskeletal, and anti-infective. R&D Pipeline
Under the management philosophy of ‘for the health of the people’, Compound Name Code Use Stage of Development
Shin Poong Pharm. Co., Ltd. specializes in manufacturing remedy SP-8008 - Anti-platelet (NCE) Preclinical
Representative drugs with sincere efforts put into producing every single tablet of
Jei Man Ryu life-saving drugs ranging from ingredients to finished products based SP-8232 - Heart failure (NCE) Preclinical
on our state-of-the-art manufacturing facilities and quality assurance
Headquarter Address system. We are committed to realizing the spirit of Shin Poong 3V SP-8356 - Atherosclerosis (NCE) Preclinical
161 Yeoksam-ro, Gangnam-gu, Seoul, (Vision, Venture and Victory) with top-notch competitiveness based FreeWink™ - Dermal/body filler (NME) Preclinical
0646, Korea on in-house ingredient synthesizing technologies obtained through
Foundation Date rigorous R&D efforts and to further developing the company into the Osteoporosis/fracture healing
SP-35454 - Phase I
1962.06.09 one that receives confidence from our customers and that contributes (NCE)
to promoting the wellbeing of human beings.
Research Focus HyalOne™ - Osteoarthritis (NME) Phase I
CV, CNS, surgical wound care,
musculoskeletal, anti-infective SP-8203 - Acute ischemic stroke (NCE) Phase II
Total Staff Pyramax Granule - FDC/Pediatric malaria (NCE) Phase III-IV

765 persons
82-31-491-6191-2
Web
www.shinpoong.co.kr/eng New Active Substances
Contact Person Product (Ingredient) Use Approval Date/Country
J. S. Hong 2011.08 / Korea
Pyramax Tab. FDC/Malaria (NCE)
2012.02 / EU
Contact Phone
82-2-2189-3509
sptrade@shinpoong.co.kr
Fiscal Year 2015 2016 2017
Sales 185,478 182,276 -
Capital 23,790 27,593 -

Main Products
SINSIN Pharmaceutical Cp., Ltd. Product (Ingredient/Formulation)
1. SINSINPAS-RX
Active ingredient : Out of 1 sheet (10x14cm, Indication

2,301.24mg) Muscular pain, Joint pain, U.S.A, Aisan Pain Relief
L-menthol 90.9mg, dl-camphor 34.1mg, Shoulder pain, backache, sounties. Patch
Mentha oil 45.46mg, Methyl salicylate 90.90mg, Bruise, Sprain
Vanillyl Nonylamide 0.114mg
Company Profile 2. SINSIN PAS Pain relief Patch

Active ingredient : Out of 1 sheet (6.2x 4.1cm, Indication
In the year 1959, few years after Korean war, SINSIN Pharmaceutical 453.29mg) Muscular pain, Joint pain, U.S.A, EU, Asian Pain Relief
Company was established during the reconstruction of post-war Methyl salicylate 29.98mg, Thymol 0.77mg, Shoulder pain, backache, countries. Patch
period for the purpose of improving the national health. L-menthol 36.32mg, Bruise, Sprain
DL-camphor 15.63mg, Borneol 1.20mg
Amidst the devastating conditions of the 1950’s SINSIN committed
to the development of top professional staff, research and Indication
development of new products and to the improvement of the Korean 3. SINSIN CAPSICUM PATCH
Muscular pain, Joint pain,
Active ingredient : Out of 1 sheet (13x18cm, U.S.A, Middle East, Pain Relief
pharmaceutical market. SINSIN’s efforts were successful in replacing Shoulder pain,
2,400mg) Asian countries. Patch
Representative the expensive Japanese Plaster and through superior quality Neuralgia, Rheumatism,
Capsicum extract 0.025%
management became the #1 Plaster company in Korea. backache
Hanki Kim
Headquarter Address SINSIN began to export it’s products in 1971 and at present time Exporting country
Korea Bio Park C - 4fl, 694-1, Sampyeong- it ships to over 30 different countries worldwide with trememdous Over 15 countries
dong, Bundang-gu, Seongnam, success. including :
• U.S.A
Geyeonggi-do, Korea 463-400 SINSIN has been given various awards including the Outstanding Indication
(CVS, Wal green)
Company Award and the Presidential award. These awards have • Muscular pain
Foundation Date • Poland
motivated SINSIN to work harder to promote national health, which 4. ICE COLD PAIN RELIEF PATCH • Joint pain
1955 • U.K (Boots ) Pain Relief
Active ingredients ( out of 8x12cm, 5.2g) • Shoulder pain
is both our responsibility to society and our original goal as a leading • Asia Patch
Research Focus • L-Menthol 5% • backache
pharmaceutical company. • Russia
Pain reliving and wound care etc. • Bruise
ICE COLD PAIN
From environmental concerns to national health SINSIN • Sprain
RELIEF PATCH
Total Staff Pharmaceutical will continue to diligently work for the improvement PAIN RELIEF HYDRO
240 persons of life. GEL PATCH
Representative Phone Code :SSP 3405
Thank you for all of your support.
82-31-776-1111
Focus Area : Pain reliving patches, Liniment, Aerosol, Wound care Exporting country
Pain Relief
Representative Fax product. Indication Over 10 countries
Patch,
82-31-776-1117 • Arthritis Deformans including :
5. KETOCLIN PLASTER Transdermal
• Peri-arthritis of shoulder • HK
Web Active ingredients (out of 10×7cm2, 0.7g ) Drug
• Tendinitis • Vietnam
http://global.sinsin.com • Ketoprofen 30mg Delivery
• Peri-tendinitis • Macao
System
• Myalgia • Iran
Contact Person (TDDS).
• Guatemala
Woongjin Han
82-31-776-1141
Contact E-mail
wjhan@sinsin.com Fiscal Year 2012 2013 2014
Sales 9,376 8,704 8,631
Capital - - -

Main Products
SK Chemicals Co., Ltd. Product (Ingredient/Formulation)
1. OMED Tab. (Omeprazole)

Use
Gastric Ulcer
Exporting Countries
EU
Remarks
2. SID710 Patch (Rivastigmine) Alzheimer's Disease EU -
Egypt, India,
China, Hong Kong,
3. SK Albumin Inj. 20% (Human Albumin) Albumin Deficiency -
Mongolia Dominican
Company Profile Republic
SK Chemicals is a member company of SK Group, the third largest Thailand, Peru, India,
4. LIV-Gamma Inj. (Human IgG) IgG Deficiency -
company group in Korea. Egypt
Since founded in 1969, SK Chemicals has focused on the development Saudi Arabia, China,
5. Trast Patch (Piroxicam) Arthritis -
of drug products targeting the diseases with unmet treatment needs Philippines
in order to fulfill its vision; “Healthcare and Earthcare”.
6. Ginexin Tab. (Ginko biloba) Blood Circulation Enhancer Saudi Arabia -
The R&D area of SK Chemicals covers a broad range of product
lines, including new chemical entities, new herbal extract drugs, 7. Joins Tab. Arthritis Australia -
Representative reformulated generics, vaccines and blood products. Owing to its
In-Serk Lee continuous efforts on R&D, SK Chemicals was able to develop three 8. SID530 Inj. (Docetaxel) Anti-cancer EU -
Headquarter Address new chemical entities (NCEs), novel drug delivery system (DDS) 9. SID820 Cap. (Esomeprazole) Gastric Ulcer EU -
686 Sampyeong-dong, Bundang-gu, flat foam technologies, recombinant DNA technology and in-house
Seongnam-si 463-400, Gyeonggi-do, premium vaccines. 10. MvixS ODF (Mirodenafil) Erectile Dysfunction - -
Korea On the basis of this strong R&D capability together with its
Foundation Date outstanding marketing operations, SK Chemicals was selected as a
member of the Korea Innovative Pharmaceutical Company.
R&D Pipeline
1969.07.01
Research Focus
NCE, Herbal, Biologics NCE 401 Fibrosis Pre-clinical
Total Staff NCE 403 Endometriosis Pre-clinical

1593 persons
HMP 301 Asthma Phase III
82-2-2008-2008 HMP 302 Alzheimer's Disease Phase III
Representative Fax HMP 304 Irritable Bowel Disease Phase II

82-2-2008-2959
Prevention of infection caused by Pneumococcal
Web NBP 606 Phase I
bacteria
www.skchemicals.com
NBP 607 Prevention of infection caused by Influenza virus Phase I
Financial Figures New Active Substances

Fiscal Year 2008 2009 2010 SUNPLA (Heptaplatin) Anti-cancer 1999
Sales 258,952 303,383 350,270 JOINS (Herbal Extracts) Arthritis 2002
R&D Expenditure 24,500 30,621 34,910
Mvix (Mirodenafil) Erectile Dysfunction 2007
Capital - - -

Main Products
SS Pharm.Co.,Ltd. Product (Ingredient/Formulation)
1. Acetyl-L-Carnitine Hydrochloride
Use
Nootropics & Neurotonics

Exporting Countries
-
Remarks
KDMF
2. Bethanechol Chloride Other Genito-Urinary - -
3. Benfotiamine Anti-oxidant - -
4. Caffeine and Sodium Benzoate Respiratory Stimulants - -

Company Profile 5. Celecoxib COX-2 inhibitor - -
SS Pharm is a manufacturer of APIs.
6. Citrulline Malate Amino acids and derivatives - -
And our facilities and operations conforms to PIC/S and WHO GMP.
7. Clopidogrel Bisulfate Anti-thrombotic - KDMF
8. Doxofylline Anti-Asthmatics - -
Retinoids, Anti-Acne
9. Isotretinoin - -
Preparations
Representative
10. Talniflumate Anti-imflammatory - KDMF
Koh, Jae-Won (CEO)
Headquarter Address 11. Cilnidipine Cardiovascular agent - -
10, Beomjigi-ro 141beon-gil, Danwon-gu,
Ansan-si
Foundation Date
1995.11.21
Research Focus
R&D Pipeline
973.783m2 Compound Name Code Use Stage of Development
Total Staff Choline Alfoscerate - Nootropics & Neurotonics Under development

24 persons
Examined for Product license
Representative Phone Nafamostat Mesylate - Anti-coagulants
by MFDS
82-31-491-6311
Examined for Product license
Web R-Thioctic acid Tromethamine salt - diabetic neuropathy
by MFDS
www.susungpharm.co.kr
Anti-histamines & anti-
Contact Person Epinastine Hydrochloride - Under development
allergics
Park, Chul-Seo
Contact Phone
82-31-491-6311
Contact E-mail
pcseo1020@nate.com Financial Figures
Fiscal Year 2015 2016 2017
Sales 7,669 8,659 9,500
Capital 2,030 2,030 2,030

Main Products
Suheung Capsule. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Empty hard gelatin capsules - more than 40 -
2. Empty hard fish capsules - more than 40 -
3. Empty hard HPMC capsules - more than 40 -
Company Profile
Since Establishment in 1973, Suheung Capsule Co., Ltd have sought
to produce only the highest quality capsules and thus grown to be
one of the world's leading manufacturers and exporters of empty hard
gelatin, fish and HPMC capsules.
Representative
Mr. Joo Hwan, YANG / CEO
Headquarter Address
Jung-An B/D 6F, 435-5 Jangan 1dong,
Dongdaemun-gu, Seoul
Foundation Date
1973
Total Staff
500 persons
82-2-2210-8193
Representative Fax
82-2-2217-2356
Web
www.suheung.co.kr
Financial Figures
Fiscal Year 2008 2009 2010
Sales 101,606 107,816 124,860
Capital 5,902 6,084 6,084

Main Products
Taejoon Pharmaceutical Product (Ingredient/Formulation)

Ophthalmic solution
Use Exporting Countries Remark
The increase of tear production in patients whose

tear production is presumed to be suppressed
1. Cyporin N ophthalmic solution (Cyclosporine) -
due to ocular inflammation associated with
keratoconjunctivitis sicca
2. MC Free ophthalmic solution Dry eyes for the temporary relief of burning,
EU, USA
(Sodium carboxymethylcellulose) irritation and discomfort
Company Profile Bond and repair corneal epithelial cells, helps cure
3. Hyaluni ophthalmic solution
Taejoon Pharm., founded in 1978, is a global pharmaceutical company corneal injuries and retain and stabilize tears, - -
(Hyaluronic acid)
dysfunction tear syndrome
accomplished in exporting aseptic eye drops to Europe for the first
4. Taejoon Ultra ophthalmic solution Temporary relief of irritation and burning due to
time in Korea. In addition, we are the first specialized company to USA -
(Polyethylene Glycol) dryness of the eye
have technologies to make all three fields of contrast media products:
Reduction of elevated intraocular pressure in
X-ray, MRI, and CT. Taejoon Pharm's Yongin plant, which was built 5. Xalost Plus ophthalmic solution
patients with open-angle glaucoma or ocular EU, Russia, China
in October, 2005, became Korea's first EU-GMP certified plant to (Latanoprost + Timolol maleate)
hypertension
produce qualified pharmaceutical products that export to Europe.
Reduction of elevated intraocular pressure in
Taejoon is implementing a marketing strategy, targeting countries 6. Xalost ophthalmic solution (Lataonoprost) patients with open-angle glaucoma or ocular EU, Russia, China -
Representative hypertension
Tae Young Lee of the world and continuously reinforcing pioneering movement
by actively participating in internationally renowned academies 7. Alpaday ophthalmic solution (Olopatadine HCl) Relief of allergic conjunctivitis - -
Headquarter Address and exhibitions. As a result, we were able to create a strong sales Inflammatory diseases of the anterior/external
8 Daesagwan-ro 31-gil, Yongsan-gu, 8. Fluvin ophthalmic solution
network among more than 50 countries, including 30 European segment of the eye (blepharitis, conjunctivitis, - -
(Fluorometholone)
Seoul countries. On this basis, we plan to strengthen the sales network with keratitis, etc)
Foundation Date the goal of simultaneous release into the world in the event of global Gastrointestinal agents
1978 product launch. We expect to increase the company's brand value by
9. Coolprep (PEG 3350) Preparation for colonoscopy -
establishing the sales network through localized sales marketing in
Research Focus particular countries, such as the U.S., China, Russia, and Europe. Hemostasis and remission of subjective symptom
10. Lamina G (Sodium Alginate) -
Ophthalmology, Gastrointestinal agents, in gastric & duodenal ulcer, erosive gastritis
Contrast media, etc Focus Area : Ophthalmology, Gastrointestinal agents, Contrast media, For elimination of gastric bubble for
etc. 11. Gasocol Susp. (Simethicone) - -
gastroendoscopy
Total Staff
385 persons 12. Colyte (PEG 3350) Preparation for colonoscopy - -
Representative Phone 13. Colyte F (PEG 3350) Preparation for colonoscopy - -
82-2-799-0072 Contrast Media

Representative Fax 14. MRbester injection Contrast medium for cranial and spinal MRI/ whole
Asia
82-2-798-6665 (Gadopentetate dimeglumine) body MRI
Myelography, angiography, urography, contrast
Web 15. Iobrix injection (Iohexol) Asia -
enhancement of computerized tomography
www.taejoon.co.kr Angiography throughout the cardiovascular system,
Contact Person including cerebral and peripheral arteriography,
coronary arteriography and ventriculography,
Mr. Andy Lee pediatric angiocardiography, selective visceral
Contact Phone arteriography and aortography, peripheral
Financial Figures 16. Radisense injection (Iopamidol)
venography (phlebography), and adult and pediatric
Asia -
82-2-799-0072 intravenous excretory urography and intravenous
Summary adult and pediatric contrast enhancement of
Contact E-mail
jhlee2@taejoon.co.kr Fiscal Year 2012 2013 2014 computed tomographic (CECT) head and body
imaging
Sales $95,043,027 $94,325,508 $90,905,789
R&D Expenditure $4,836,463 $6,355,765 $7,686,165
Capital $92,603,127 $101,850,598 $91,917,685

Product (Ingredient/Formulation) Use Exporting Countries Remark
17. Iversense injection (Ioversol)

For cerebral angiography and peripheral
arteriography, contrast enhanced computed
tomographic imaging of the head and body,
- -
Taiguk Pharm. co., Ltd.
venography, and intravenous excretory urography
1. Intra-arterial intra-arterial digital subtraction
angiographyangiocardiography (left
ventriculography and selective coronary
18. Visisense injection (Iodixadol) arteriography), peripheral arteriography, visceral - -
arteriography, and cerebralarteriography
2. Intravenous CECT imaging of the head and body,
excretoryurography, and peripheral venography.
Company Profile
Contrast enhanced x-rays or computed “Supply best quality pharmaceutical products to customer.” Since
tomographic imaging (CAT scan, CT scan; a type established in 1957, Tai Guk Pharm. Co., Ltd. has been manufacturing
of body scan that uses a computer to put together
pharmaceutical products. We have focused on development of OTC
19. Solotop-HD (Barium sulfate) x-ray images to create cross-sectional or three Asia -
dimensional pictures of the inside of the body) of products such a hydroquinone cream and professional and leading
the esophagus (tube that connects the mouth and manufacturer of ointments(ointment, cream, gel) in Korea. We have
stomach), stomach, and intestine largest plant in Korea for ointments at Buyeo and pushing to FDA
approved Buyeo plant. We can also undertake contact manufacturing
Tablet, Capsule, Internal & External liquid, and specially Ointments.
Representative We are export to USA and many other countries.
Chang Koo Lee
Focus Area : Ointment & Cream
Headquarter Address
123, Jeyakgongdan 3-gil, Hyangnam-eup,
R&D Pipeline Hwaseong-si, Gyeonggi-do, Korea
Compound Name Code Use Stage of Development Foundation Date
Age-related Macular Degeneration 1957
- AMD Phase 2/3
(New Biological Entity)
Total Staff
Antibiotic product 284 persons
- Bacterial conjunctivitis Pre-clinical
(New Chemical Entity)
Dry eye product
- Dry eye Pre-clinical 82-2-3474-7761
(New Chemical Entity)
Combination or Improved drugs - Ophthalmic/GI indications Phase 3 ~ Pre-clinical Representative Fax
82-2-2051-2597
Web
http://www.taiguk.co.kr
Contact Person
You Mi Kim
Contact Phone
82-2-3474-7761
Contact E-mail
taiguk3@korea.com Financial Figures
Fiscal Year 2012 2013 2014
Sales 38,000 43,000 50,000
Capital 16,000 17,000 20,000

Main Products
THERAGEN ETEX CO., LTD.
1. Highrosone Cream
Dermatitis Cambodia -
(Hydrocortisone / Cream)
2. Paracool Cream
(Methyl Salicylate, l-Menthol, dl-Camphor / Pain Relief Vietnam -
Cream)
Company Profile
3. Pramyxin Ointment
(Bacitracin Zinc, Neomycin sulfate , Polymyxin B Antibiotics Hongkong - THERAGEN ETEX CO., LTD. is a leading pharmaceutical company to
Sulfate, Pramoxine HCl / Ointment) develop innovative and personalized new drugs having a world class
analysis technology of individual genome.
4. Partygel Suspension Excellent System : We have manufactured outstanding
Hyperacid Vietnam -
(Almagate / Gel) pharmaceuticals by controlling all lines at GMPs factory from
manufacturing to quality controls in compliance with WHO/ICH
5. Miobi soft cap. Guideline.
Multi Vitamin Ecuador -
(Vitamin A and other ingredients / Capsule) Representative Best Bio center : Our laboratory having the best analysis technology
JI KYU WON and excellent analysts of the genome in Korea. The first and the best
Headquarter Address results of studies to be recognized in the world - Whole genome
5F, 32, Nonhyeon-ro 30-gil, Gangnam-gu, mapping of woman, tigers and whales(the first in the world) -
Seoul, Korea Commercialized personal genome analysis service(the first in Asia)
Foundation Date Innovative New drug : THERAGEN ETEX CO., LTD. has built
1st. OCT. 1990 databases and infrastructures to dvelop personalized pharmaceuticals
by analysing individual's deases genes as the only pharmaceutical
Research Focus manufacturing facilities and genome analysis service in Korea.
First Generic & Slow release type drug
Focus Area : E.N.T & Cardiovascular
Total Staff
216 persons
82-2-3463-7111
Representative Fax
82-2-3463-8111
Web
http://www.thera-gen.com
Contact Person
Sun-Hee, Kim
Contact Phone
Contact E-mail
k37818@etexpharm.com
Fiscal Year 2012 2013 2014
Sales 65,757 56,398 52,244
R&D Expenditure 5,710 3,914 2,815
Capital 13,627 13,887 13,887

Main Products
Union Korea Pharma Co., Ltd.
Memory disorder,
1. ETEXCITICOLINE Tab. (Cilticoline 500mg) Vietnam -
Ischemic stroke
2. CELEMIN Cap. 200mg (Celecoxib 200mg) NSAID Vietnam -
3. NEXON Tab. 20mg/40mg

Gastritis Vietnam -
(Esomeprazole 20mg/40mg)
Company Profile
4. RABEZOLE 10mg/20mg
(Rabeprazole 10mg/20mg)
Gastritis Vietnam - Union Korea Pharma is pharma manufacturing company, certificated
GMP compliance of tablet, capsule, injection(ample, vial) and
5. EXPERA Tab. 5/80 cephalosporin powder from MFDS Korea.
Hypertension Phillipine -
(Amlodipine 5mg + Valsartan 80mg) We have exported to Vietnam, Cambodia, Philipine, Hongkong,
Mongo, Peru, Chile, Bolivia, Yemen, Azerbaijan etc, and we had
6. ATOSEN Tab. (Atorvastatin 10mg) Hyperlipidemia Vietnam -
received Presidental Award by small and medium enterprise export
7. ETEX ROSUVASTATIN Ca Tab. support center in 2009.
Hyperlipidemia Phillipine -
(Rosuvastatin Ca 5mg/10mg/20mg) Representative Focus Area : Antibiotics(Cepha inj.), Cardiovascular, Degenerative
Sung Jun Kim Disease, Contrast media, Ophthalmology
8. ZAKUTEX Dry syrup 156.25mg/5mL
(Amoxiciliine hydrate 21.6248g + Chronic branchitis Myanmar - Headquarter Address
Diluted potassium calvulanate 10.8124g) Wonwae B/D 5F, 26, Olympic-ro 43-gil,
Songpa-gu, Seoul, Korea
9. ZAKUTEX Neo Dry syrup
(Amoxiciliine hydrate 54.5454g + Acute otitis media for children Vietnam - Foundation Date
Diluted potassium calvulanate 7.8g) Nov. 1956
Research Focus
10. CLAROCIN Tab. (Clarithromycin 250mg) Antibiotics Vietnam -
Infectious disease
11. UMCKAMAX Syrup Bronchitis Total Staff
Vietnam -
(Pelargonium sidoides 11%EtoH ext.17.16mg) Laryngopharyngitis 220 persons
12. CRANTOL Syrup Representative Phone
Cough Nigeria -
(Amboroxol HCl 150mg + Clenbuterol HCl 0.1g) 82-2-489-3611
Representative Fax
13. CITLEN Solution (Citrulline maleate 1g) Fatigue recovery Vietnam -
82-2-487-3611
14. ETEX CYCLOSERINE Cap. (Cycloserine 250mg) Tuberculosis Vietnam - Web
www.ukp.co.kr
Uzbekistan
15. ZENTOX Tab. (Albendazole 400mg) Anthelminthic Azerbaijan - Contact Person
Kyrgyzstan Jeongsu Ock
16. OEANZIL Vaginal Soft Cap. Contact Phone

Myanmar 82-2-489-3611(Ext.311)
(Neomycin 35,000IU, Nystatin 10,000IU, Vaginal infection
Cambodia
- Financial Figures
Polymyxin B sulfate 35,000IU) Contact E-mail
jsock@ukp.co.kr
17. SIMTUM-TWO Tab. Fiscal Year 2012 2013 2014
(Acetaminophen 325mg, Phenylphrine HCl 5mg
Cold Hongkong - Sales 42,294 40,467 48,715
Dextromethorphan hydrobromide 10mg,
Chlorpheniramine maleate 2mg) R&D Expenditure 781 987 712
Capital 2,100 2,100 2,100

Main Products
Product (Ingredient/Formulation) Use
Respiratory system infection, infection
WHITE LIFE SCIENCE
related otolaryngology renal and urinary
tract infection, septicemia meningitis,
1. Unitiaxone Inj. Vietnam, Philippines,
prophylactic of pre/post operation -
(Ceftriaxone Sodium 1g) Yemen
infection, osteoarthritis, skin and soft
tissue infection, cholecystitis, G.I. tract
infection.
Hepatic dysfunction - Acute and chronic Company Profile
2. Uni-Infusion Inj. hepatitis, alcoholic liver disease; post
Vietnam, Mongol - White Life Sciences Co., Ltd. was founded in 2012 as White
(L-Ornithine-L-Aspartate 500mg) hepatitis convalescence, cirrhosis, along
with hepatotoxic drugs. Pharmaceuticals to create value for both clean and innovative
companies through rapid change and innovation.
Acute or chronic bronchitis, bronchiectasis,
bacterial pneumonia, pneumonial abscess, We strive to be “company that contributes to the right of everyone to
3. Union Cefuroxime Sodium Inj.
(Cefuroxime Sodium 750mg)
post-operational chest infection, sinusitis, Vietnam, Philippines - the same level of health care.“
tonsilitis, pharyngitis, nephropyelitis,
cystitis, cellulitis, eryspelas We launched a stomach medicine (“STOCURE“ Rebamipide)
in October 2013. Since then, more than 200 items have been
4. Climycin Inj. Infections caused by susceptible anaerobic Representative
Vietnam, Philippines - approved, including circulatory, respiratory, urinary, circulatory, and
(Clindamycin phosphate 600mg) bacteria
Yang Won Cheol musculoskeletal, and more than 100 items were sold. Also we are
Fever and pain due to cold, headache, establishing a foundation to become Korea's leading global company
5. Unifenac Inj. neurodynia, muscle ache, menstrual Headquarter Address
Vietnam - 621,Yeongdongdaero,Gangnam-gu, Seoul, through partnership with multinational pharmaceutical companies.
(Diclofenac Sodium 75mg) cramps, rheumatoid arthritis, arthralgia,
toothache Republic of Korea In 2017, we changed our company name to White Life Sciences,
Foundation Date we will do business not only in medicines but also in biotechnology,
2012 medical devices and cosmetics. We promise to listen to the voice
of the patient for 365 days and 24 hours and to be a pharmaceutical
Research Focus company based on communication and trust based on customer's
hypertension, diabetes mellitus, needs. We would like to extend my sincere gratitude to all those who
Hyperlipidemia have supported the White Life Sciences Co.,Ltd.,
R&D Pipeline Total Staff
Compound Name Code Use Stage of Development 100 persons
Combined antibiotics with beta- bacterial infections (upper Representative Phone
- Phase III trial
lactamase respiratory tract infections).
82-2-541-4884
Web
www.whitels.co.kr
Contact Person
Lee sang won
Contact Phone
82-2-541-4884
swlee@whitels.co.kr
Fiscal Year 2015 2016 2017
Sales 11,467 11,677 14,384
Capital 3,370 4,203 4,203

Main Products
1. Atrode Tab (atorvastatin calcium)

Use
Anti hypertension
Exporting Countries
-
Remarks
-
WhanIn Pharm Co., Ltd.
2. Cholestop Tab (rosuvastatin calcium) Anti hypertension - -
3. Alforen soft Cap (choline alfoscerate 400mg) Anti psychotics - -
4. Itclor Cap (cefaclor) Anti biotic - -
5. Candino Cap (fluconazole) Anti fungal agent - -

Company Profile
WhanIn Pharm is Korea's No.1 CNS company. We provide the
6. Albid Tab
best psychotherapeutic solutions which includes Antipsychotics,
(ranitidine HCl, sucralfate, tripotassium bismuth Anti ulceratives - -
Antidementia drugs, Antidepressants, Antiparkinson drugs,
dicitrate)
Antiepileptics, Anti-ADHD agents, Anxiolytics, and Alcoholism
peripheral circulatory treatment.
7. Sarpogrel Tab (sarpogrelate hydrochloride) - -
disturbance
8. Loxocool Tab (loxoprofen sodium) analgesic - -

Representative
9. Rabepezole Tab (rabeprazole sodium) Anti ulceratives - - Wonbum Lee
10. Valsapine Tab (amlodipine besylate, valsartan) Anti hypertension - - Headquarter Address
11, Beobwon-ro 6-gil, Songpa-gu, Seoul,
Republic of Korea
Foundation Date
June 5, 1978
R&D Pipeline Research Focus
Compound Name Code Use Stage of Development CNS disorders & Neurodegenerative
diseases, Age-related disorders and new
Anti fungal agent WLS-001 Anti fungal agent Stability
areas of unmet medical needs
Obesity treatment WLS-002 Obesity treatment Formulation development Total Staff
460 persons
analgesic WLS-003 analgesic Formulation development
Anti ulceratives WLS-004 Anti ulceratives Formulation Research 82-2-405-3000
Anti hypertension WLS-005 Anti hypertension Formulation Research Web
www.whanin.com
Contact Person
Seunghoon Suh
Contact Phone
82-2-405-3049
Financial Figures
Contact E-mail
suhsh@whanin.com Summary (1 Million Won)
Fiscal Year 2015 2016 2017
Sales 145,397 141,376 72,805
R&D Expenditure 5,522 7,834 4,638
Capital 206,594 220,130 231,460

Main Products
1. Quetapin tab. (Quetiapine)
Use
Antipsychotics
Exporting Countries
Asia, Middle East
Remarks
-
Won Kwang Pharm. Co., Ltd
2. Riperidon tab. (Risperidone) Antipsychotics Asia, Middle East -
3. Alpram tab. (Alprazolam) Anxiolytics & hypnotics Asia, Middle East -
4. WI Donepezil tab. (Donepezil Hydrochloride) Antidementia drugs Asia, Middle East -
5. U-Rantac tab./U-Rantac inj. (Ranitidine) Gastrointestinal drugs - -
Company Profile
6. Zyrepin tab. (Olanzapine) Antipsychotics Asia, Middle East -
Founded by Winkwang University on the basis of Bohwadang, a
7. Neuoxitam tab. (Oxiracetam) Nootropics - -
pharmacy established in 1934 under the slogan"Save all living things
8. WI Acamprosate tab. (Acamprosate Calcium) Alcoholism treatment - - from distress and sickness" Wonpharm Co., Ltd. manufactures over
9. Proiban tab./Proiban inj. (Ibandronate) Osteoporosis treatment - - 180 medicines, lncluing Gyeongokgo under strict quality control, and
over 20 health foods, incluing Wonkwang Bohwaokgo Bohwaokgo
10. Zolpiram tab. (Zolpidem Tartrate) Anxiolytics &hypnotics - - and Hyosam Forte, at its KGMP-certified factory equipped with clean
facilities.
Headquarter Address Wonpharm CO., Ltd., which has been designated as cooperative
R&D Pipeline 827 Shindong-ri, Chunpo-myeon, Iksan-si, business for research in pharrmaceutical resources as well as the
Jeonrabuk-do practice factory for Pharmacy College, Wonkwang University, devotes
itself to technical development for a society free from disease.
WIP-MO14 WIP-MO14 Dementia Clinical Foundation Date
May, 1934 tit has aiso established a solid educational industrial research system
WIB-801CE WIB-801CE Blood circulation Clinical with research system with medical College, Oriental Medical Center
WIP-DT14 WIP-DT14 BPH Clinical Research Focus of Wonkwang University.
Save all livings from distress and sichness
WIP-LG15 WIP-LG15 Lumbar Spinal Stenosis Preclinical
Total Staff
WIP-PX16 WIP-PX16 Schizophrenia Research 40 persons
WIP-AX16 WIP-AX16 Schizophrenia Research Representative Phone
WIP-DX16 WIP-DX16 Dementia Research 82-80-359-3333
WIP-LX16 WIP-LX16 Anti-Epileptic Research Representative Fax
WIP-DF17 WIP-DF17 Depression Research
82-63-833-4114
WIN-1601 WIN-1601 Memory impairment Research Web

www.wonpharm.co.kr

NEPONID (Nemonapride) Antipsychotics Jan. 1994 / Republic of Korea
Financial Figures
Summary
Other
Fiscal Year 2008 2009 2010
Sales 2,790,000,000 3,125,000,000 3,567,000,000
WhanIn provides you with best quality products with Bioequivalance study.
We hope that we would make long and sincere relationship with you. R&D Expenditure 4,500 3,600 3,200
Capital 3,000,000,000 3,000,000,000 3,000,000,000

Main Products
BoHwa KyungOkKo is composed of Korean Ginseng Hoelen, Rehmannia juice, and sweet honey based on the prescription of the
korean traditional medical book known as Dong Eui Bo Kam (UNESCO recognizes as a world legacy of the record). This product is
WOORIDUL PHARMACEUTICAL LTD.
well recognized as a restorative enforcing the vitality of whole organs, and also as elimination fatigues, exhaustion followed by
weariness. Because of the special properties that had no any interferences against any foods, this product has been used by the
ancient royal family and the nobles. Especially this product improves the growth df children and the recovery from weariness due to
illness of stress.

1. Bohwa Kyungokgo - - - Company Profile
2. Bohwa Sohap won - - - WOORIDUL PHARMACEUTICAL LTD. was established in 1957,
where it researched, produced and sold pharmaceutical products.
3.Woohwang chungsimwon Suspension liquid - - - Manufacturing plant is currently located in Hyang Nam Industrial
complex in Gyeong gi province, which has GMP qualified
manufacturing facilities with highly hygienic manufacturing
environment and high technology. Thus, the plant can produce
pharmaceutical products that will satisfy in both quality and quantity.
In 1990, after initial public offering, our company has not only
Representative continuously grown but also has been designated as one of growing
Nam-Hyun Ryu export companies.
Headquarter Address Our company also invests on researching new drugs and
10th Fl., Korea Fire Officials Credit Union Incrementally Modified Drugs. With continuous producing and
Bldg., 274 Songpa-daero, Songpa-gu, researching based on Platform, R&D Power, our company researches
Seoul, Korea, 05719 on safe and high-performance cosmetic products.
Foundation Date
26.Oct. 1957
Research Focus
ETC, OTC Drugs, Cosmetics, Food
supplements
Total Staff
245 persons
82-2-80-080-4211
Web
http://wooridulpharm.com/main.do
Contact Person
Chul-Hee Choi
Contact Phone
82-2-2194-3525
Financial Figures
Contact E-mail
chchoi@wooridulpharm.com Summary (1 Million Won)
Fiscal Year 2015 2016 2017
Sales 60,405 71,546 79,846
Capital 29,106 36,835 47,047

Main Products
1. NEPHRIS-S Tab. (Ononidis radix
YOOYOUNG PHARMACEUTICAL
extract 100mg, Orthosiphon Adjunctive treatment of acute ∙ choronic nephritis, cystitis, bladder
CAMBODIA
folium extract 100mg, and kidney stones
Solidaginis extract 200mg)
2. NEPHRIS Soft Cap. (Ononidis
1. S easonal and perennial allergic rhinitis
radix extract 30mg, Orthosiphon
2. Chronic idiopathic urticaria MONGOLIA
extract 100mg, Uvae ursi extract
3. D ermatitis and eczema accompanied with itchiness, eczema Company Profile
80mg)
1. Seasonal and perennial allergic rhinitis Yooyoung has established a foothold for growth through consistent
3. CETINZAL Tab. (Levocetirizine
2. Chronic idiopathic urticaria CAMBODIA increasing sales, and we are growing as a leading pharmaceutical
HCl 5mg)
3. Dermatitis and eczema accompanied with itchiness, eczema company in Korea by fulfilling our medium and long term mission.
1. Treatment of peripheral and central neuropathic pain in adults
4. PRENEW Cap. (Pregabalin 2. Epilepsy: Adjuvant for partial seizures with or without Focus Area : Arthritis, Anti-Thrombosis, Mixed-Dylipidemia, etc.
-
75mg, 150mg) secondary systemic symptoms in adults
3. Treatment of fibromyalgia
5.POTALION Tab. (Bepotastine Allergic rhinitis, chronic urticaria, pruritus associated with skin
-
besilate 10mg) diseases(eczema, dermatitis, skin pruritus, prurigo) Representative
6. VARDIPINE Tab. 5/80mg, Mr. Woo-Pyoung Yoo
Treatment for essential hypertension that is not controlled
10/160mg, 5/160mg - Foundation Date
properly with monotherapy using amlodipine or valsartan
(Amlodipine/Valsartan)
Dec. 23, 1981
7. NEULOS Cap. (Gabapentin
Epilepsy, neuropathic pain - Research Focus
100mg, 300mg)
New Drug & IMD
8. LOXORON Tab. (Loxoprofen 1. Chronic rheumatoid arthritis, osteoarthrosis, low back pain
-
60mg) 2. Acute upper respiratory inflammation Total Staff
1. Hyperlipidemia 320 persons
9. LIVATIN Tab. (Atorvastatin
2. Reduce risks of myocardial infarction, stroke, revascularization, -
10mg, 20mg) Representative Phone
chronic angina
82-2-6207-6114
10. WOORIDUL RANITIDINE HCl Gastro-duodenal ulcer, Zollinger-Ellison syndrome, reflux
- Representative Fax
Tab. (Ranitidine 75mg, 150mg) esophagitis etc.
82-2-6202-7067
Web
www.yypharm.co.kr
R&D Pipeline
Contact Person
Compound Name Code Use Stage of Development Mr. Choi
Confidential WRDP001 Central Nervous System Drugs Non-clinical
Contact Phone
Confidential WRDP002 Anti-Histamines Non-clinical 82-2-6202-7116
Antipyretic, Analgesic, Anti- Contact E-mail
Confidential WRDP003 Non-clinical
Inflammatory Drugs khchoi2@yypharm.co.kr
Confidential WRDP004 Anti-Diabetics Non-clinical Financial Figures
Confidential WRDP005 Anti-Diabetics Non-clinical
Confidential WRDP006 Anti-Atherosclerotics Non-clinical Fiscal Year 2012 2013 2014
Antipyretic, Analgesic, Anti- Sales 74,169 75,372 85,651
Confidential WRDN001 Research
Inflammatory Drugs R&D Expenditure 3,535 2,640 3,418
Confidential WRDN002 Anti-Peptic Ulcer Drugs Research Capital 3,000 3,000 3,000

Main Products
Poland, Syria, UAE,

Remarks
Yuhan Corporation
Arthritis, Scapular CTD Dossier
1. Ati Injection Russia, Vietnam,
periarthritis Available
Japan
Arthritis, Scapular Poland, UAE, Russia, CTD Dossier

2. Atri Plus Injection
periarthritis Malaysia Available
3. Cnoxane Injection LMWH : Anti-Coagulant

Russia, Syria, CTD Dossier Company Profile
Philiphine, Vietnam Available
Founded in 1926 with the mission of supporting South Korea by enhancing
4. Asasulfan Tablet Ulcerative colitis Japan - the quality of life for all Korean people, Yuhan has been providing high
quality medicines for the last 91 years as one of the leading pharmaceutical
companies in South Korea.
API and Intermediate
Yuhan provides the custom-tailored contract services in research,
R&D Pipeline development, and manufacturing of APIs, key intermediates, and RSMs at
two sites under cGMP, approved by FDA(US), EDQM(EU), TGA(Australia),
Compound Name Code Use Stage of Development Representative
PMDA(Japan) and MFDS(Korea), to the global pharmaceutical companies
Junghee Lee with excellent quality. And Yuhan offers one-stop services from process
Stem cell Neuronata-R ALS On Market
Headquarter Address development through commercial manufacturing.
IMD/DDS Artis-FR Gastic ulcer Registration 74, Noryangjin-ro, Dongjak -gu, Seoul, Finished product
Korea
Monoclonal Antibody YYB101 Anti-cancer Phase 1 Yuhan is supplying various categories of high quality pharmaceutical
Foundation Date finished products including cardiovascular, metabolic, respiratory, antibiotic,
IMD/DDS YY1201 OA Phase 1 Dec. 1926 anticancer products and OTC products to both domestic and overseas
markets. In terms of Antiphlamine Lotion(anti-inflammatory agent) and
IMD/New combination YYC301 Neuropathic Pain Preclinical Research Focus Yumangel suspension(antacid), they are all market leaders in the relevant
Cancer, Metabolic disease market of Korea and Vietnam.
IMD/Release control YYD601 GERD Preclinical
Total Staff R&D
IMD/New HA filter YYD701 Dermal Filler Preclinical 1,770 persons
Yuhan is focusing its R&D capabilities on developing innovative small
Fusion Protein YYB102 Anti-cancer Discovery Representative Phone molecule and biological medicines, especially in the therapeutic areas of
82-2-828-0181 cancer and metabolic diseases. Its advanced drug-delivery technology also
supports the development of incrementally modified drugs (IMDs) such as
Web fixed-dose combination and controlled release drugs.
www.yuhan.co.kr
Contact Person
K. C. Lee
Contact Phone
82-2-828-0194
Contact E-mail
kichul@yuhan.co.kr Financial Figures
Fiscal Year 2015 2016 2017
Sales 1,120,937 1,312,018 1,451,988
R&D Expenditure 71,543 85,191 101,609
Capital 1,285,767 1,390,818 1,487,991

Main Products
1. CMO (New Drug APIs)
Use
HIV
Exporting Countries
USA, Europe
Remarks
-
Yuyu Pharma., Inc.
2. CMO (New Drug APIs) HCV USA, Europe, Asia -
3. CMO (New Drug API) Rheumatoid Europe -
4. CMO (New Drug APIs) ß-lactamase inhibitor Europe -
5. Levofloxacin (Generic API) Antibiotic Canada, Japan -
6. Cilostazol (Generic API) Anti-platelet Japan -
Neonatal Respiratory Bovine lung
Company Profile
7. Newfactan (Finished product) ASIA, Middle East
Distress Syndrome surfactant Yuyu Pharma Inc, established in 1941, is a company that sales,
Lotion type of markets and manufactures pharmaceutical products in Korea and
8. Antiphlamine S Lotion (Finished product) ASIA -
Anti-inflammatory agent has developed its business through not only in-house developed new
Fixed Dose drugs but also various partnerships with global companies such as
Combination drug
9. Duowell tab. (Finished product) Hypertension, Hyperlipidemia Under registration Sanofi-Aventis, Pfizer, GSK and Novartis by incensing in their original
of Telmisartan &
products for the Korean market.
Rosuvastatin
10. Nazacare Nasal Spray Sol. 140dose &
Allergic rhinitis Nasal polyps Under registration -
Yuyu Pharma has focused on how to serve the aging population, as
60dose (Finished product) people are living longer and searching for ways to live a healthier
Representative
r. Seungpil Yu, Ph.D. / CEO life. This has led us to be a specialist in the fields of neurology,
osteoporosis, cardiovascular and nephrology. Yuyu’s treatment in
R&D Pipeline Headquarter Address these areas has proven to be fruitful and we will continue to focus on
Compound Name Code Use Stage of Development Hyein Building, 200 Jangchungdan-ro, these therapeutic categories. In order to expand the business, we are
Jung-gu, Seoul, Korea also expanding our presence in the field of gastrointestinal diseases
- YHP1604 Hypertension/Dyslipidemia Phase 3
Foundation Date and antibiotics.
- YHP1701 Hypertension/Dyslipidemia Phase 3
- YHP14755 Dyslipidemia/Diabetes Phase 3 1941 Also, Yuyu has completed new state-of-art factory in 2006. The
- YH22162 Hypertension Phase 3 Research Focus factory designed in accordance with cGMP and EU GMP. Tablets,
New Drug, Botanical Drug capsules and cream are manufactured with advanced equipment
- YHD1119 Neuropathic pain Phase 3
under cGMP compliance.
- YH23537 Peridontitis/Arthritis Phase 2 Total Staff
- YH26153 Peri-implantitis Phase 1 299 persons We would like to have an opportunity for the business relationship
with your company who is dealing with imported finished
- YH12852 Postoperative ileus Phase 1 Representative Phone pharmaceutical products.
- YH25448 Cancer Phase 1/2 82–2–2253-6600
- YH26136 Dyslipidemia/Thrombosis Preclinical Web
- YH25724 NASH Preclinical www.yuyu.co.kr
- YH24931 Cancer Preclinical Contact Person
Brian Jung
Contact Phone
82-2-6972-9173
Contact E-mail
Revanex (Revaprazan) Duodenal Ulcer, Gastric Ulcer, Gastritis Sep. 2005 / Korea bkjung@yuyu.co.kr Financial Figures
Other Fiscal Year 2015 2016 2017
1. Yuhan is a leading pharmaceutical company in Korea with generating more than KRW 1.4trillion in sales. Sales 69,743 71,579 53,518
2. Yuhan has come out on top at the Korea's Most Admired Companies Awards in its industry category for 14 consecutive years. R&D Expenditure 1,245 2,246 2,000
3. Yuhan is strictly abiding by Compliance Program. Capital 7,835 7,835 7,835

Main Products
1. Dusta soft capsule (Dutasteride)

Use
BPH&Alopecia
Exporting Countries
Mongolia
Remarks
-
C&R Research Inc.
2. Bonky soft capsule (Calcitriol) Osteoporosis Malaysia, Cambodia -
3. Bonky Injection (Calcitriol) Hypocalcemia Malaysia, Azerbaijan -
4. Yupan-C tablet Vitamin-C Mongolia, Syria -
5. Yupan-C pop Vitamin-C Mongolia - Company Profile

6. Maxmarvil tablet (Alendronate, Calcitriol) Osteoporosis Thailand, Myanmar -
We, the most representative Contract Research Organization in
Korea, has performed over 1,200 clinical trials projects for drugs and
7. Yuachoo Day&Night (DL-Methylepadrine) Cold Mongolia - medical devices since it was built in 1997, and there are about 300
employees including professional medical doctors and experienced
Colorless transparent &
8. Veonplus Gel (Heparin Sodium)
smooth gel
Russia - clinical specialists. Moreover, We have secured its position as a
leading CRO since it was awarded <South Korea Clinical Research
9. Barosofen soft capsule (Dexibuprofen) Anti-inflammatory Mongolia - Organization of the year>(2008, Frost & Sullivan Awards).
Foundation Date Besides, C&R Research Ltd. Inc. has run various subsidiary companies
1997 such as Quality Assurance expert company (C&R QA), pharmacometric
analysis center (Q-fitter) and education institution approved by MFDS
Research Focus (C&R Academy) to offer multi-directional and professional clinical
Contract Research Organization trial total solutions, and expanded global influences through Chinese
R&D Pipeline Total Staff branch in Beijing, and C&R Healthcare Global in Singapore.
300 persons
YY-102 YY-102 Dry eye Preclinical
82-2-6251-1500
YY-201 YY-201 Benign prostatic hyperplasia Phase 1
Web
YY-312 YY-312 Obesity NDA www.cnrres.com
Contact Person
Tanamin Tab. - Circulatory Improvement Launched
Song, Yunseok
Maxmarvil Tab. - Osteoporosis Launched
Contact Phone
Marvil W plus Tab. - Osteoporosis Launched 82-10-2342-2812
Contact E-mail
Marvil M Tab. - Osteoporosis Launched
song.yunseok@cnrres.co.kr
Newmacor soft capsule - Hyperlipidemia Launched
Dustar (6oblong) - Benign prostatic hyperplasia Launched
Dustar (2oval) - Benign prostatic hyperplasia Launched
Financial Figures
Fiscal Year 2015 2016 2017
Sales 20,273 23,348 29,360
Capital (1,541) (1,422) 2,840

Other
C&R Subsidiaries CrystalGenomics, Inc.
[C&R ACADEMY]
C&R Academy was founded in May 2010 aimed at being a clinical trial training center in Northeast Asia, offering a wide range of
training programs related clinical trials.
Now C&R Academy provides professional, comprehensive and practical “hand-on” clinical research training and continuous Company Profile
education programs to researchers (PI) and research nurses (CRC) as well as CRA, PM, CRM to improve the quality of clinical trials.
CrystalGenomics, Inc. is a commercial stage biopharmaceutical company that
Training programs of C&R Academy is consists of Fundamental Course, Basic Course, Monitoring Practice, Clinical Project is dedicated to the discovery and development of novel pharmaceuticals with
Management, GCP Training, Oncology Clinical Trial, Early Phase Study, Introduction to Clinical Trial and so on. All training programs innovative platform technologies to address significant unmet medical needs
can expect the effect of intensive training workshop conducted in the form of a small two-way communication. in the areas of infectious disease, oncology, and inflammatory diseases. The
Company is headquartered in Korea and has a US presence for multi-national
In addition, since 2011, C&R Academy introduced LMS (Learning Management System) and have been strived to improve the clinical development in California, and it is publicly traded on the KOSDAQ
validation and quality of educational services for all C&R Academy as ISO9001 certified company. C&R Academy will to be oriented exchange.
to international standards of clinical training services continuously. CrystalGenomics currently has one product on the market and is developing
Representative two additional novel drug candidates in different therapeutic areas. The
Joong Myung Cho, Ph.D. marketed product is Acelex® (polmacoxib), a next generation COX-2 inhibitor
[C&R QA] for the treatment of signs and symptoms of osteoarthritis. The first clinical
Headquarter Address stage program is CG400549, a novel targeted antibiotic for MRSA where its
C&R QA Inc., founded in Aug 2014, is the first company specialized in quality assurance of clinical trials in South Korea. 5th F. Bldg.A, Korea Bio Park, 700 phase 2a skin infection study in the US has been completed with a positive
Daewangpangyoro, Bundanggu, outcome of 100% clinical cure rate. The second program is CG200745, an
C&R QA is established for the purpose of enhancing the professionalism of the quality assurance work of clinical trials independently
Seongnamsi, Gyeonggido, 13488 Korea epigenetic anti-cancer therapeutic for various types of solid and liquid tumors
from C&R Research that had provided quality assurance services such as audits in a variety of therapeutic areas, education and and currently, two clinical studies are ongoing for pancreatic cancer and
preparation for government authority inspection. As the importance of quality assurance of clinical trials has been increasingly Foundation Date MDS.
emphasized, C&R QA is aiming to provide quality assurance services of clinical trials to customers with credibility. July 7, 2000
The Company's therapeutic candidates are discovered and developed through
All auditors of C&R QA have a membership of RQA (Research Quality Assurance) and Auditor certificates, especially lead auditors Research Focus its proprietary discovery platform technology which employs integrated
have a certificate of ‘Registered Quality Assurance Professional’ by SQA(Society of Quality Assurance). Discovery, R&D and commercialization of technologies of the SPS™ (technology for structure determination), the SCP™
novel therapeutics (technology for the generation of lead compounds) and the SDF™(technology
C&R QA will continue to devote itself to be the best partner for customers in the field of quality assurance of clinical trials by used for lead optimization) technologies.
Total Staff
ensuring that the clinical trial is performed and the data are generated, documented (recorded), and reported in compliance with
80 persons By leveraging its capabilities and the know-how in novel drug discovery and
Good Clinical Practice (GCP) and the applicable regulatory requirement(s).
development, CrystalGenomics will continue to strive in making significant
Representative Phone contributions to improve human health.
82-31-628-2700
[Q-fitter]
Web
Q-fitter Inc. is dedicated to help customer through the drug development process. Main job is to perform a high quality www.cgxinc.com
pharmacometric analysis-the use of modeling and simulation that quantifies drug, disease and trial information to support efficient
drug development and regulatory decisions- and provide clinical services to support the management of early phase clinical trials. Contact Person
Steven Kim
Contact Phone
[C&R Healthcare Global]
82-31-628-2720
Financial Figures
C&R Healthcare Global provides business platform that supports bio-healthcare industries in advancing to global market. Based on Contact E-mail
accumulated clinical development experience and global network of leading CRO ‘C&R Research’. C&R Healthcare Global will fulfill skim@cgxinc.com Summary (1 Million Won)
the platform through incubation, matching the investment manufacture, and distribution to maximize corporate value. Fiscal Year 2015 2016 2017
Sales 6,136 14,525 14,685
R&D Expenditure 6,102 7,066 7,000
Capital 73,639 83,265 97,258

Main Products
Dong-A ST: commercial

GL PharmTech
Currently none;
partner for Korea.
Turkey, Lebanon, Saudi
1. Acelex® (polmacoxib) Osteoarthritis TR-Pharm: commercial
Arabia, Kuwait, UAE:
partner for Turkey &
2018~2019 (projected)
MENA region
Company Profile
R&D Pipeline GL PharmTech (GLPT) has focused on developing improved versions
Compound Name Code Use Stage of Development of the currently marketed pharmaceutical products with reduced side
effects, greater therapeutic efficacy and better patient compliance
HDAC inhibitor (NCE) CG200745 Pancreatic cancer Phase 2 in progress
using our proprietary drug formulation and delivery technologies since
myelodysplastic syndrome 2002.
HDAC inhibitor (NCE) CG200745 Phase 1b in progress
(MDS)
We have provided more than 50 pharmaceutical companies in Korea
HDAC inhibitor (NCE) CG200745 Acute myeloid leukemia (AML) IND preparation with value-added drug formulations and delivery technologies for
Phase 2a completed; Representative generic and improved version of marketed drug.
FabI inhibitor (NCE)Polmacoxib & MRSA & other serious staph
CG400549 IND preparation with newly Hunsik, Wang We are now transitioning from a being a technology transfer-based
Tramadol (FDC with NCE) infections
formulated drug product
Headquarter Address operation to being a specialty pharmaceutical company capable of
BTK/Flt3 inhibitor (NCE) CG100650 Various acute & chronic pain IND submitted #714 Jungang Induspia V, 137, developing and delivering new product lines by ourselves from 2010.
Sagimakgol-ro, Jungwon-gu, Seongnam, We are doing this based on intensive investment in various clinical
CG026806 Preclinical (Out-licensed to
BTK/Flt3 inhibitor (NCE)
(CG'806)
AML, MCL, CLL
Aptose Bioscienses in 2016) Gyeonggi-do, Korea studies of products currently in our pipelines and using our already-
established drug delivery platform technologies.
Foundation Date
Aug, 2002 Technology - GLARS(Geometrically Long Absorption Regulated
System)
Research Focus
New Active Substances Conventional sustained release drug delivery systems such as ALZA’s
IMD(Incrementally Modified Drugs)
OROS (Osmotic Release Oral System) and Skyepharma’s Geomatrix,
Total Staff have enjoyed great success in the field of a drug dosage form
Acelex® (polmacoxib) Osteoarthritis Feb. 2015 / Korea 29 persons reformulation. Although these systems extend the drug release up to
Representative Phone 24 or 48 hours, the simple extension of drug release time would be
82-31-739-5220~3 meaningless because a practical absorption site of overall drugs is
generally limited to a small intestine consider the total transit time
Web along the small intestine with absorption will be only 4 to 6 hrs. This
http://www.glpt.co.kr means that relatively large amounts of the incorporated drug would
Contact Person pass out without a sufficient practical absorption.
Jun Sang Park
Contact Phone
82-31-739-5220 (#324)
jspark@glpt.co.kr
Fiscal Year 2014 2015 2016
Sales 7,301 6,475 4,636
R&D Expenditure 1,158 1,034 1,130
Capital 1,162 2,323 3,022

To overcome the shortcomings of the currently existing sustained Product (Ingredient/Formulation) Use Exporting Countries Remarks
release drug delivery technologies we have recently developed
8. GL1405(Paroxetine CR) Depression - -
a novel drug delivery system to enable a drug to be dissolved
irrespective of the surrounding environment and further absorbed up 9. GL1502(Limaprost) Buerger's disease - -
to colon. We coined this “Geometrically Long Absorption Regulated
System (GLARS)”. 10. GL1505(Tolterodine LA) Benign Prostatic Hyperplasia - -
Basically, this system is a triple-layered tablet, comprised of upper 11. GL1507(Rabeprazole) Gastric ulcer - -
and lower layers that swell and draw a sufficient amount of water,
plus a highly water-soluble middle layer that rapidly draw water into 12. GL1606(Tramadol plus acetaminophen) Pain - -
the tablet core simultaneously.
13. GL1608(Atorvastatin) Hyperlipidemia - -
As the middle layer induces a rapid water draw into the tablet core,
the penetrated water also diffuses to the upper and lower layers, 14. GL1712(Tacrolimus) Immunosuppressant - -
which makes the tablet to rapidly swell and controls drug release.
15. GL2803(Gimepiride plus Metformin XL) Diabetes - -
At virtually the same time, the swollen upper and lower layers form
to surround a lateral side of the middle layer, which can, in turn,
further control drug release. This relatively rigid swollen matrix
structure makes drug release not affected by surrounding mechanical
flux, which can provide relatively consistent in vivo drug release R&D Pipeline
irrespective of degree of gastrointestinal motility.
The water drawn into the tablet (about 3 to 5 times the weight of
IMD
the tablet itself) functions as an additional media which enables
additional and later drug release out of the dosage form. This serves Pregabalin QD GLA5PR Pain Phase III
to overcome the shortage of surrounding media that has been
reported to be one of the key reasons for mal-absorption of a drug in Risedronate + Vitamin D3
GLE1RCW Osteoporosis Phase I
Effervescent tablet
colon.
Paroxetine CR GLE3PA Vasomotor Symptoms Phase III
Generic
Ropinirole XL GL1901 Parkinson's disease Bioequivalence test
Mirabegron PR GLG1MI Overactive bladder Bioequivalence test
Main Products
1. G-soren Tab. (Artemisiae Argyi Folium

Gastritis - -
Isopropanol ext.(20 -> 1))
2. GL1203(Tamsulosin) Benign Prostatic Hyperplasia - -
3. GL1204(Felodipine ER) Hypertension - -
4. GL1314(Ramipril) Hypertension - -
5. GL1317(Pantoprazole) Gastric ulcer - -
6. GL1319(Nifedipine SR) Hypertension - -
7. GL1320(Doxazosin XL) Benign Prostatic Hyperplasia - -

Medi Help line Pharmicell Co., Ltd.
Company Profile Company Profile

Since its foundation in Feb.1998, Medi Help Line has conducted Since its establishment in 2002, Pharmicell has devoted to developing
average annual number of 150 RA projects for new drugs, innovative stem cell drugs to benefit more people with desperate needs and
drugs, medical devices and quasi-drugs for 13 years and has a successfully developed the world’s first stem cell drug on July 1st,
well-established business partnership with many domestic and 2011, marking a new era in the world history of cell treatment.
international companies based on the performance of the strategic The path for innovation and challenge pioneered by Pharmicell to
consulting services as well as RA outsourcing services, accumulated become the world first, has set Korean Standards in the area of stem
database of the various projects and communication know-how with cell drugs and has changed the spectrum of the overseas stem cell
the KFDA. industry beyond the boundary of Korea. In addition, Pharmicell has
Representative Representative emerged as the global leader of biopharmaceutical raw materials
Mr. Ok-nam PARK/ CEO We provide a real Total Package Service from the consulting service Hyun-Soo Kim, Seong-Lae Kim development and is recognized for its technology with our exporting
for research and development strategy to the outsourcing services
Headquarter Address Headquarter Address performance of raw medicine to prominent global pharmaceutical
including KFDA IND/NDA, HIRA listing and KGMP.
8-1207 Woorim Lion's Valley, Digital 7th Floor, Ssangbong B/L, Unju-ro 874, companies. Moreover, Pharmicell strives further to develop the next
3rd Complex, 371-28 Gasan-dong, Gangnam-gu, Seoul Korea generation of new drugs based on the management value of fusion
Geumcheon-gu, Seoul 153-786 and challenge. Pharmicell will take the lead for Korea to become
Foundation Date the outstanding leader of biopharmaceutical industries of the world
Foundation Date 1968. 8. 20 (Listing: 1988.5.20) through continuous R&D and ultimately create value for a healthy and
1998 happy human life.
Research Focus
Total Staff Stem Cell
30 persons
Total Staff
Representative Phone 115 persons
82-2-2026-0707
Representative Fax 82-2-3496-0114
82-2-2026-0708
Web
Web http://www.pharmicell.com
WWW.MEDIHELPLINE.NET
Contact Person
Sungpill Park
Contact Phone
82-2-3496-0181
Contact E-mail
Financial Figures sppark@pharmicell.com Financial Figures
Summary (1 Million Won) Summary (1 Million Won)
Fiscal Year 2008 2009 2010 Fiscal Year 2015 2016 2017
Sales 1,558 1,338 1,590 Sales 25,176 27,839 25,197
R&D Expenditure - - - R&D Expenditure 2,597 4,941 4,029
Capital 50 - - Capital 28,617 29,191 29,204

Main Products
1. Cellgram-AMI Acute myocardial infarction - World first stem cell drug
R&D Pipeline
KPBMA Member
Expected to be launched
Cellgram-LC - Liver Cirrhosis
in May 2018
Company List
Cellgram-ED - Impotence Phase 1
Cellgram-IS - Acute cerebral infarction Phase 3
Cellgram-SCI - Spinal cord injury Phase 2/3
Cellgram-CLI - Critical lower limb ischemia Phase 1
2018 DIRECTORY OF KOREAN PHARMACEUTICAL INDUSTRY

Regular Members(2018. 4) No Company Phone Fax Address Homepage
24, Pangyo-ro 255beon-gil, Bundang-gu,
No Company Phone Fax Address Homepage 26 Corestem Inc. 82-2-497-3711 82-2-6349-8666 www.corestem.com
Seongnam-si, Gyeonggi-do, Korea
1 Aestura Corporation - - 100 Cheonggyecheon-ro, Jung-gu, Seoul www.aestura.com/ 218-7 Anyang7-dong Manan-gu, Anyang si, www.
27 Crown Pharm. Co., Ltd. 82-31-443-3922 82-31-443-3921
993-75 Daelim-dong, Yeongdeungpo-gu, Gyeonggi-Do crownpharm.co.kr
2 Ahn-Gook Pharm. Co., Ltd. 82-2-3289-4200 82-2-847-8867 www.ahn-gook.com
Seoul Koreabiopark A, 5F, 700, www.
www. 28 Crystal Life Sciences. 82-31-628-2900 82-31-628-2901 Daewangpangyo-ro, Bundang-gu, crystallifescience.
3 Aju Pharm Co., Ltd. 82-2-2630-0700 82-2-2636-7519 413-13 Shindolim-dong, Guro-gu, Seoul Seongnam-si, Gyeonggi-do com
asiapharm.co.kr
CTC Building, 13 Jungdaero 40 gil,
662 Jinjeong-ri, Sanyang-myeon, www. 29 CTCBIO, Inc 82-2-70-4033-0200 82-2-449-6966 www.ctcbio.com
4 Alpha Pharm. Co., Ltd. 82-54-552-5381 82-2-54-552-5385 Songpa-gu, Seoul
Mungyeong-si, Gyeongsangbuk-do alphapharm.co.kr
778-1 Ilpae-dong, Namyangju-si,
13F. TWO IFC Bldg. 10 Gukjegeumyung-ro, www. 30 C-Tri 82-31-557-0001 82-31-557-6622 www.c-tri.co.kr
5 Alvogen Korea. Co., Ltd. 82-2-2047-7700 82-2-443-0589 Gyeonggi-do
Yeongdeungpo-gu, Seoul, Korea alvogenkorea.com
www.
(Namsung Plaza, Gasan-dong) 405, 130, 31 Dae Woo Pharm. Ind. Co., Ltd. 82-51-204-3831 82-51-202-3397 153 Dadaero, Saha-gu, Busan
daewoopharm.com
6 Antrogen. Co., Ltd. 82-2-2104-0391 82-2-2104-0393 Digital-ro, Geumcheon-gu, Seoul, 08589, www.antrogen.com
Korea 122B-9L, 692-8, Gojan-dong, Namdong-gu, www.
32 Daebong LS 82-32-712-8800 82-32-817-8808
Incheon daebongls.co.kr
545, Dunchon-daero, Jungwon-gu, www.
7 Aprogen Pharmaceuticals 82-31-625-4045 - 308 Masan-ri, Heongseong-gun,
Seongnam-si, Gyeonggi-do aprogen-pharm.com 33 Daehwa Pharm. Co., Ltd. 82-33-342-5140 82-33-342-0576 www.dhpharm.co.kr
Gangwon-do
Alico Building, 70-5 Yangjae-dong, Seocho-
8 Arlico.co.Ltd. 82-2-520-6943 82-2-3474-3281 www.arlico.co.kr www.
gu, Seoul 34 Daewon Pharm. Co., Ltd. 82-2-2204-7000 82-2-498-9108 229-3 Yongdap-dong, Seongdong-gu, Seoul
daewonpharm.com
GumHa B/D 6F 41-2 Chungdam-dong, www.
9 ASTELLAS Pharm Korea, Inc 82-2-3448-0504 82-2-3448-0510 www.
Gangnam-gu, Seoul astellas.com/kr 35 Daewoong Pharm. Co., Ltd. 82-2-550-8800 82-2-550-3530 163-3 Samsung-dong, Gangnam-gu, Seoul
daewoong.co.kr
Posco center 13F, 892 Daechi-dong,
10 B. Braun Korea. Co., Ltd 82-2-3459-7800 82-2-3453-3060 www.bbraun.co.kr 8-3 Yangpyeong-dong 4-ga, Yeongdeungpo-
Gangnam-gu, Seoul 36 Dai Han Pharm. Co., Ltd. 82-2-2678-8445 82-2-2671-9636 www.daihan.com
gu, Seoul
11 Baxter Inc. 82-2-6262-7100 82-2-6272-7101 KNTO B/D 5F,10 Da-dong, Jung-gu, Seoul www.baxter.co.kr
Posco West 3F, Daechi4-dong, Kangnam-gu, www.
Kyung B/D .Gaepo-dong 1184-8 , Gangnam- 37 Daiichi Sankyo Korea Co.,Ltd. 82-2-3453-3300 82-2-3452-9756
12 Bc world pharm. Co.,Ltd. 82-2-2182-0403 82-2-574-5064 www.bcwp.co.kr Seoul daiichisankyo.co.kr
gu, Seoul
907-5 Sangsan-ri, Hyangnam-eup, www.
Ilshin B/D, Dohwa-dong 541, Mapo-gu, 38 Dalim Biotech Co., Ltd. 82-31-535-6091 82-31-535-6093
13 Binex Co., Ltd. 82-6710-7235 82-2-6710-7299 www.bi-nex.com Hwaseong-si, Geonggi-do dalimmedical.co.kr
Seoul
491 Mansu-ri, Gangwoe-myeon,
307-1 Songsan-ri, Yanggam-myeion, 39 DHP Korea Co., Ltd. 82-43-239-3303 82-43-239-3308 www.dhpkorea.co.kr
14 Bolak. Co., Ltd. 82-31-352-6455 82-31-352-4341 www.bolak.co.kr Cheonggwon-gun, Chungcheongbuk-do
Hwaseong-si, Gyeonggi-do
Shiwah Complex 1 Ra No.603,1248-8 www.
Boryung B/D, 66-21 Wonnam-dong, Jongno- 40 Dong In Dang Pharm. Co., Ltd. 82-31-319-1990 82-31-319-1995
15 Boryung Pharm. Co., Ltd. 82-2-708-8000 82-2-708-8439 www.boryung.co.kr Jungwang-dong, Siheung-si, Gyeonggi-do dongin-dang.co.kr
gu, Seoul
41 Dong Koo Pharm. Co., Ltd. 82-2-2688-5421 82-2-2681-1880 195-2 Gocheok 2-dong, Guro-gu, Seoul www.dongkoo.co.kr
16 Bukwang Pharm. Co., Ltd. 82-2-828-8114 82-2-828-8029 398-1 Daebang-dong, Dongjak-gu, Seoul www.bukwang.co.kr
42 Dong Kook Pharm. Co., Ltd. 82-2-2191-9900 82-2-566-8542 997-8 Daechi 3-dong, Gangnam-gu, Seoul www.dkpharm.co.kr
17 Celltrion Pharm. Inc 82-32-850-5000 82-32-850-4309 13-6, Songdo-dong, Yeonsu-gu, Incheon www.celltrionph.com
Daeyeongak tower 12F, 25-5 Chungmuro www.
43 Dong Kwang Pharm. Co., Ltd. 82-2-776-7641 82-2-777-4874
7 Neungan-ro, Danwon-gu, Ansan-si, 1-ga, Jung-gu, Seoul dkpco.co.kr
18 Chemtros Co., Ltd 82-31-491-0653 82-31-491-0881 www.chemtros.com
Gyeonggi-do www.
44 Dong Wha Pharm. Ind. Co., Ltd. 82-2-2021-9300 82-2-778-2336 5 Sunwha-dong, Jung-gu, Seoul
Ace Techno Town 1F, 55-7 Moonrae-dong 3 dong-wha.co.kr
19 Cho-a Pharm. Co., Ltd. 82-2-2166-4000 82-2-2166-4111 www.choa.co.kr
ga,Youngduengpo-gu, Seoul 45 Dong-A Pharmaceutical 82-2-920-8112 - 64 Cheonhodaero, Dongdaemun-gu, Seoul en.dapharm.com
20 Chodang Pharm. Co., Ltd. 82-2-869-0181 82-2-869-1192 44 Guro 5-dong, Guro-gu, Seoul www.chodang.com 46 Dong-A ST 82-2-920-8111 - 64 Cheonhodaero, Dongdaemun-gu, Seoul en.donga-st.com/
Chong Kun Dang B/D 368, Chungjeongno www.dongsung-
21 Chong Kun Dang Pharm. Corp. 82-2-2194-0300 82-2-2194-0369 www.ckdpharm.com 47 Dongsung Pharm. Co., Ltd. 82-2-6911-3600 82-50-5191-69081 703-14 Banghak-dong, Dobong-gu, Seoul
3-ga, Seodaemun-gu, Seoul pharm.co.kr
246-47 Dodang-dong, Wonmi-gu, Pucheon- Revessant B/D 10F, 147-17Samseong-dong,
22 Chunhedang Pharm. Co., Ltd. 82-31-675-5561 82-31-676-6320 - 48 Eisai Korea Inc. 82-2-3451-5500 82-2-3451-5599 www.eisaikorea.com
si, Gyeonggi-Do Gangnam-gu, Seoul
CJ Cheiljedang Center, 330, Dongho-ro, 2F Kyungpung Building, 788-26 Yeoksam-
23 CJ Healthcare 82-2-6740-2119 - www.cjp.co.kr/ 49 Elyson Pharmaceutical Co. Ltd. 82-2-6342-7001 82-2-6342-7003 www.elyson.co.kr
Jung-gu, Seoul 100-400, Korea dong, Gangnam-gu, Seoul
7F MJL Building, 204-5 Nonhyun-dong, www. Daekwan B/D 5F, 15-1 Yangjae-dong, www.
24 CMG Pharmaceutical CO.,Ltd. 82-2-3453-8816 82-2-3453-8819 50 Estech Pharma Co., Ltd. 82-2-3471-2078 82-2-3471-2079
Gangnam-gu, Seoul cmgpharma.co.kr Seocho-gu, Seoul estechpharma.com
157-3 Dodang-dong, Wonmi-gu, Pucheon- Songwon B/D 7F, 59-5 Banpo-dong, Seocho-
25 Cmic CMO Korea Co.,Ltd. 82-32-678-5771 82-32-675-3385 www.cmic-cmo.co.kr 51 Ferring Pharm. Korea Co.,Ltd. 82-2-534-2761 82-2-534-2956 www.ferring.co.kr
si, Gyeonggi-Do gu, Seoul

No Company Phone Fax Address Homepage No Company Phone Fax Address Homepage
47, Baekseokgongdan 1-ro, Seobuk-gu, 1529-4, Songjeong-dong, Gangseo-gu,
52 Firson Co., Ltd. 82-2-1833-8200 82-41-566-8321 www.firson.co.kr 77 Huniz. Co., Ltd. 82-51-831-1030 82-51-831-1040 www.huniz.kr
Cheonan-si, Chungcheongnam-do, Korea Busan
SaemaeulUndong B/D 3F, 1008-4 Daechi- www. C-901 PangyoInoBelly, 621 Sampyeong-
53 Fresenius Kabi Korea Ltd. 82-2-3484-0900 82-2-3484-0957
dong, Gangnam-gu, Seoul fresenius-kabi.com 78 Huons Co., Ltd 82-31-854-4700 82-31-6455-0740 dong, Bundang-gu, Seongnam-si, Gyeonggi- www.huons.com
do
Fresenius medical care korea Landmarktower 7F, 837-36 yeoksam-dong, www.
54 82-2-2112-8800 82-2-2112-8804
co.,Ltd Gangnam-gu, Seoul fmc-korea.co.kr 555-2 Yeongchun-ri, Dongtan-myeon,
79 Hutecs Korea Co., Ltd 82-31-377-7900 82-31-377-7911 www.hutecs.co.kr
Hwaseong-si, Gyeonggi-do
Bando B/D 7F, 48-1 Banpo-dong, Seocho- www.
55 Galderma Korea Ltd. 82-2-6717-2000 82-2-6717-2001
gu, Seoul galdermakorea.com Hyungai pharm B/D, 204-4 Nonhyeon-dong, www.
80 Hyundai Pharm. Ind. Co., Ltd. 82-2-2600-3813 82-2-2693-7628
LS Youngsan tower 9F, 92, Hangang-daero, Gangnam-gu, Seoul hyundaipharm.co.kr
56 GlaxoSmithKline Korea 82-2-709-4116 82-2-796-4710 www.gsk-korea.co.kr
Yongsan-gu, Seoul Room 1305 Technopark Techcentre, 190-
GlaxoSmithKline Korea LS Youngsan tower 9F, 92, Hangang-daero, 81 Icure Pharm. Inc. 82-31-776-3776 82-31-776-3770 1 Sangdaewon-dong, Jungwon-gu, www.icure.co.kr
57 82-2-709-4305 82-2-798-0985 www.gsk-korea.co.kr Seongnam-si
Consumer Healthcare Yongsan-gu, Seoul
2F, 4159 Shingil 6-dong, Yeoungdeungpo- Iksoo B/D, Amsa-dong 488-20, Kangdong-
58 Green Pharm. Co., Ltd. 82-2-842-1301 82-2-842-1302 - 82 Ik-Su Pharm. Co., Ltd. 82-2-416-1112 82-2-416-1118 www.iksu.co.kr
gu, Seoul gu, Seoul
303 Bojeong-dogn, Giheung-gu, Yongin-si, www. 83 Il Dong Pharm. Co., Ltd. 82-2-526-3114 82-2-526-3030 60 Yangjae-dong, Seocho-gu, Seoul www.ildong.com
59 Greencross Corporation 82-31-260-9300 82-31-260-9413
Gyeonggi-do greencross.com 84 Ilsung Pharm Co., Ltd. 82-2-3271-8800 82-2-2701-6335 44-7 Wonhyoro1-ga, Yongsan-gu, Seoul www.ilsung-ph.co.kr
4&6th floor, 278, Beotkkot-ro, Geumcheon- www. 85 Ilwha Co., Ltd. 82-31-550-0100 82-31-550-0105 437 Sutaek1-dong, Guri-si, Gyeonggi-Do www.ilhwa.co.kr
60 Greencross Cell 82-2-2101-0600 82-2-2101-0601
gu, Seoul, 08511, Korea greencrosscell.com
86 Il-Yang Pharm. Co., Ltd. 82-2-570-3700 82-2-570-3708 544-5, Dogok-dong, Gangnam-gu, Seoul www.ilyang.co.kr
7th Floor, Dodam bldg B-dong, 246
www. Inist Bio Pharmaceutical. Co., 34-40, Jaeyakgongdan 2-gil, Hyangnam- www.inist.co.kr/
61 Greencross WellBeing 82-31-629-8600 82-31-629-8601 Hwangsaeul-ro, Bundang-gu, Seongnam, 87 82-31-370-7300 82-31-354-1539
greencrosswb.com Ltd. eup, Hwaseong-si, Gyeonggi-do inistbio
Gyeonggi-do
701, 2nd Geumgang High-Tech 159,
94-119 Yeoungdeungpo-dong 2-ga, www.
62 Guju Pharm. Co., Ltd. 82-2-2672-1122 82-2-2679-7569 www.gujup.co.kr 88 Inist ST Co., Ltd. 82-31-669-9520 82-31-737-4198 Sagimakgolro, Joongwon-gu, Seongnam-si,
Yeongdeungpo-gu, Seoul inist.co.kr/inistst
Gyeonggi-do
8F Joil Building 62 Nonhyeon-dong, www.
63 Hamsoa Pharm. Co., Ltd. 82-2-2176-2180 82-2-3443-0825 Yeonse medical school 6F, Sinchon-dong
Gangnam-gu, Seoul hamsoapharm.com 89 Isu Abxis Co., Ltd. 82-2-2227-8888 82-2-2227-8887 www.abxis.com
134, Seodaemoon-gu, Seoul
1181 Geodu-ri, Dongnae-myeon, www.
64 Han Kook Korus Pharm. Co., Ltd. 82-33-264-5771 82-33-264-5774 25F LG Yongsan Tower B/D, 191 Hangang- www.
Chuncheon-si, Gangwon-do koruspharm.co.kr 90 Janssen Korea Ltd. 82-2- 2094-4500 82-2- 538-5632
ro 2ga , Yongsan-gu, Seoul janssenkorea.com
Rocket B/D 6~7F, 747-29 Yeogsam-dong,
65 Hana Pharm. Co., Ltd. 82-2-577-7667 82-2-577-6003 www.hanaph.co.kr 91 Je Il Pharm. Co., Ltd. 82-53-583-6226 82-53-583-5775 Daechun-dong 739, Dalseo-gu, Daegu city www.jeilphar.co.kr
Gangnam-gu, Seoul
Jamsil I-Space 6F, 11-10 Shinchon-dong, 92 Jeil Pharm. Co., Ltd. 82-2-549-7451 82-2-549-4045 343, Sapyeong-daero, Seocho-gu, Seoul www.jeilpharm.co.kr
66 Hanall Bio Pharm. Co., Ltd. 82-2-2204-1928 82-2-2414-7474 www.hanall.co.kr
Songpa-gu, Seoul www.
93 Jin Yang Pharm. Co., Ltd. 82-2-3470-0300 82-2-3470-0390 1532-9 Seocho-dong, Seocho-gu, Seoul
67 Handok Pharm. Co., Ltd. 82-2-527-0114 82-2-527-5001 132 Teheran-ro, Gangnam-gu, Seoul www.handok.co.kr jinyangpharm.com
805-15 Jungsan-ri, Yangchon-myeon, www.

68 Hankooksinyak Pharm. Co., Ltd. 82-41-740-8900 82-41-740-8849 www.hsp.co.kr 94 JW Pharmaceutical 82-2-840-6777 82-2-841-1213 698 Shindaebang-dong, Dongjak-gu, Seoul
Nonsan-si, Chungcheongnam-do jw-pharma.co.kr
69 Hanlim Pharm. Co., Ltd. 82-2-3489-6000 82-2-3489-6101 1656-10 Seocho-dong, Seocho-gu, Seoul www.hanlim.com 3F 13cha Daeryung Techno Tower, Gasan- www.
95 JW Shinyak 82-2-2109-3300 82-2-2109-3388
dong, Geumcheon-gu, Seoul jw-shinyak.co.kr
Hanmi Tower, 45 Bangi-dong, Songpa-gu,
70 Hanmi Pharm. Co., Ltd. 82-2-410-9114 82-2-410-9259 www.hanmi.co.kr 492-12, Maetan 3-dong, Yeongtong-gu,
Seoul 96 KMS Pharm Co., Ltd. 82-31-215-5456 82-31-215-5925 www.kmspharm.com
Suwon-si, Gyeonggi-do
71 Hanpoong Pharm. Co., Ltd. 82-2-586-5211 82-2-583-8584 981-52 Banbae-dong, Seocho-gu, Seoul www.hanpoong.co.kr
170-7 Seojeong-ri, Jeonui-myeon, Yeongi-
41 Poseunggongdan-ro, Poseung-eup, www. 97 Kolmar Korea 82-41-862-1057 82-41-862-7637 www.kolmar.co.kr
72 HanseoChem 82-31-682-8655 82-31-682-8656 gun, Chungcheongnam-do
Pyeongtaek-si, Kyeonggi-do hanseochem.co.kr
93 Biovalley 2-ro, Jecheon-si,
Chungpyeong-gil 2-11 (Docheong-lee 98 Kolmar pharma 82-43-640-0088 82-43-640-0007 www.kolmar.co.kr
www. Chungcheongbuk-do
73 Hansol Pharm. Co., Ltd. 82-43-881-6333 82-43-881-6332 33-32), Geumwang-eup, Eumsung-gun,
hansolpharm.com Floor 7, Kolon Tower annex, Kolon 13,
Choongcheongbook-Do 99 Kolon Life Science Inc. 82-2-3677-4150 - www.kolonls.co.kr
Gwachun-si, Gyunggi-do
74 Hanwha Pharma. Co., Ltd. 82-2-959-3161 82-2-959-3621 261 Seokkwan 2-dong, Seongbuk-gu, Seoul www.hwpharm.com
6F Annex to Kolon Tower, 1-22 Byeoryang- www.
www. 100 Kolon Pharma 82-2-2120-8300 82-2-2120-8301
75 Hawon Pharm. Co. 82-2-554-2012 82-2-554-4557 788-1 Yeogsam-dong, Gangnam-gu, Seoul dong, Gwacheon-si, Gyeonggi-do kolonpharm.co.kr
hawonpharm.co.kr
Advanced Reactor Development Institute,
Room 502 Anyang-megavalley, 268 Hagui- Korea Atomic Energy Research
76 Humedix. Co., Ltd. 82-70-7492-5600 82-31-420-5650 humedix.com 101 82-42-868-4641 82-42-868-2106 Daedeok-daero 989-11, Yuseong-gu, www.kaeri.re.kr
ro, Dongan-gu, Anyang-si, Gyeonggi-do Institute
Daejeon

417-4, Seokchon-ri, Jongcheon-myeon, www. Myungin B/D, 1539-9 Seocho-dong, www.
102 Korea Global Pharm. Co., Ltd. 82-41-951-4300 82-41-951-4344 127 Myung In Pharm. Co., Ltd. 82-2-587-9060 82-2-585-0352
Seocheon-gun, Chungcheongnam-do globalpharm.co.kr Seocho-gu, Seoul myunginph.co.kr
7F Gookmin-1 B/D, 302 Yeongdong-daero, www. Myungmoon B/D, 946-18 Dogok-dong,
103 Korea Kowa Company Ltd. 82-2-6930-4800 82-2-6930-4808 128 Myung Moon Pharm. Co., Ltd. 82-2-6711-2000 82-2-572-5137 www.mmpharm.co.kr
Gangnam-gu, Seoul kowakorea.com Gangnam-gu, Seoul
713-2, Jung-ri, Dongtan-myeon, Hwaseong- www. Nelson B/D 3F, Seocho-dong 1462-17, www.
104 Korea mcnulty. Co., Ltd. 82-31-378-1460 82-31-378-1468 129 Nelson Korea Pharm Co.,Ltd. 82-2-588-0941 82-2-588-0170
si, Gyeonggi-do koreamcnulty.co.kr Seocho-gu, Seoul nelsonkorea.co.kr
105 Korea Otsuka Pharm. Co., Ltd. 82-2-3287-9000 82-2-3287-9019 770-9 Yeoksam-dong, Gangnam-gu, Seoul www.otsuka.co.kr 836 Seryu3-dong, Gwonsun-gu, Suwon-si,
130 Nensys Co., Ltd. 82-31-232-5285 82-31-234-4410 www.nensys.co.kr
Baeklim B/D 8F, 823-33 Yeogsam-dong, www. Gyeonggi-Do
106 Korea Pharma Co., Ltd. 82-2-558-1277 82-2-558-1677
Gangnam-gu, Seoul koreapharma.co.kr BK Tower 11F, 942-2 Daechi 2, Gangnam- www.
131 Newgenpharm Inc. 82-2-580-5900 82-2-580-5999
Daein Building, 158-3 Daein-dong, Dong-gu, www. gu, Seoul newgenpharm.com
107 Korea Prime Pharm. Co., Ltd. 82-62-233-1110 82-62-233-3298
Gwangu koreaprime.co.kr 13F, The-K twin towers B, 50 Jong-ro 1-gil,
132 Ono Pharma Korea Co., LTD. 82-2-928-8423 82-2-925-2151 www.ono.co.jp/eng/
108 Korea United Pharm. Inc. 82-2-512-9981 82-2-548-4599 154-8 Nonhyun-dong, Gangnam-gu, Seoul www.kup.co.kr Jongno-gu, Seoul
Doowon B/D, 87-3 Garak-dong, Songpa-gu, www. PharmaResearch Products Co., 74, Pangyo-ro 255beon-gil, Bundang-gu, www.
109 Korea Vaccine Co., Ltd. 82-2-443-1961 82-2-443-4484 133 82-31-8039-1500 -
Seoul koreavaccine.com Ltd. Seongnam-si, Gyeonggi-do pr-products.co.kr
www.nicepharma. 7F Samhomulsan Building A, 275-1 Yangjae-
110 Korean Drug Co., Ltd. 82-2-529-6100 82-2-529-6114 423-2 Dogok-dong, Gangnam-gu, Seoul 134 Pharmbio Korea Co., Ltd 82-2-587-2551 82-2-587-2552 www.pharmbio.co.kr
com dong, Seocho-gu, Seoul
Osong B/D 27-11Jeong-dong, Jung-gu, 135 Pharvis Bio Tech Korea Corp. 82-2-579-6262 82-2-579-0880 517-9 Doggok-dong, Gangnam-gu, Seoul www.pharvis.co.kr
111 Kuhnil Pharm. Co., Ltd. 82-2-714-0091 82-2-719-0493 www.kuhnil.com
Seoul 726-4 Bugok-dong, Sanrok-gu, Ansan-si, www.
136 PMG PHARM Co., Ltd 82-31-439-5470 82-31-405-5471
49 Sandan-ro, Heungdeok-gu, Cheongju-si, www. Gyeonggi-do pmgpharm.co.kr
112 Kukbo Science Co., Ltd. 82-43-264-7765~8 82-43-267-7769
Chungcheongbuk-do kukboscience.co.kr www.
137 Reyon Pharm. Co., Ltd. 82-2-793-5557 82-2-798-7538 38-6 Dongbinggo-dong, Yongsan-gu, Seoul
513-2 Yatap-dong, Bundang-gu, Seongnam- www. reyonpharm.co.kr
113 Kukje Pharm. Ind. Co., Ltd. 82-31-781-9081 82-31-781-6040
si, Gyeonggi-do kukjepharm.co.kr Danam B/D 22F, 120 Namdaemoonno 5-ga,
138 Richwood Trading Co., Ltd. 82-2-757-3071 82-2-3789-6993 www.richwood.net
114 Kwang Dong Pharm. Co., Ltd. 82-2-6006-7777 82-2-6006-7024 1577-4 Seocho-dong, Seocho-gu, Seoul www.ekdp.com Jung-gu, Seoul
345-6 Silok-dong, Asan-si, Chuncheongnam- 139 RP BIO. Co., Ltd 82-2-568-0051 82-2-554-0871 163-3 Samsung-dong, Gangnam-gu, Seoul www.rpskorea.com
115 Kyongbo Pharm. Co., Ltd. 82-41-545-0456 82-41-546-8427 www.kbpharma.co.kr
do Samoh B/D 4F, Yeoksam1-dong 751-10,
140 Sae Han Pharm. Co., Ltd. 82-2-533-7417 82-2-553-7416 www.shpharm.co.kr
Kyowa Hakko Kirin Korea Co. 5F Poonglim Building, 823 Yeoksam-dong, www.kyowa-kirin- Kangnam-gu, Seoul
116 82-2-3471-4921 82-2-3471-4322
Ltd. Gangnam-gu, Seoul korea.com 141 Sam Chun Dang Pharm. Co., Ltd. 82-2-2046-1100 82-2-2046-1101 Seocho-dong 1606-1, Seocho-gu, Seoul www.scd.co.kr
117 Kyung Dong Pharm. Co., Ltd. 82-2-576-6121 82-2-577-5195 1659-5 Inheon-dong, Gwanak-gu, Seoul www.kdpharma.co.kr
Sama B/D, 80-18 Cheongdam-dong, www.
142 SamA Pharm. Co., Ltd. 82-2-2056-7200 82-2-2056-7300
www. Gangnam-gu, Seoul samapharm.co.kr
118 Kyung Nam Pharm. Co., Ltd. 82-2- 3490-5105 82-2- 3490-5129 889-13 Daechi-dong ,Gangnam-gu, Seoul kyungnampharm.
Dongbo B/D 4F, 1253 Sungin-dong, Jongno-
co.kr 143 Samik Pharm. Co., Ltd. 82-2-928-0661 82-2-924-3749 www.samik.co.kr
gu, Seoul
LG Gwangwamoon Building, 92 Sinmun-ro
119 LG Chem 82-2-3773-1114 82-2-6924-3051 www.lgchem.com www.
2ga, jongno-gu, Seoul 144 Samil Pharm. Co., Ltd. 82-2-520-0300 82-2-588-5924 990-1 Bangbae1-dong, Seocho-gu, Seoul
samil-pharm.com
3, 8F Medica Building, 1489-2 Seocho 3 www.
120 Medicakorea Co., Ltd. 82-70-4018-8000 82-2585-9689 www.
dong, Seocho-gu, Seoul medicakorea.com 145 Samjin Pharm. Co., Ltd. 82-2-3140-0605 82-2-338-8032 338-8 Seokyo-dong, Mapo-gu, Seoul
samjinpharm.co.kr
626 Teheran-ro, Gangnam-gu, Seoul,
99-1 Sang-ri, Geumsan-eup, Geumsan-gun, www.
121 Meditox 82-2-3471-8319 82-2-3476-8372 Republic of Korea (Medytox Building, www.medytox.com 146 Samnam Pharm. Co., Ltd. 82-41-754-3771 82-41-752-0086
Chuncheongnam-do samnam51.com
Daechi-dong)
Yangjae B/D, Yangjae-dong 261, Seocho-gu, www. 147 Samsung Pharm. Ind. Co., Ltd. 82-2-3408-4500 82-2-3408-4702 614-4 Junggok-dong, Gwangjin-gu, Seoul www.sspharm.co.kr
122 MG Co., Ltd. 82-2-2057-1002 82-2-2057-1003
Seoul medi-green.co.kr www.
www. 148 Samyang Biopharm. Corp. 82-2-740-7116 82-2-743-6626 263 Yeonji-dong, Jongno-gu, Seoul samyangbiopharm.
123 Mirae Pharma. Korea 82-2-583-9077 82-2-583-7421 174 Saimdang-ro, Seocho-gu, Seoul miraepharmkorea. co.kr
co.kr www.
149 Samyang Chemical Co., Ltd. 82-2-3488-5592 82-2-521-3100 1500-10 Seocho 3-dong, Seocho-gu, Seoul
Mitsubishi Tanabe Pharma Korea R902 9F Yookyung Building, 239-1 www.mt-pharma- samyangchem.com
124 82-2-579-0121 82-2-579-0125
Co., Ltd Nonhyeon-dong, Gangnam-gu, Seoul korea.com Yonsei severance B/D 18F, 84-11
150 SANDOZ Korea Co., Ltd 82-2-768-9300 82-2-753-1287 www.sandoz.com
1-702 Gasandigital 2-ro, Geumcheon-gu, www. Namdaemonn-ro 5ga, Junggu, Seoul
125 Mother's Pharmaceutical co., Ltd 82-2-2026-8890 82-2-2026-8094
Seoul motherspharm.com 151 Santen Pharm. Korea Co., Ltd. 82-2-754-1434 82-2-754-2929 1678-4 Seocho-dong, Seocho-gu, Seoul -
www. www.seoulpharma.
126 Mundipharma Korea 82-2-568-5689 82-2-568-5634 541 Namdaemoon-ro 5, Jung-gu, Seoul 152 Seoul Pharma co. Ltd. 82-31-497-1931 82-31-431-0715 Kyungje-ro 59, Siheung-si, Gyeonggi-do
mundipharma.co.kr com

www. Yu Yu B/D, 358-9 Shindang-dong, Jung-gu,
153 Shin Poong Pharm. Co., Ltd. 82-2-2189-3426 82-2-2189-3439 748-31 Yeoksam-dong, Gangnam-gu, Seoul 178 Yuyu Pharma, Inc. 82-2-2253-6600 82-2-2253-6200 www.yuyu.co.kr
shinpoong.co.kr Seoul
Sinil B/D, 315-18 Jangan 2-dong
154 Sinil Pharm. Co., Ltd. 82-2-2211-6700 82-2-2212-6539 www.sinilpharm.com
,Dongdaemun-gu, Seoul
776-6 Wonsi-dong, Danwon-gu, Gyeonggi-
155 Sinsin Pharm. Co., Ltd. 82-31-491-6151 82-31-491-6153 www.sinsin.com
do
686 Sampyung-dong, Bundang-gu, www. Associated Members(2018. 4)
156 SK Chemicals Life Science 82-2-2008-2008 82-2-2008-2009
Seongnam-si, Gyeonggi-do skchemicals.com
No Company Phone Fax Address Homepage
533-2 Bongkok-ri, Banpo-myun, Gongju-si, www.
157 SS Pharm Co.,Ltd 82-31-491-6311 82-31-491-4797 Room1704 Ace High-end Tower2, 222-14
Chungchungnam-do susungpharm.co.kr 1 Abnoba Korea Co.,Ltd 82-2-6340-5114 82-2-6340-5588 www.krabnoba.com
Guro3-dong, Guro-gu, Seoul
435-5 Jangan 3-dong, Dongdaemun-gu,
158 Suheung Capsule. Co., Ltd. 82-2-2210-8116 82-2-2217-2357 www.suheung.co.kr 13 Techno8-ro, Yuseong-gu, Daejeon, www.
Seoul 2 BioLeaders 82-42-934-7671 82-42-934-7670
Korea bioleaders.co.kr
Sungwon Adcock Pharm. Co., Room 302 Gayang-technotown, 1487
159 82-2-3665-2872 82-2-3665-2874 www.swpharm.com R519 Seoul Technopark, 172 Gongneung www.
Ltd. Gayang 3-dong, Gangseo-gu, Seoul 3 Biosolution Co., Ltd. 82-2-3446-8884 82-2-3445-1380
2-dong, Nowon-gu, Seoul biosolutions.co.kr
160 Taejoon Pharm. Co., Ltd. 82-2-798-6601 82-2-795-8873 657-87 Hannam-dong, Yongsan-gu, Seoul www.taejoon.co.kr
Daerung Techno Town 17th, 25 Gasan
4 BL&H Co., Ltd. 82-2-3282-4710 82-2-3281-9081 www.blnh.co.kr
Seowoo B/D 6F, Yeoksam-dong 837-12, Digital 1-ro, Geumcheon-gu, Seoul
161 Taiguk Pharm. Co., Ltd. 82-80-3474-7761 82-2-3472-5501 www.taiguk.co.kr
Kangnam-gu, Seoul 6th Floor, Seoul National University Cancer
Takeda Pharmaceuticals Korea 12F KT&G Cosmodaechi Tower, 945-10 www. 5 CellBion Co., Ltd. 82-2-743-3311 82-2-743-3399 Research Institute 101, Daehak-ro, Jongno- www.cellbion.co.kr
162 82-2-3484-0800 82-2-3484-0808 gu, Seoul
Co., Ltd. Daechi-dong, Gangnam-gu, Seoul takeda-asia.com
C-403 ,253, Pangyo-ro, Bundang-gu, 6 Central Medical Service 82-10-4070-2417 82-2-3394-5165 793 Cheonho-daero, Gwangjin-Gu, Seoul www.cmscorea.co.kr
163 TDSPHARM Co., Ltd. 82-31-8018-7337 - www.tdspharm.com
Seongnam-si, Gyeonggi-do 5F, Garosu Bldg., 103, Bokjeong-ro,
www.
www. 7 CorePharmBio 82-2-927-8220 - Sujeong-gu, Seongnam-si, Gyeonggi-do,
164 Teva-Handok. Co., Ltd. 82-2-521-5501 82-2-527-5510 132 Teheran-ro, Gangnam-gu, Seoul corepharmbio.com
teva-hahdok.co.kr 13112
Kyunghee B/D 5F, 517-5 Dogok-dong, 3F Leeyangwon Building, 63-7 Kyungwoon-
165 Theragen Etex Pharm. Inc. 82-2- 3463-7111 82-2- 3463-8111 www.etexpharm.com 8 C&R Research 82-2-6251-1500 82-2-6251-1504 www.cnrres.co.kr
Gangnam-gu, Seoul dong, Jongno-gu, Seoul
R38 6F Asandigital Park, 1123 Shingil-dong, www. 5F, Tower A, Korea Bio Park 700,
166 UK Chemipharm Co., Ltd. 82-31-310-1983 82-31-310-1985 www.
Danwon-gu, Ansan-si, Kyunggi-do ukchemipharm.com 9 Crystalgenomics 82-31-628-2700 82-31-628-2701 Daewangpangyo-ro, Bundang-gu,
crystalgenomics.com
Seongnam-si, Cyeonggi-do
Unimed B/D, 250-8 Jamsilbon-dong,
167 Unimed Pharm. Inc. 82-2-2240-5100 82-2-2240-5115 www.unimed.co.kr Daegu-Gyeongbuk Medical www.
Songpa-gu, Seoul 10 82-53-790-5113 82-53-790-5119 2387 dalgubeol-daero, Suseong-gu, Daegu
Innovation Foundation medivalley.re.kr
Wonwae B/D 5F, 389-1 Poongnap 2-dong,
168 Union Korea Pharm. Co., Ltd. 82-2-489-3611 82-2-487-3611 www.ukp.co.kr R1010 Jeokseon-Hyundai Building, 80
Songpa-gu, Seoul 11 DreamCIS Inc. 82-2010-4500 82-2-720-5385 www.dreamcis.com
Jeokseon-dong, Jongno-gu, Seoul
169 Whan In Pharm. Co., Ltd. 82-2-405-3000 82-2-404-2518 84-1 Munjeong-dong, Songpa-gu, Seoul www.whanin.com
B-4F Korea Bio Park, 694-1, Sampyeong-
White Global Pharmaceutical 12 Genexine Co.,Ltd. 82-31-628-3200 82-31-628-3229 dong, Bundang-gu, Seongnam-si, www.genexine.com
170 82-2-541-4884 82-2-541-8448 621, Yeongdong-daero, Gangnam-gu, Seoul www.whpharma.com Gyeonggi-do
Corp.
827 Shindong-ri, Chunpo-myeon, Iksan-si, www. R714 Chungang Induspia 5th,
171 Won Kwang Pharm. Co., Ltd 82-63-832-3114 82-63-833-4114 13 Glpharmtech.corp. 82-31-739-5220~3 82-31-739-5224 Sangdaewon-dong, Jungwon-gu, www.glpt.co.kr
Jeonrabuk-do wonpharm.co.kr
Seongnam-si, Gyeonggi-do
10F, Korea Fire Officials Credit Union
www. 141 Gajeong-ro, Yuseong-gu, Daejeon 305-
172 Wooridul Pharmaceutical Ltd. 82-2-582-4211 82-2-582-5666 Building, 274, Songpa-daero, Songpa-gu, 14 Korea Institute of Toxicology 82-42-610-8250 82-42-610-8085 www.kitox.re.kr
wooridulpharm.com 343
Seoul
173 Yoo Young Pharm. Co., Ltd. 82-2-6207-6114 82-2-6207-6135 915-9 Bandbae 1-dong, Seocho-gu, Seoul www.yypharm.co.kr R1207 Woorim Lions Building B, 371-28 www.
15 Medi help line 82-2-2026-0707 82-2-2026-0708
Gasan-dong, Geumcheon-gu, Seoul medihelpline.co.kr
174 Young Poong Pharm. Co., Ltd. 82-2-823-3251 82-2-821-2913 402-1 Daebang-dong, Dongjak-gu, Seoul www.yppharm.co.kr 12F Chungho Building, 120 Dosandae-ro, www.
16 PHARMICELL Co.,Ltd 82-2-3496-0114 82-2- 3496-0159
Gangnam-gu, Seoul pharmicell.com
175 Yuhan Corp. 82-2-828-0181 82-2-828-0300 49-6 Daebang-dong, Dongjak-gu, Seoul www.yuhan.co.kr
www.
17 Samsung Bioepis Co., Ltd 82-32-455-3114 82-32-455-6119 107, Cheomdan-daero, Yeonsu-gu, Incheon
365-1 Shinwon-ri, Iwol-myeon, Jincheon- samsungbioepis.com
176 Yuil Pharm Tech. Co., Ltd. 82-43-537-2161 82-43-537-2163 www.yuilpharm.co.kr
gun, Chungcheongbuk-do 394 Songjeong-ri, Byungcheon-
www.
18 SK Bioland 82-41-564-8615 82-564-8619 myeon, Dongnam-gu, Cheonan-si,
177 Yungjin Pharm. Co., Ltd. 82-2-2041-8200 82-2-2041-8219 451-20 Chonho 3-dong, Gangdong-gu, Seoul www.yungjin.co.kr biolandkorea.com
Chungcheongnam-do

MEMO MEMO

MEMO MEMO

MEMO

KPBMA Directory 2018

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

KPBMA Directory 2018

Uploaded by

Copyright:

Available Formats

2018 DIRECTORY OF KOREAN

Greetings ..................................................................................................................................................................... 004

No Company Page No Company Page No Company Page No Company Page

2 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 3

4 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 5

Drug Export Volume by Export Destination (Unit: USD 1,000, %)

Development of New Drugs

Government’s Policies to Promote and Support

6 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 7

8 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY

Ahngook Pharmaceuticals Co., Ltd. Product (Ingredient)

10 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 11

AJU PHARM CO., LTD. Product (Ingredient)

Company Profile 5. Omeperazole+NaHCO3

Research Focus Esomeprazole+ NaHCO3 Tablet Gastro-Intestinal Under clinical trial

12 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 13

Astellas Pharma Korea Product (Ingredient)

14 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 15

BC World Pharm. Co., LTD. Product (Ingredient) Use Exporting Countries

Financial Figures BCWP-A001 Antibiotics Pre-Clinical

16 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 17

Binex Co., Ltd. Product (Ingredient)

1. C ontract Development and Manufacturing

Service - Binex manufactures client's

Company Profile 2. Human Growth Hormone Growth Hormone Deficiency -

18 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 19

Boryung Pharmaceutical Co., Ltd. Product (Ingredient) Use Exporting Countries

1. Kanarb Tab. (Fimasartan) Anti hypertension NCE(New chemical entity)

Company Profile 5. Pitavastatin Hyperlipimedia Japan API

20 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 21

CHO-A PHARM.CO.,LTD. Product (Ingredient)

22 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 23

Chong Kun Dang Pharmaceutical Co. Product (Ingredient)

Total Staff CKD-11101 Anemia Phase III

24 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 25

26 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 27

10. OmapOne Peripheral Inj.

11. Machkhan Tab. (Candesartan, Amlodipine) Treatment of hypertension -

12. Vogmet (Voglibose, Metformin) Treatment of diabetes -

13. CONDITION CONDITION LADY

15. HUTGAESOO Natural oriental raisin tea with zero calories

28 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 29

CMG Pharmaceutical Co., Ltd. Product (Ingredient)

Foundation Date Aripiprazole ODF - Schizophrenia, Bipolar I disease US Pre-NDA, 505(b)(2)

Representative Phone NCE CCN-007 Solid cancer Hit selection

30 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 31

CORESTEM Inc. Product (Ingredient)

Company Profile R&D Pipeline

32 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 33

CTCBIO, Inc Product (Ingredient) Use Exporting Countries

Company Profile R&D Pipeline

34 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 35

Daewoo Pharmaceutical Co., LTD 1. O

36 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 37

Daebong LS Co., Ltd Product (Ingredient)

R&D Expenditure 1,524 1,856 2,422 Launched in 4Q

38 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 39

Contact Phone DHP23007 DHP23007 Antiviral agent New formulation

40 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 41

DAEWON Pharm. Co., Ltd Product (Ingredient) Use

R&D Expenditure 16,713 18,978 20,000 Anti-inflammatory, analgesic

42 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 43

Daewoong Pharmaceutical Co., Ltd. Product (Ingredient) Use Exporting Countries

Australia, Canada, CIS 12 countries,

Drug Export Volume by Export Destination (Unit: USD 1,000, %)

Company Profile 5. Omeperazole+NaHCO3

1. C ontract Development and Manufacturing

10. OmapOne Peripheral Inj.

13. CONDITION CONDITION LADY

15. HUTGAESOO Natural oriental raisin tea with zero calories

etformin hydrochloride 500mg

· P reservative-free, 30 Single Dose

13. FINECLE EYE DROPS (Chondroitin

14. one&day FRESH EYE DROPS

1. Dermotasone MLE Cream

ong Sung Cheong Ro Hwan

2. Dong Sung Cheong Ro Hwan (Sugar Coated Tablet)

3. Oxiklorin tablet 100mg/150mg/200mg/300mg Rheumatoid arthritis, Malaria

· A-/Hypogammaglobulinemia Fibrinogen (Factor I) GC5112A Congenital fibrinogen deficiency Pre-clinical

5. Ready-Q ; Drink and Delicious hangover remedy contains